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I am among those who think that science has great beauty. A scientist in his laboratory is not only 
a technician: he is also a child placed before natural phenomena which impress him like a fairy 
tale. We should not allow it to be believed that all scientific progress can be reduced to 




The wonder of nature does not become smaller because one cannot measure it by the 




My life seemed to be a series of events and accidents. Yet when I look back, I see a pattern. 
 




Class A serotonin (5-hydroxytryptamine) 2A (5-HT2AR) and class C metabotropic 
glutamate 2 receptors (mGluR2) are seven transmembrane receptors (7TMRs or G 
protein-coupled receptors – GPCRs) involved in multiple neuropsychiatric disorders 
including schizophrenia. Previous findings from our laboratory reported that 5-HT2AR and 
mGluR2 are dysregulated in the prefrontal cortex of patients suffering from this psychiatric 
condition, although 5-HT2AR’s expression was recovered in antipsychotic-medicated 
patients. Genome-wide association studies on schizophrenia reported that endosomal 
trafficking that regulates cell surface abundance of another 7TMR implicated in this 
disease (dopamine D2 receptor) can be altered. Ligand-activated receptors, including the 
7TMR superfamily, are dynamic entities whose signaling depends on trafficking, and 
trafficking on signaling. Impairments in the spatial and temporal regulation of 7TMRs result 
in homeostasis perturbations and later in diseases. Like other cell surface proteins 
expressed in mammals, such as enzyme-associated receptors and ligand-gated ion 
channels, 7TMRs form homo- or hetero-oligomers, conferring novel and unique functional 
properties to the complex. Our previous findings suggested that 5-HT2AR and mGluR2 are 
assembled in a functional GPCR heteromeric complex in both heterologous expression 
systems and in mouse and human brain frontal cortex. However, evidence that GPCR 
heteromerization can directly affect receptor subcellular organization and localization is 
missing, especially across classes. Here, we showed in mammalian HEK293 cells that 5-
HT2AR affected the localization and trafficking of mGluR2 through a mechanism that 
required their physical assembly. In the absence of agonists, 5-HT2AR was primarily 
localized within intracellular compartments. Intriguingly, the plasma membrane-localized 
mGluR2 was redistributed in internal compartments when coexpressed with 5-HT2AR. 
Agonists for either 5-HT2AR or mGluR2 differentially affected trafficking through Rab5- or 
Rab7-positive endosomes in cells expressing the receptors alone, or together. In addition, 
overnight blockade of 5-HT2AR with antipsychotic clozapine, but not with M100907, 
decreased mGluR2 density through a mechanism that involved 5-HT2AR-mGluR2 
heteromerization. Using TAT-tagged interfering peptides and a chimeric construct unable 
to heteromerize with 5-HT2AR, we showed that heteromerization was necessary for the 5-
HT2AR-mediated co-trafficking of mGluR2. Furthermore, using bimolecular fluorescence 
complementation (BiFC), we tracked the maturation of the 5-HT2AR-mGluR2 complex in 
the endoplasmic reticulum and the Golgi apparatus. In accordance with our findings in 
HEK293 cells, mGluR2/Rab5 colocalization was diminished in neuronal cortical primary 
culture of 5-HT2AR-/- mice as compared to controls. Additionally, mGluR2 was mostly 
localized near the plasmalemma in brain sections of 5-HT2AR-/- mice frontal cortex 
glutamatergic excitatory postsynaptic compartments. Together, our data suggest that 







With more than 800 members (a number that varies across studies) counting for about 2-3% of 
the total human protein-encoding transcripts1–3, guanine nucleotide binding protein (G protein)-
coupled receptors (GPCRs), or more accurately, heptahelical or seven transmembrane receptors 
(7TMRs), constitute the largest superfamily of spanning membrane proteins in the Metazoa and 
the mammalian genome. Mammals express about 400 non-odorant 7TMRs4. As a matter of 
comparison, the second largest family of receptors, the receptors-enzyme tyrosine kinase (RTK) 
family counts about 58 receptor-types in 20 subfamilies5. Because they represent fundamental 
interfaces between a tremendous diversity of extracellular stimuli*, triggering inner molecular 
cascades, cellular responses and genes transcription, 7TMRs provide highly valuable targets for 
clinical pharmacology. About 34% of FDA approved drugs target 107 unique 7TMRs, of which 27% 
treat neuropsychiatric disorders6,7. Often termed metabotropic receptors, as opposed to ionotropic 
receptors, whose activation and subsequent cell reaction is faster than the former, they process 
and transduce signals throughout structural and biochemical steps much slower than receptor 
channels. A cell response is always a combination and a cooperation between fast and slow 
transmitters. The classical/canonical mode of signal transduction through 7TMRs cognate G 
proteins is widely accepted, although recent findings proposed G protein independent signaling8–
10. For a concern of accuracy over widely acceptance, this report will use the term 7TMRs.  
7TMRs and G protein signaling likely appeared before Plants, Fungi and Animals, and diverged 
from their common ancestor about 1.2 billion years ago11. Primitive structures of 7TMRs existed 
in unicellular eukaryotes that resemble Metazoa cells12. The glutamate-receptor-like receptor is 
one of the oldest. The serotonin receptors subfamily is also one of the oldest in class A/rhodopsin-
                                               
* Stimuli can be exogenous chemical ligands such as drugs, vitamins, odorants, tastants, and viruses, and physical 
stimuli such as photons. Endogenous ligands can be biogenic amines, nucleotides, hormones, large and small peptides, 
cations and lipids, small molecule neurotransmitters, chemokines, and more. 
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like 7TMRs, which appeared between 700 and 800 million years ago13. This evolutionary success 
gives an idea of the robustness of such biostructures, having evolved and diversified under 
selective pressure, to finally regulate almost all aspects of living organisms’ physiology. 7TMRs 
share a minimal and unique common attribute that is the seven transmembrane α-helices domain 
connected by three extracellular (EC1, EC2, EC3) and three intracellular (IC1, IC2, IC3) alternated 
loops, in between an extracellular N-terminus and an intracellular C-terminus, often ended by a 
so-called helix 8.  
Classification of 7TMRs 
All characterized 7TMRs, as well as the orphan 7TMRs, are classified and categorized within the 
International Union of Basic and Clinical Pharmacology (IUPHAR) database†, which recognizes 6 
classes, widely used among studies. Several other classifications are often based on structural 
homology, but not only. 7TMRs are organized into 5 or 6 major nomenclatures according to their 
sequence similarity and functional properties (A to F)14, as well as structural and ligand-binding 
features (1 to 5)15. Also referenced phylogenetically as GRAFS16, acronym for Glutamate, 
Rhodopsin, Adhesion, Frizzled/Taste2, Secretin, the rhodopsin-like or class A/1 is the most 
represented subfamily in the human genome. The class A includes, with light-activated rhodopsin 
and highly numerous olfactory receptors, monoaminergic norepinephrine, dopamine and 
serotonin neurotransmitters/modulators transducers. Their homology of sequence indicates that 
they also share palmitoylated cysteine at their C-terminal tail, as well as a triplet of 
glutamic/aspartic acids - arginine/tyrosine termed E/DRY motif on their helix III17. This motif is the 
target of a strong ionic interaction that is involved in receptor activation as shown for the 5-HT2A 
receptor, thought to be a generalizable activation system within the class A18. Another shared 
feature of class A receptors is that they harbor a long N-terminus with conserved cysteines17. 
Class B/2 are secretin-like 7TMRs among which corticotrophin-releasing factor (CRFR1, CRFR2), 




parathyroid hormone (PTHR1, PTHR2) and glucagon-like peptide receptors (GLPR) among 
others may be mentioned. Class C/3 regroups metabotropic glutamate (mGluR) and gamma-
aminobutyric acid type B receptors (GABABR), which bind respectively the main 
excitatory/inhibitory neurotransmitters in the central nervous system (CNS), along with the sweet 
and umami taste receptors (T1R1/2+3) and the calcium sensing receptors (CaSR). Classes D and 
E constitute two minor families not represented in vertebrates, like cAMP receptor involved in 
protozoan chemotaxis signaling, and class F includes frizzled/smoothened receptors19. Further 
analogies between those nomenclatures remains unlikely since the criteria used are not conform. 
Signal transduction 
External ligands or stimuli are typically treated in two ways. Ionotropic receptors convey fast 
information flux, whereas metabotropic receptors transmit signals slowly, engaging a series of 
chemical and/or physical modifications from ligand binding to cell response. The signal 
transduction can be simply represented as an information crossing a regulated field. Information, 
the ligand, is treated, sorted and processed by the transmitter and its cognate G proteins, together 
with intracellular signaling molecules. A series of phosphorylations takes place within cascades, 
where the signal can be amplified and/or transmitted to the different target components. Because 
cell’s phospholipid bilayer membrane must maintain the system closed and tightly regulated, 
communications operate uniquely through transmitters and channels, or both, and by 
endo/exocitic vesicular trafficking. Nonetheless, it is likely that other modes exist 
(gasotransmitters20). 
Receptor activation starts with ligand binding that initiates conformational changes within the 
seven transmembrane domains that resonate to receptor extremities, and convey signal 
transduction through heterotrimeric αβγ G proteins’ subunits. The inactive state, reflecting basal 
activity, remains stable during low ligand concentration. Upon binding of its ligand, receptor 
changes its conformation that activates its cognate G protein. The activation/deactivation process 
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should not be envisioned as an on/off switch, with two distinct conformations. Receptors are in 
constant and continuous vibration, oscillating between a multitude of different conformations, 
toward active or inactive state, and get stabilized by the ligand21. It is considered as a multi-active 
state model22. 
The specificity of the GPCR-mediated signal transduction was initially thought to solely lay in the 
dissociation of the trimeric G protein’s αβγ subunits upon ligand binding. The α subunit catalyzes 
GDP to GTP to exchange and split from the tripartite GTPase to signal downstream effectors and 
second messengers, while βγ is involved in regulating ions channels switching, as well as other 
effector proteins. The GTPase family of G proteins is also well diversified, the four main G proteins 
being Gαs, Gαi/o, Gαq/11 and Gα12/13. The first two respectively stimulate or reduce adenylyl cyclase 
activity, resulting in the augmentation or the reduction of cyclic adenosine monophosphate (cAMP) 
internal concentration. The cAMP-dependent protein kinase A (PKA) signal is amplified or 
dampened accordingly, which modulates specific cell responses. A typical example is the human 
class A Gαs-coupled β2 adrenergic receptor (β2AR), which triggers cardiac myocytes contraction 
after binding of adrenaline in tissues involved in sympathetic neurotransmission26. Class C 
mGluR2/3 glutamatergic receptors are linked to the Gαi/o pathway that inhibits cAMP production 
and reduces glutamatergic tone in presynaptic terminals where it acts as an autoreceptor. The 
class A 5-HT2A receptor provides an example of Gαq/11 coupling. Agonist binding stabilizes the 
receptor in its active conformation that triggers the phospholipase C (PLC) DAG/IP3/PKC 
pathway. For example, in 5-HT2AR-expressing neurons, the Gαq activates PLC-β which catalyzes 
the hydrolysis of phosphatidyl inositol-bisphosphate (PI(4,5)P2) into two second messengers, 
diacylglycerol (DAG) and inositol triphosphate (IP3). DAG remains attached to the membrane and 
recruits the protein kinase C (PKC), while IP3 diffuses in the cytoplasm to trigger calcium release 
from the endoplasmic reticulum storage. While diffused into the cytoplasm, Ca2+ can operate 
several cellular events such as activation of PKC (feedback), stimulation of ionic channels and 
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enzymes recruitment that together modulate synaptic transmission. The PKC is also involved in 
triggering cellular responses, such as neuronal plasticity, cell survival, and transcription factors 
activation. Several studies recently showed that the canonical linear model was not sufficient to 
describe unexpected results while tracking G protein activation. This led to separate G protein-
dependent and -independent signaling8–10,23–26. 
To prevent response overload, and/or to return to basal state, i.e. low ligand concentration, a 
termination mechanism shuts down the signaling components by acting directly on the receptor, 
typically involving two major pathways: the receptor phosphorylation by G protein-coupled 
receptor kinases (GRK), and the subsequent recruitment of β-arrestins (1 or 2). GRK are recruited 
by Gβγ once released upon ligand-dependent receptor activation and split from the α subunit, so 
that receptor phosphorylation happens relatively fast after ligand binding. β-arrestins are thought 
to specifically bind GRK-phosphorylated receptors while competing with the G proteins in the 
vicinity. Arrestins are responsible for the recruitment of the endocytic machinery that involves 
dynamin and the formation of clathrin-coated vesicles. Successive intracellular mechanisms such 
as Rab-dependent desensitization (receptor endocytosis) and recycling from endosomes further 
affect receptor’s fate and cell’s responsiveness. 
7TMRs structure and oligomerization 
Class A 7TMRs or rhodopsin-like receptors share the minimal features that defines the 
superfamily, a seven transmembrane (TM) spanning helices domain, or heptahelical domain, 
connected by three intracellular loops (IL1-3) and three extracellular loops (EL1-3). This class of 
receptors has an extracellular cavity within their TM domain dedicated to the binding of the 
orthosteric ligand. They have also in common few conserved motifs27. They are devoid of the large 
extracellular bilobal domain (ECD) characteristic of the class C 7TMRs, the Venus Fly Trap (VTF) 
domain. The typical receptors of this family, the GABAB and the metabotropic glutamate receptors 
(mGluRs), share this VFT domain dedicated to the binding of the orthosteric ligand, as well as 
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holding a cysteine disulfide bridge necessary for the receptors obligatory dimerization. A cysteine 
rich domain is also partially involved in the dimeric interface, and proposed to relay ligand-induced 
conformal adjustment28. The lack of covalent bond between protomers have led some reports to 
justify that class A dimers are not stable enough to remain bound supported by weak interactions29. 
Class A receptor dimers are indeed less stable than class C30,31. This does not rule out that they 
are functional. The rapid conversion between monomers and dimers and their resulting ratio may 
regulate receptor function30. 
Since the first biochemical findings showing that a peptide derived from a 2 adrenergic receptor 
(β2-AR) transmembrane (TM) domain prevented both receptor complex formation and agonist-
promoted stimulation of adenylyl cyclase activity32, the class A 7TMRs never ceased to attract 
attention for their ability to associate as dimers or higher oligomers33,34. Despite certain limitations 
and caveats of most biophysical and biochemical approaches and technologies, including 
coimmunoprecipitation (CoIP), crosslinking, bioluminescence and Förster resonance energy 
transfer (BRET/FRET), SNAP- or CLIP-tag35,36, bimolecular fluorescence complementation (BiFC) 
and other protein complementation assays (PCA), these studies generally provide evidence 
related to the fundamental role of class A 7TMR homo/heteromerization in the control and 
regulation of both agonist-induced receptor-G protein coupling37,38 and trafficking39–43. Similarly, 
contemporary advanced techniques such as single molecule imaging in intact cells indicate that 
certain class A 7TMRs form stable homomers41,44–46, while others, using similar approaches, have 
shown either transient interactions30,47,48, or negligible to absence of class A dimerization49–51. 
Accordingly, many questions still remain open about the role of receptor complex formation in 
7TMR’s dynamics and behavior. 
Between 2000 and 2004, a series of articles published in the Journal of Biological Chemistry (JBC) 
by several laboratories either directly implied the oligomeric association as a mean for 7TMRs to 
undergo internalization after ligand binding or assumed that receptor oligomerization could 
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influence both trafficking and signaling. These results directly followed pioneer discoveries about 
both class A and class C 7TMRs with the case of β2-AR and GABABR, respectively (see below). 
Among those studies, the scope has been extended to several other subtypes, β2-AR 
heterodimerization with β1-AR52–54, β2-AR with β3-AR55, oligomerization of other adrenergic 
subtypes alpha, such as α1a- and α1b-AR56, but also across subtypes57. Likewise, an early study 
demonstrated that the δ-opioid receptor dimerize, suggesting that such receptor-receptor-
interaction (RRI) was particularly important for their desensitization and subsequent 
internalization58,59. Dimerization was also found to play a critical role in the agonist-independent 
desensitization and internalization of the human platelet-activating factor receptor (hPAFR)60. 
These novel ideas also emerged within the opioid receptor subfamily following a series of impactful 
discoveries, such as the oligomerization of the μ- and the δ-opioid  receptors61, where again, the 
scope extended the idea that those associations, this time among different protomer subtypes, 
would create novel functional properties that was not previously observed by classical 
pharmacological characterization. In the same journal, another study implicated heteromerization 
of somatostatin and μ-opioid receptors as a principal component of the cross-phosphorylation and 
the desensitization of both receptors62.  
Although few studies directly implicated the 7TMRs homo/heteromerization in both endocytosis 
and biosynthesis processes, several of them though clearly suggested that such interactions can 
modulate function and trafficking. Opioid receptors were the first class A 7TMR to be thoroughly 
studied following the discoveries of dimerization and oligomerization within the subfamily. The μ- 
and the δ-opioid receptors have been demonstrated to heterodimerize using epitope tagged 
constructs submitted to subsequent immunoprecipitation. Moreover, whereas DAMGO (μ 
selective agonist) did now affect desensitization of the receptors expressed together, treatment 
with DPDPE (δ selective agonist) induced a resistance to desensitization and internalization of the 
two receptors. Opioid receptors are well studied for their capacity to be internalized and 
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desensitized after ligand binding. The fact that this process was affected by the coexpression and 
the putative interaction between μ and δ suggested that heteromerization can also affect basic 
components of class A receptors function such as internalization and desensitization61, as well as 
binding affinities of the ligands63. These two studies published the same year demonstrated that 
oligomerization is an important feature of the opioid receptor subfamily. Heterodimerization also 
was demonstrated to create novel functions for the δ- and the κ-opioid receptors64. Although the 
three opioid transmitters share a relatively high homology of sequence (about 65% identical amino 
acids), the diversity of RRIs demonstrates a great variety of novel functions that affect most 
aspects of receptor signaling and trafficking. Together these pioneer studies provided the first 
indirect evidence that one protomer is able to affect both signaling and trafficking of another 
protomer within the class they belong to. 
Within the class C, aside from similar conclusions about the novel properties provided by receptor 
homo/heteromerization, it has been shown that such associations are necessary for the proper 
cell surface addressing of the protomers together, as a single entity. The classical case illustrated 
by the class C GABABR remains remarkable as it is considered a paradigm. This obligate dimer 
is composed by the GABABR1 protomer that is unable to trigger G protein-activated inwardly 
rectifying K+ channels (GIRKs) signals alone, when overexpressed in mammalian cells: it requires 
heterodimerization with GABABR2, a subsequently described protomer that shares 35% homology 
with the subtype R165. The reason behind this resides in the early association of the two subunits; 
while crossing the endoplasmic reticulum during the protomers biosynthesis, R2 masks a retention 
motif lodged at the R1 C-terminus66,67, allowing the full heteromer to exit the ER, otherwise retained 
in the organelle as single units. Here, heterodimerization is necessary for the cell surface 
addressing of a functional GABABR. These findings also indicated that the GABAB receptor is an 
obligate dimer. More recently, a group demonstrated that GABABR2 competes with a gatekeeper 
protein termed PRAF2, which results in passing prerequisite quality controls prior to ER exit68. It 
9 
 
highlights that 7TMRs can hold the role of chaperonin-like proteins, although finely regulated by 
resident chaperone molecules69–71. Similarly, the class A β2-AR homodimerizes in the ER to allow 
upward trafficking to the plasma membrane. Using two different mutation approaches, it was 
revealed that retention/export motifs mutants act as dominant negative on WT β2-AR species, 
precluding their ER export and migration to the cell surface: first, by generating a chimera where 
the C-terminus tail of the β2-AR is interchanged with that of GABABR1, containing the above-
mentioned retention motif; second, by mutating an ER export signal from the D1R sequence in 
order to generate an unrecognizable binding site for specific resident proteins involved in the ER 
exit of D1R. The structure/function role of such coupling has also been illustrated by the required 
dimerization of metabotropic glutamate receptor 2 to enable ligand-induced G protein activation, 
while monomeric 7TM domain appears sufficient for its coupling72, supporting the idea that dimers 
are the minimal signaling units, constituting a 2:1 ratio with the G protein they are associated to70. 
Although truncated mGluR2 lacking their ECD can homodimerize using only the 7TM interface, 
the stability of this formation is assured by the cysteine 121 located in the VFT that provides a 
covalent intersubunit disulfide bound. Isolation of truncated receptors (purified 7TM domains) in 
lipid nanodiscs producing two different fractions enriched with two or one receptor, mGluR2 was 
able to signal with the latter fraction using positive allosteric modulator (PAM), which binds the 
ECD, but not the VFT. However, truncated mGluR2 lacking the VFT domain were unable to 
activate the G protein in presence of the orthosteric ligand glutamate, supporting the fact that only 
full length dimeric species can activate Gαi protein signaling as assessed by GTPγS assay, while 
monomeric species are sufficient to the coupling to the G protein73. 
The accurate description of the interactions between residues that hold weak forces and stabilize 
oligomeric interfaces is an essential component of the pharmacological properties of 7TMRs, 
besides providing important information for the development of therapeutics and 3D models, which 
simulate dynamic structures and interactions at the atomic level. Advances in structural biology 
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technologies have allowed to elucidate and validate the precise transmembrane domains and 
often the residues involved in the conformations responsible for the activation/deactivation of 
oligomeric receptors. Across studies, TM domains I, IV and V typically appear to be the implicated 
interfaces in the formation of transient and/or stable class A 7TMRs oligomers74. 
How TM domains associate is well illustrated by the class C metabotropic glutamate receptors, 
which exhibit the most stable RRI within the superfamily. It was first proposed that the mGlu5 
receptor is a naturally occurring dimer linked by a disulfide bound at the extracellular domain, and 
that concept could be generalizable to all mGluRs75. The prototypic class A dimerization held by 
the μ-opioid receptor has been challenged, suggesting that the dimer populations are scarce and 
negligible at physiological concentrations51. Nevertheless, a great majority of theoretical 
approaches remain in favor of receptor oligomerization that provides an array of supplementary 
functions: antagonistic assemblies to cross-modulate protomer signaling, chaperones and guides 
through the biosynthesis pathway, subcellular co-trafficking and co-desensitization: dynamic or 
stable, kiss-and-fly or covalent76,77. 
In a review focused on class A 7TMRs homo/heterodimerization, several studies are listed 
according to the technique used and the involvement of the TM interaction to stabilize the dimeric 
formation, seven of nine class A receptor homo/heterodimers involve at least the TM IV and/or TM 
V. In a second chart similar findings are proposed78. The diversity of the TM interaction is provided 
by the highly flexible linkers and loops that allow fast conformational modifications and relatively 
large movements of the TM domain78,79. TM I and II were also mentioned for the muscarinic 
receptor 3 (M3), suggesting that each combination of the transmembrane interfaces is specific to 
a mode of functioning, either active or inactive states74. At the time of this report, a study elucidated 
the active and inactive conformation used by the mGluR2 dimer to activate Gαi protein using 
cryoEM technology, showing asymmetric positioning of the TM helices both during activation and 
at basal inactive state, involving TM III/IV, and TM VI/VI respectively80. 
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As illustrated by the muscarinic acetylcholine receptor 2 (M2R) case, which has been found as 
monomeric, but also in dimeric and tetrameric forms by three different studies using different 
techniques and systems, class A 7TMRs could associate in various homomeric ratios74,81–83. 
Although discrepancies for the same target receptor may be interpreted as a lack of reproducibility, 
feeding the debate on class A 7TMRs oligomerization, it might instead indicate that each study 
has revealed a different state of this receptor at a different time and under different conditions, as 
has been noted, 
“Until recently, these were often considered to be mutually exclusive scenarios, but the co- 
existence and potential interchange between such forms, based in part simply upon mass action, 
has resulted in a more textured view.”84 
Receptor oligomers can be formed by different mechanisms, by weak forces at the plasma 
membrane, or covalently during biosynthesis. The origin of the coupling must have a physiological 
significance85–87. Homo or heterodimerization most likely occurs within the same 7TMRs classes 
due to more compatible structural homology of their TM domain15,70, the natural interface of 
receptor coupling. Nevertheless, interclass receptor associations are progressively more 
reported86. A remarkable association has yet been suggested for the 5-HT2R and the CRFR188. In 
this proposed model, 5-HT2R cell surface expression and signaling is increased by agonist-
stimulated CRFR1 trafficking. The accuracy in detecting the physical interaction at the interface of 
TM dimerization starts to provide more granular visualization on how oligomers associate and 
function89. The proof provided by visual evidence is also a criteria in favor of 7TMRs 
oligomerization90. Finally, the theory of moonlighting proteins, as a powerful and economic natural 
feature of proteins to organize, associate and function, support the idea that (receptor) 
oligomerization is not a rare and fortuitous event, but rather a common mechanism found 





Serotonin is the first neurotransmitter/trophic factor to appear in both Protozoan and Metazoan94, 
probably inherited from unicellular eukaryotic precursors, which likely firstly evolved in 
mitochondria a billion years ago95. Plants produce a large amount of serotonin for both trophic 
factor that regulates growth together with auxin and antioxidants to preserve cell from damages 
provoked by excessive production of molecular oxygen96. Serotonin-based analogs and alkaloids 
such as ibogaine, mescaline, dimethyltryptamine (DMT) and psilocybin (in the Fungi) are produced 
by plants and fungi to resolve the problem of oxidation and protect them from radical oxygen, 
which is intrinsic to their photosynthetic abilities95. Serotonin is a biogenic amine synthetized from 
indole precursor tryptophan primarily after its hydroxylation into 5-hydroxytryptophan by the 
tryptophan hydroxylase enzyme. Its product subsequently undergoes a decarboxylation by a 
decarboxylase enzyme in presence of the cofactor pyridoxal phosphate which produces 5-
hydroxytryptamin (5-HT). Serotonin does not cross the blood brain barrier (BBB) but L-tryptophan 
does, being the rate-limiting precursor for the synthesis of serotonin. After being released 
presynaptically in the extracellular milieu (synaptic cleft), serotonin is either metabolized by 
monoamine oxidase (MAO) into 5-hydroxy indole acetic acid (5-HIAA), or recycled by serotonin 
reuptake transporter (SERT) or autoreceptors. 5-HIAA is an interesting metabolite that could be 
used as a marker because of its suggested abnormal levels in psychiatric disorders (often found 
as decreased), reflecting serotonin levels in the brain97. Altered blood, serum or cerebrospinal fluid 
(CSF) levels of both serotonin and its metabolites have been associated with impulsive and 
aggressive behaviors in general98–102 and in suicide103–106 and autism107–111 in particular, although 
these findings are still under debate112. 
Serotonin can be found in all human body tissues and fluids. In the CNS, it modulates a large 
number of cerebral, cognitive, hormonal and emotional functions. Mood, appetite and sleep, 
aggressive and sexual behaviors, locomotion, learning and memory consolidation are all regulated 
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by serotoninergic neurons. Additionally, it regulates pulmonary and cardiovascular physiology, 
hemostasis, and endocrine functions. As a trophic factor, it is involved in neural development, 
homeostasis and plasticity. Serotonin is synthesized in dorsal raphe nuclei located in the primitive 
brainstem, but about 95% is found in blood platelets, insuring aggregation and vasoconstriction of 
blood vessels, and in enterochromaffin cells within the digestive apparatus113. The remaining 
synthesized neurotransmitters are delivered throughout the entire brain using outputs originating 
from the caudal raphe to innervate the spinal cord, while medial and dorsal raphe nuclei project 
toward almost all brain areas113,114 (for a map of the main serotonin projections in the brain and 
the spinal cord, see figure 7 in ref96). Within the forebrain, the frontal cortex, together with the 
corpus striatum, the lateral region of the hypothalamus and the amygdala are innervated by 
projections issuing from the dorsal division of the nucleus centralis superior96. An exhaustive listing 
of the areas innervated by the dorsal raphe is not relevant for this report, but the extent to which 
serotonin influences the overall brain activity by its ubiquitous presence demonstrates its 
pleiotropic role over all other monoamines115. All effects and regulatory processes controlled or 
modulated by serotonin necessitate its interaction with serotonin receptors. 
Serotonin receptors 
The serotonin receptors appear to be among the oldest neurotransmitter receptor system within 
the rhodopsin-like 7TMR subfamily11,116. All subtypes are expressed in the CNS by nineteen genes 
(14 metabotropic receptors and 5 ionotropic receptor subunits) coding for seven different receptor 
types composed by nineteen different subtypes. Except for the 5-HT3  receptor (constituted by 5 
subunits 5-HT3(A,B,C,D,E)) forming a pentameric structure) which are a cys-loop ligand-gated ion 
channels activating inward K+/Na+ currents117,118, all other receptors are metabotropic and 
classified in three categories according to their G protein signaling. The 5-HT1A, 5-HT1B, 5-HT1D, 5-
HT1E, 5-HT1F and the 5-HT5A, 5-HT5B receptors are inhibiting cAMP accumulation after release of 
the Gαi/o subunit following receptor activation. The 5-HT1CR has been revealed to be the 5-HT2CR 
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receptor. Conversely, the 5-HT4, 5-HT6 and 5-HT7 are Gαs-coupled and stimulate cAMP production 
in cells. The subtype 2 regroups the 5-HT2A, 5-HT2B and 5-HT2C mostly coupled to production of 
IP3 and DAG after hydrolysis of PIP2 following activation of the Gαq/11 pathway, also stimulating 
PLC and PKC. 
5-HT2A receptor 
The class A 5-HT2A receptor, encoded by the HTR2A gene, is a subtype of the 5-
hydroxytryptamine receptors type 2 and shares this subgroup with 5-HT2B and 5-HT2C receptors. 
These subgroup 2 receptors share 45-60% of sequence homology and are coupled to their 
canonical Gαq/11 signaling pathway119. Although found outside the CNS, a study provided evidence 
that serotonin-induced activation of 5-HT2AR in cultured rat renal cells produced about 50% 
inhibition of forskolin-stimulated cAMP accumulation, a signal that was reversed by application of 
the antagonist ketanserin, indicating that this mainly Gαq/11 coupled receptor can activate Gαi/o 
signaling pathway, at least in this peculiar primary culture120. 
The 5-HT2AR is by far one of the most studied 7TMR and consequently, one of the most known 
serotonin receptor121. This is in part due to its atypical and unique pharmacology, as well as its 
wide distribution in the CNS and substantial involvement in neuropsychiatric disorders. 
5-HT2A receptor distribution 
A recent study analyzed the human biodistribution of the 5-HT2AR by positron emission 
tomography (PET) with two specific radioligands and showed a wide expression in numerous 
organs and tissues122. In the brain, it is well characterized and widely distributed in Rodents123 and 
non-human Primates124, and although mostly present in postsynaptic neurons125–127, its 
presynaptic activity has been demonstrated124,126–128. It is also present on astrocytes127,129. In rat 
and human, [3H]ketanserin radioligand binding co-distributes and overlaps with mRNA 
histochemistry demonstrating dense labelling of the major parts of the cerebral cortex regions, 
though denser in laminae I, IV and Va, the piriform and the entorhinal cortexes, as well as the 
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claustrum119. Using another 5-HT2AR radioligand antagonist, [3H]MDL100,907, radiolabeling 
signals coupled to in situ hybridization (ISH) showed a matching overlap of both transcripts and 
protein in the rat brain, confirming most of the cortical regions previously described in Mammals 
and in Rodents, with a preference for the layer V of prefrontal cortex pyramidal neurons130. Lesser 
densities are found in the basal ganglia, in particular the caudate-putamen nucleus (CPN) and the 
nucleus accumbens (NAc). The cerebellum seems exempt of signal across many studies and 
often used as a control or reference area119,131,132, however some findings involved serotonin 
receptor localization and dysfunction in this area in humans and in rats133,134. Caution must be 
taken about the specificity of the radioligands used to label expressed receptors prior to the 
development of [3H]MDL100,907114,135 and [11C]-Cimbi-36136, accounting for their technical 
limitations and caveats114. 
In situ hybridization enabled to localize 5-HT2AR mRNA in diverse cell types of the rat brain, mostly 
pyramidal neurons of the neocortex and the hippocampus, as well as interneurons of the piriform 
cortex132. The lamina IVc of the human striate cortex also showed positive signal. Immunoreactivity 
in the rat brain displays dense staining in the apical dendrites of pyramidal shaped neurons of the 
neocortex, as well as both parvalbumin positive and negative interneuron bodies137. 
The cellular and subcellular distribution of this receptor remains difficult to ascertain. Despite 
numerous examples of its localization both at the plasma membrane and within neuron somas, 
there is to date no definitive accordance on its spatial distribution either in heterologous cell 
systems or in native tissues. It is however accepted that 5-HT2AR acts both intracellularly and as 
a prototypical plasma membranous 7TMR depending on the brain regions and/or the 
neuronal/peripheral function involved (see discussion below). Therefore, the localization of the 5-





5-HT2A receptor pharmacology 
5-HT2A receptor is the target of endogenous neuromodulator serotonin (5-HT). It is also targeted 
by atypical antipsychotics (AAP) such as clozapine, olanzapine, quetiapine, paliperidone, 
aripripazole and risperidone, but also M100907, altanserin, mianserin, and ketanserin, acting as 
inverse agonists or neutral antagonists. It is also bound by agonists and partial agonists among a 
wide range of hallucinogenic compounds (HAL) which effects are psychedelic, phenethylamine-
like, e.g. DOI, DOB, and indolamine-like, e.g. mescaline, dimethytryptamine (DMT), psilocybin, 
lysergic acid diethylamide (LSD), acting as partial agonists138–140. Remarkably, some compounds 
are not hallucinogenic (NHAL) (e.g. lisuride, ergotamine) despite high molecular similarity with 
HALs. 5-HT2AR thus exhibits a singular pharmacology141, being the primary target of pro- and 
antipsychotic drugs114,140,142,143. Such psychedelic compounds elicit response in humans that 
profoundly affects behavior and consciousness139,144. In peak phases, this singular response is 
often compared to delusions and hallucinations that resemble acute positive symptoms of the 
schizophrenia spectrum disorder145,146. However, while psilocybin provokes psychosis-like 
behavior in healthy volunteers via 5-HT2AR activation138, other agonists, including psilocybin, are 
currently considered as potential treatment for depression and other psychiatric conditions147–155. 
This is indeed of particular interest for psychiatric disorders and related pharmacology, because 
HALs are employed to model psychosis in Rodents and in Humans138,156. Activation of 5-HT2AR is 
not sufficient to elicit hallucinogenic response, but it is necessary140,143,157. 
5-HT2A receptor signaling and trafficking 
Serotonin regulates essential functions in the CNS such as mood appetite and sleep, along with 
peripheral vasoconstriction and organs development. The 5-HT2AR transduction model describes 
the Gαq/11-coupled signaling pathway upon ligand binding, stimulating PKC through PLC 
recruitment, to finally mobilize calcium release from the ER158. The trafficking of the 5-HT2AR has 
been described as atypical. Internalized by either agonists or antagonists, this is a specificity 
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hardly found in other classes and other types of 7TMR159,160. The 5-HT2AR is also thought to 
activate pathways differentially and promote agonist-directed trafficking of receptor stimulus161. 
Latter termed “biased agonism”, this functional selectivity has been shown to differentially signal 
downstream upon activation by either psychedelic or non-psychedelic agents. While canonical 
signaling through Gαq/11 would be responsible for non-hallucinogenic-mediated downstream 
activation, hallucinogens require in addition to signal through pertussis toxin-sensitive Gαi/o 
pathways140,162. Similar to this concept of signaling, it has also been shown that the 5-HT2AR is at 
the center of a biased phosphorylation which provides additional trafficking and internalization 
selectivity through the β-arrestin dependent pathway163. While ERK-dependent phosphorylation 
by HAL such as LSD and DOI is abolished by pretreatment with pertussis toxin, ergotamine and 
lisuride NHAL signaling remained unaffected, comforting the idea that two G protein-activated 
pathways are required to elicit hallucination-like behavior in vivo, using the Head-Twitch Response 
as a proxy of hallucinogenic intoxication response in mice164) or the ERK signaling readout in 
pyramidal neurons, as well as in in vitro heterologous systems114.  
5-HT2A receptor oligomerization 
The 5-HT2AR has been shown to form homo/heterodimers165–170 and oligomers with other 
7TMRs171–175. Several lines of evidence have shown that 5-HT1A and 5-HT2A receptors, which are 
co-expressed in cortical pyramidal neurons, form an antagonistic receptor heteromer by 
modulating NMDAR currents114. 5-HT2AR and D2R have been shown to associate as a functional 
receptor heteromer eliciting a signaling crosstalk signaling in cells172,176. 
Physiopathology of the 5-HT2A receptor 
5-HT2A receptor  is involved in the pathophysiology of schizophrenia-like phenotypes, depression 
and suicide, to name a few131,177–187. It has been linked along with other subtypes to 
physiopathology of psychiatric and cognitive disorders, such as mood disorders and depression, 
suicide and schizophrenia, associative learning, where preferentially affecting areas regrouped in 
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the neocortex, in which the prefrontal cortex (PFC) seems to play an important 
role124,125,143,183,187,188. The list of disorders implicating the 5-HT2AR is long, and it is clear that the 
receptor regulate many diverse systems and functions in the body and the brain; it comprises 
Alzheimer disease, autism, Parkinson disease, obsessive compulsive disorder, addiction, suicide, 
cardiovascular lung and skin disorders, as well as diabetes and inflammation, to name a few. What 
is unclear though, is how dysregulated is the receptor in many neuropsychiatric disorders. 
Discrepancies about the level of 5-HT2A protein and mRNA, often is post-mortem human brains, 
is still a matter of debate185,189.  
Glutamate 
Neurotransmission in the mammalian brain is usually depicted as a synchrony between excitatory 
and inhibitory electrochemical signals. L-glutamate is known to be the main excitatory190,191 and 
the most abundant192 non-essential amino acid in the mammalian CNS, while GABA relays 
inhibitory neurotransmission. Glutamate concentration is high in the CNS, partly because it is not 
solely used for excitatory neurotransmission, thus holding other metabolic activities in glia and 
neurons193. Both glutamate and GABA are synthesized from glutamine precursor. Glutamine is 
synthetized from glutamate by ATP-dependent glutamine synthetase in astrocytes. Glutamine is 
exported to the neuron by glycine/glutamine transporters. In the neuron, it is then converted into 
glutamate by the phosphate-activated glutaminase194. Glutamate is decarboxylated by the 
glutamic acid decarboxylase in presence of cofactor pyridoxal phosphate and converted into 
GABA. After vesicular glutamate transporter 1 (VGLUT-1)-mediated packaging of glutamate in 
synaptic vesicles, it is released to bind both post synaptic ionotropic and post/presynaptic 
metabotropic glutamate receptors/autoreceptors respectively. This results in modulation of Ca2+ 
release, acting as a second messenger required for the activation of signaling cascades. It is 
removed from the synaptic cleft back to the astrocytes through transmembranous excitatory amino 
acid transporter (EEAT), thus completing the glutamate-GABA/glutamine cycle. It also suggests 
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the existence of different pools of glutamate-containing neural cells, providing the resources to 
tightly regulate glutamine, glutamate and GABA homeostasis in the brain. Glutamate 
concentration is maximal intracellularly, and extracellular increase of glutamate produce neuron’s 
excitotoxicity195–197. 
Glutamate receptors 
As mentioned above, there are two types of glutamate receptors expressed in the CNS. Ionotropic 
glutamate receptors (iGluRs) are fast-acting ligand-gated ion channels that are non-selective 
cations channels, thus mainly exchanging Na+ and K+, together with lesser concentration of Ca2+ 
(in the case of NMDAR). They are termed according to their main activating ligand: NMDA (N-
methyl-D-aspartate), AMPA (α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate), and kainate 
(kainic acid) receptors. As cation channel, their carry out excitatory post synaptic currents resulting 
in cell depolarization and in optimal cases, creation of an action potential. As their related 
metabotropic cousins, iGluRs can be both pre- and post-synaptic, complexifying the simplistic 
black and white view on presynaptic mGluRs and postsynaptic iGluRs198. Slow modulation of 
glutamate release is accomplished by metabotropic glutamate receptors (mGluRs). Indeed, the 
role of mGluRs differs from that of fast-acting ion channels, because they can be sensitive to both 
orthosteric and allosteric pharmacological compounds and drugs, thus changing the excitability of 
the postsynaptic neurons. Additionally, their G protein coupling triggers intracellular messengers 
that affect neuron homeostasis, function and transmission. 
To date, the class C 7TMRs mGluRs are categorized into 3 different groups according to their G 
protein coupling and sequence homology199,200. Splicing variants are common in this subfamily 
(subscript letters). Group I contains Gαq/αs-mediated signaling subtypes, mGlu1(a, b, c, d, e, f), taste-
mGluR1 and mGlu5(a, b) receptors. Group II and III are mainly inhibitory-mediated signaling, 
coupled to Gαi protein, decreasing adenylyl cyclase activity, stimulating K+ inward ion channels 
and altering Ca2+ currents, thus negatively affecting neurons firing and excitability by an overall 
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reduction of glutamate neurotransmission. Group III is composed by mGlu4 and taste-mGlu4 (a 
shortened, less sensitive version of mGluR4201) receptors, the retinal mGlu6(a, b, c) and the 
presynaptic mGlu7(a, b, c, d, e) and mGlu8(a, b, c) receptors. mGlu2 and mGlu3(A2, A4, A2A3) receptors form 
the Group II, sharing homology of structure and Gαq protein signaling and pharmacological 
characteristics. They all bear a large extracellular domain responsible for the binding of orthosteric 
ligands, the VFT. 
mGlu2, mGlu3 receptors distribution 
Group II mGluRs are encoded by the GRM2 and the GRM3 genes. The homology of sequence 
between the two genes approximates 67%, with 70% among the conserved regions between 
mGluR1, 2, 3, and 4, especially at the c-terminus and at the VFT domain. Besides, they do not 
share any similarly with the other 7TMR classes202. In situ hybridization studies indicate a wide 
distribution of mGluR2 in discrete cell types in the rat CNS. It is high in the olfactory bulb and the 
cerebral cortex. Immunohistochemistry studies with a specific mGluR2/3 antibody showed 
expression of both receptors in many regions of the mouse brain with variable expression patterns 
and intensities. This suggests that a wide array of subregions where both receptors are 
coexpressed and possibly interact203. Additionally, the cell types are distinguishable among 
regions but both pre- and post-synaptic neurons are positive for either mRNAs or protein 
expression of mGluR2/3, as well as substantial glial expression203. In the cerebral cortex, layer I 
to IV were highly stained, as well as deeper regions in the layer V and VI of medium and pyramidal 
neurons203. Other important reactive regions were the piriform, frontal and entorhinal cortexes, 
subregions of the hippocampus, the thalamus, and main nuclei of the basal ganglia such as 
nucleus accumbens and caudate putamen. A study using autoradiography coupled to 
electrophysiology with the selective mGluR2/3 radioagonist [3H]LY459477 in WT, mGluR2-/- and 
mGluR3-/- mice, to specifically address distribution of each receptor, matched most of the regions 
cited above in CD-1 mice204. In the basal ganglia, no signal could be found outside the substantia 
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nigra, though both caudate-putamen and nucleus accumbens shell were mGluR2 positive, in 
accordance with monoclonal antibody immunoreactivity in both mouse and rat, which also 
detected mGluR2 in the ventral tegmental area (VTA)205. mGluR3 was also found in the same 
subcortical regions with high immunolabeling ultrastructure resolution206. The claustrum was also 
positive for mGluR2 and mGluR3 radioactivity with different amounts, although the above study 
using immunohistochemistry technique reported a weak signal205. This study204 was also able to 
differentiate regions expressing either mGluR2, such as prefrontal cortex, and mGluR3, such as 
dorsolateral and entorhinal cortexes.  
Whereas electron microscopy study found mGluR2/3 staining in many glial processes, vesicles of 
putative excitatory synapses, presynaptic terminals near synaptic clefts of the layer I cerebral 
cortex, signal was also high in postsynaptic small spine synapses. Glial staining was detected in 
all layers, although the authors commented on the difficulty to delineate accurately the processes 
that seemed positive203. Conversely, no glial cell expressing mGluR2 were found with monoclonal 
immunostaining technique at the EM resolution205. Subsequently, other EM studies demonstrated 
the presence of mGluR2/3 in astrocytic bodies that ensheathed glutamatergic-like synapses, and 
confirmed the localization of both receptors indistinctly in pre- and post-synaptic processes such 
as axons, dendrites and spines of the dorsolateral prefrontal cortex of non-human Primates207. In 
the same region of the same animal model, it was specified the relative amount and presence of 
both mGluR2 and mGluR3. Because this region is critical for many neurodegenerative and 
psychiatric disorders, the localization of group II mGluRs invests a substantial importance. 
mGluR2 is mostly reported as a presynaptic terminals autoreceptor200,208–210, and, to a lesser 
extent, on a variety of spines, but mostly as an extrasynaptic receptor. It was also clearly present 
in astrocytes although previously thought to be absent in glia205; mGluR3 seemed to be the 
prominent glial receptor211. mGluR3 was mostly present on astrocytes and postsynaptic spines, 
where it was shown to negatively modulate cAMP production212. These findings suggested, in the 
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context of delayed neurons firing in the layer II of the dorsolateral prefrontal cortex, that mGluR2 
and mGluR3 have distinct functional roles in distinct regions of the tripartite synapse, although it 
was previously assumed that they could share similar brain functions, where mGluR2 was 
assumed to reduce neurons sensitivity together with other Gαi-coupled mGluRs200,213,214, while 
mGluR3 would act as a potent mechanism of reuptake glutamate following vesicular release in 
the extracellular field of excitatory glutamatergic terminals197. 
Most of these regions also express the 5-HT2AR, in particular the layer Va of the prefrontal cortex 
that showed dual labelling of [3H]LY459477 and either [125I]DOI or [3H]M100907 (in mGluR3 KO 
mice)204, indicating that 5-HT2AR and mGluR2 co-distributed in critical regions involved in 
neuropsychiatric disorders, as previously reported130. Both receptors are expressed and detected 
in thalamic regions, the prefrontal cortex, hippocampal subregions such as the entorhinal cortex, 
as well as the dorsal and ventral striatum and the amygdala204. 
mGlu2, mGlu3 receptors pharmacology 
Group II mGluRs can be sensitive to the same agonists as of their ionotropic cousins. Glutamate 
is obviously one of them, but also quisqualate, which initially served as a selective agonist for 
mGluR2 and mGluR3 with differential cellular electrophysiology in cloned expressed 
receptors200,202. As of today, and to our knowledge, agonists sufficiently selective to distinguish 
mGluR2 from mGluR3 are still not available. This is due to the sequence proximity at the 
extracellular orthosteric binding site. Pharmacological design has however progressed in the 
selectivity of this Group II agonists, and a compound, partial agonist at mGluR2 and antagonist at 
mGluR3 has been developed and tested215. Another compound, N-acetylaspartylglutamate 
(NAAG), the most abundant peptide in the mammalian brain, elicited high mGluR3 selectivity but 
not at other mGluRs, including mGluR2, implicated in synaptic plasticity and neuroprotection 
against excitotoxicity216,217. Although selective, it remains an endogenous mGlu3 receptor agonist. 
Other agents could possibly be used in some cases, but the constraints over group II mGluRs 
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pharmacology limit studies that would be able to distinguish the exact role held by each receptor. 
This issue can be somewhat overcome by the recent availability of positive and negative allosteric 
modulators, (PAM or ago-PAM and NAM respectively218–220). 
The development of highly selective orthosteric mGluR2/3 agonists such as LY379268, 
LY354740, LY2140023 (the LY404039 prodrug) and LY404039 enabled to refine the function of 
each receptor in experiments in vitro, but also in clinical trials to treat neuropsychiatric disorders 
such as schizophrenia and anxiety, stress and neurodegeneration, and even cancer and pain 
management, to name a few221–235. Additionally, the affinity of such drugs can differ from one brain 
area to another, or across different neuronal cell types236. LY379268, LY2140023 (the LY404039 
prodrug) and LY404039 suppress the behavioral and physiological effects of psychotomimetic 
drugs and serotonergic hallucinogenic drugs, both enhancers of glutamate release, and show their 
efficacy in the treatment of schizophrenia211. The metabotropic glutamate receptors, including 
mGluR2 and mGluR3 are considered new targets for their antipsychotic activity and, despite 
undergone a hold in clinical application, their effects on the positive, negative and cognitive 
symptoms of schizophrenia continue to raise hopes170,218,226,234,237–240. 
mGlu2, mGlu3 receptors signaling 
Because of their similarity in residues sequence, cognate G protein and pharmacology, it has long 
been assumed that they also share function and similar roles in the brain, despite being localized 
in different amounts in different localizations and cellular types. The overall decrease of 
glutamatergic excitability follows the reduction of presynaptic vesicle release caused by the 
inhibition of Ca2+ inward currents. Moreover, ligand-induced dissociation of the Gαi protein βγ 
subunit can signal through a wide array of second messengers, typically the mitogen-activated 
protein kinase (MAPK) and the extracellular signal-regulated protein kinases (ERK) pathways, 
mediated by the phosphatidylinositol 3 kinase (PI3K)241. This is a fundamental signaling route 
involved in critical cellular responses such as cell proliferation and transcription factors regulation. 
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The loss of function remains a pertinent strategy to decipher to study the role of a protein or a 
gene. As mGluR2 and mGluR3 being very close on many aspects, the use of knock-out animal 
models, or even double knock-outs, has provided important information about the precise 
functions of each receptor in the rodent brain. It offers a unique way to study such features, coping 
with the issue of non-selective agonists within the mGluRs group II. To that end, several studies 
have attempted to discern the specific role of mGluR2 over mGluR3 in pain242, cognition, arousal 
and anxiety239,243, and the circadian system244. With regards to circadian rhythm and sleep 
disruption, it is a comorbid symptom of schizophrenia, affecting 30-80% of patients245. When mice 
were depleted of both mGluR2 and mGluR3, their sleep was perturbed, reduced and fragmented, 
implicating group II mGluRs in sleep regulation244. It also suggests a possible link between the 
implication of both receptors in schizophrenia and such perturbations of fundamental 
physiology246. The above-mentioned mGluR2 agonists are used in clinical trial to test a new kind 
of antipsychotics or anxiolytic medications, among other targeted neuropsychiatric disorders. They 
were suggested to show reduced heavy side effects associated with atypical antipsychotics or 
benzodiazepines. Although there is to date no correlation between the GRM2 gene and 
schizophrenia, GRM3 abnormalities however have been detected multiple times in genome of 
patients suffering from this syndrome. 
mGlu2 receptor oligomerization 
As mentioned above, class C 7TMRs are obligate dimers though their function in signaling G 
protein is mitigate by their stoichiometry. They also form heterodimer within their class and across 
subtypes, including mGluR2/mGluR3 heterodimers240,247–249. 
Pathophysiology of the mGlu2 receptor 
Some authors have associated schizophrenic phenotype with mutations within mGlu receptor 
genes GRM2 and GRM3211. Altered dimerization of type 3 has been implicated in schizophrenia250. 
Structural and functional interactions have been reported for the mGluR2-5-HT2A 
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heterocomplex183,251–254. Both receptors, but especially mGluR2 has been the center of intense 
researches for its potential antipsychotic activity with potentially less side effects. 
Summary 
Given the number of matched regions expressing either 5-HT2AR, mGluR2 and mGluR3, there is 
a high probability that a single neuron expresses these receptors or receives input from one and 
expresses the second. Because their synaptic localization is also pre- and postsynaptic, as well 
as glial, (i.e. all membranes and soma of the tripartite synapse), it increases the probability for a 
functional role of the interaction formed by 5-HT2AR and mGluR2 or by mGluR2 and mGluR3 (or 
by 5-HT2AR and mGluR3 even if they do not seem to interact directly183). Together this information 
provides evidence and leads in the involvement of 5-HT2A and mGlu2 receptors, in participating in 
brain functions and their alterations. They co-distribute and colocalize, their antagonistic signaling 
is physiologically relevant and different from each other canonical signaling255–257. Moreover, the 
absence of one affects the behavioral effect of the other. All those criteria are consistent to the 
required properties necessitated by a receptor heteromer86. 
5-HT2A-mGlu2 receptor heterocomplex 
Those two receptors have been reported to play independently and then likely as a heterocomplex, 
significant roles in psychiatric disorders and especially schizophrenia183. As previously mentioned, 
the PFC represents the area of interest demonstrated by previous electrophysiological studies 
that suggested an antagonistic crosstalk125. In situ hybridization experiments reported that both 
receptors are co-transcribed in pyramidal neurons of mouse cortex and human PFC, where they 
co-immunoprecipitate and show close molecular and functional interactions revealed by B/FRET 
analyses coupled to functional assays, excluding 5-HT2A/mGluR3 assembling183,252. Electron 
microscopy by immunogold particles colocalization confirmed close proximity in ultrastructural 
resolution of pre- and post-synaptic elements252. Additionally, this interclass association 
modulates Gαq and Gαi pathways in an antagonistic and specific manner and support evidences 
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of heteromeric structures with physiological relevance67,69,70,251,254. The structure interface 
responsible for their heteromerization has been established by a mutation study of the TM4 of the 
glutamate receptor252. In follow up experiments, these findings have been corroborated using 
photocrosslinking assay, where the covalent linkage between the unnatural amino acids in the TM 
regions occurs within a distance of 2-4 Å89. 
7TMR trafficking and biosynthesis 
7TMRs are synthesized throughout the maturation pathway from ribosomal translation processes 
at the edge of the endoplasmic reticulum where they are folded and glycosylated, undergoing 
quality control checkpoints258. The Golgi apparatus constitutes the exit pathway as an active post-
translational element, finalizing 7TMR biosynthesis. This export process is highly regulated by 
cargo and scaffold proteins70,258. 7TMRs are described as actual signaling units when reaching 
the plasma membrane, but increasing evidence suggest signaling can occur from endosomes259. 
It is also of particular interest that 7TMR signaling may occur during their trafficking stages260. 
Although it is not the case for all of them, as β-arrestin-independent mechanisms have been 
described158,261–263, most 7TMRs undergo ligand-induced endocytosis through β-
arrestin/dynamin/clathrin-coated-pits interactions, a 7TMR core process. Among 7TMR 
subcellular trafficking regulators, the Ras-family small-GTPases Rab proteins are ubiquitous258,263. 
In particular, Rab5 regulates endocytic/early endosomal processes, Rab4 and Rab11 control rapid 
and slow recycling from recycling endosomes, Rab7 is a regulator of the late endosomes and the 
lysosomal degradation pathway taken by ubiquitylated proteins. Localized throughout specific 
intracellular stages, they can therefore serve as exploratory molecules to characterize GPCRs 
trafficking pathways. 
Rab proteins 
Navigating through the ultra-dense network of actin fibers and microtubules necessitates the 
guidance of proteins and cargoes to their appropriate destinations. These two last words suggest 
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specific recognition and trajectories taken by the cargoes. This is accomplished by a set of proteins 
counting around 60 subtypes: Rab proteins are small monomeric G proteins constituting the 
largest group of the Ras-like protein superfamily and hold a common GTPase activity. They 
orchestrate trafficking events between donor and target membranes. Each Rab protein is a 
resident of the organelle membrane they regulate, providing an identity to the subcellular 
compartment264. Organelles are also defined by specific scaffold proteins that anchor them to the 
cytoskeleton, but also by the lipid composition of their membrane layers. Rab1 interacts with the 
Golgi apparatus and the ER protein complexes each dedicated to their organelles functioning, to 
activate the environing SNAREs, and to “read” compartments scaffolds to facilitate transport in 
between the ER and the Golgi apparatus264. 
The duration the GTPase activation cycle is regulated by guanine nucleotide exchange factor 
(GEFs), who sustains the GDP/GTP exchange, and terminated by hydrolysis of GTP carried out 
by GTPase activating proteins (GAPs). Rab proteins partner with Arf family to interact with the cell 
cytoskeleton and in particular with the motor proteins that mediate the transportation of cargoes 
along the microtubule/actin networks, in both directions265,266. For instance, Rab7a promotes the 
trafficking of cargoes by recruiting the dynein/dynactin motor protein complex to the late 
endosomes, to direct the enriched vesicles toward the perinuclear areas267. Similarly, Rab5 binds 
to the early endosome antigen 1 protein (EEA1) to recruit the early endosome target, with 
concomitant association to PI3P. Rab5 also recruit membrane effectors that allow interaction with 
SNAREs for further engage membrane fusion268,269. 
Rab proteins, besides providing identity and mobility to their respective organelles, can interact 
with specific GEFs and GAPs of the next Rab protein, thus creating “Rab cascades” that will orient 
and organize transitions between compartments. In particular, it has been proposed that Rab7 is 
present on early Rab5 endosomes. Rab7 buds then grows on the Rab5 early endosome 
membrane and likely interacts with converter proteins. These proteins would turn off the recycling 
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properties of the sorting early endosomes (which are defined by Rab4 and Rab11), and convert it 
to a late endosome270. Rab5 is displaced and Rab7 is activated. Because effector protein GEF 
can recognize an increase in Rab5 and PIP3, this gives selectivity to the process. It is also 
coincident with the membrane recruitment, therefore allowing Rab5 displacement toward Rab7 at 
a specific time in a specific localtion271. This example demonstrates a mechanism that 
synchronizes protein trafficking in time and space.  
Considered as master regulators272, Rab proteins regulate vesicle sorting, docking, budding, 
tethering and membrane fusion. They define the secretory and the endocytic routes by interacting 
with specific components along these pathways. They also specify the microdomain occupied by 
the organelle they control, underneath the plasma membrane. Rab proteins also regulate the 
trafficking of 7TMRs, and it has been demonstrated that the basic four Rab proteins (4, 5, 7 and 
11) direct and orient internalization and recycling of several 7TMRs273. Following β-arrestin-
dependent desensitization after being internalize, 7TMRs follow multiple routes in accordance with 
their interacting Rab protein, effector, or β-arrestin type. Indeed, it has been shown that 7TMRs 
can follow two different arrestin-mediated pathways274. Following ligand-induced internalization, 
β2AR has been shown to traffic through Rab5 endosomes275. Overstimulation of Rab5 by 
expressing a dominant positive mutant affect β2AR trafficking through early endosomes. 
Conversely, dominant negative Rab5 impairs early trafficking of the receptor. This was also the 
case for the D2R, which is regulated by dynamin following phosphorylation by GRK2276. 
Interestingly, the class A angiotensin receptor 1A (AT1AR) has been shown to use both β-arrestin-
dependent and -independent pathways without being regulated by Rab5, although it is bound by 
the receptor. This suggests that Rab5 mediates different endocytic mechanisms277.  
Endosomes 
Endosomes are dynamic cytoplasmic vesicles acting as trafficking regulators and sorting platform. 
Their importance has generated much attention as targets for novel therapeutics278,279. They 
29 
 
provide the necessary space and means to regulate the trafficking, and identify not only the nature 
of the entrant and recycled particles, endocytosed receptors and lipids, but also a platform for 
receptor signaling, whether they come from the plasma membrane or from the secretory pathway. 
They appear poorly studied despite their critical role in protein trafficking, as well as in receptor 
signaling280.  
Usually categorized as early (EE), sorting (SE), recycling (RE), or late endosomes (LE), they adopt 
different shapes structured around the cytoskeleton with specific cellular functions. They can be 
ramified to tubular extensions (EE, multi-vesicular body MVB) or simply remain spherical-like, 
mostly depending on their function and associated motility, sustained over the microtubular 
network281. The pH gradient between the cytoplasm and the lumen of intracellular vesicles 
provides the differential ionic concentration that serves to dissociate the ligand from its receptor, 
the former often directed to degradation whereas the latter can either been rerouted to the plasma 
membrane or follows the same fate as its ligand282. The role of each endosome also depends on 
their localization underneath the plasma membrane, constituting functional microdomains. Their 
identity is determined by the combination of regulatory proteins and lipids that are unique to each 
specialized endosome283. 
A pH gradient spans through the cytoplasm from the plasma membrane to deeper compartments. 
The higher pH is found right under the plasma membrane, where early endosomes control the 
endocytic trafficking of newly endocytosed elements284 (recycling endosomes have a slightly 
higher pH). They are thought to constitute the first and only entry point of endocytosed 
proteins/lipids independently of the internalization mode, such as clathrin-mediated and lipid raft-
mediated endocytosis or pinocytosis, as well as the first recycling platform283,285. To that end, their 
structure consists in several cisternal areas associated with budding vesicles and thin tubular 
emanations (for a stunning visualization by electron microscopy of the EE structure see ref283). A 
complex association and interplay of specific resident proteins participate to endosomal transport, 
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morphology, sequestration, docking, etc.283. Among them, Rab5 and its effectors appears to be 
the main regulators that take on several functions such as spatial organization, docking affectation 
from either trans-Golgi or plasma membrane. Membrane budding, fission and interaction with the 
cytoskeletal components are also among Rab5 attributes (see above)268,286,287. 
The model describing the compartmentalization of endosomes has been proposed by early 
studies that investigated fluorescent markers routing and chased their cellular destination and 
trafficking in a timely manner, usually depicting a common network of specialized vesicles as a 
general trafficking model288. Although it was assumed that integral proteins, ion channels and 
receptors underwent at least two types of internalization processes, degradation or recycling, the 
putative motion of different membrane-based vesicles was described as a bulk flow process, 
without specificity288. This model has been refined to the point that there is no longer such a bulk 
flow of membranes that fusion and interact, but rather a complex interplay orchestrated by 
specialized proteins and adaptors along endosomal-mediated tubular networks289, sorting motifs 
attached to internalized cargoes that orient their route according to the cell needs290. 
EE provide both fast and slow recycling pathways285, though evidence suggested that LE can also 
recycle cargoes. Lumen pH is lower in LE, which link endocytosed cargoes to degradation 
pathway through EE sorting284,291. Within the EE or the LE, cargoes routed to the recycling pathway 
should avoid inclusion in intermediate degradative vesicles (intraluminal vesicles) to be able to 
reach back to the plasma membrane, either by the slow or the fast recycling routes290. Thus, LE, 
also identified to MVB, function as sorting dispatchers290. 
A major shift in envisioning receptor signaling was provided by findings in regard to intracellular 
signaling, and more precisely, on signaling from endosomes. Receptor endocytosis has been 
studied as a termination mechanism to regulate available receptor density at the cell surface and 
mitigate cell responsiveness following agonist stimulation. Receptor desensitization and 
resensitization are not general mechanisms that all 7TMRs undergo. Although β-arrestin-
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dependent internalization of clathrin-coated pits and adapter protein-2 complex (AP-2), in 
response to GRK-mediated receptor phosphorylation, plays a major role in 7TMR internalization, 
besides being the most well characterized system, some receptor types are recycled, some are 
not and get degradated292. Recycling endosomes employs several Rab proteins (Rab5, 4, and 11) 
while late endosomes are often related to degradation pathways and mostly regulated by Rab7 
(and Rab9). The early or sorting endosome is the first encountered container of most internalized 
proteins and lipids285. 
Together, this information suggests that the endosomal network is finely regulated by resident and 
adaptor proteins, and that, together with the architecture of the specified endosomes, produces 
subcellular microdomains composed by the vesicles tubular extensions over the actin/microtubule 
skeleton293. Each microdomain, regulated by a specific Rab protein, serves as orientation 
platforms to either degrade or recycle cargoes that are either endocytosed or synthetized. 
Schizophrenia 
Schizophrenia, or schizophrenia spectrum disorder (or syndrome), is a serious multifactorial 
mental illness affecting up to 0.65% of the USA population and 20 million people worldwide294 (up 
to 0.75%), with chronic, and in great majority, life-lasting social, emotional and cognitive 
alterations. Clinical symptoms are often grouped as so-called negative, positive, and 
cognitive295,296. Studies and definitions converge to acknowledge that a combination of genetic 
susceptibilities and harmful environmental factors participate to its etiology, which remains 
unknown. Nonetheless, despite a raise in the prevalence of brain disorders and consequent 
increase economic and social burden297–300, where schizophrenia costs are disproportionately 
high301, pharmacological companies have halted avenues of research for claimed financial 
reasons302–308, creating a gap between a steady clinical and fundamental research and the 
availability of commercialized medications. 
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The classical hypothesis of dopaminergic hyperactivity gained attention since the antipsychotic 
activity of several commercialized dopamine receptor (DR) antagonists (typical) would correct 
some of the positive symptoms, especially delusions and hallucinations. The dopamine hypothesis 
suggests that there is an imbalance of the dopaminergic tone in the prefrontal cortex that can be 
rectified by treatment with D2R antagonists, such as chlorpromazine, pioneer molecule to treat 
positive symptoms309. Compared to the first generation antipsychotics (the typical D2R/D3R 
antagonists), atypical antipsychotics (AAP) have more affinity for the 5-HT2AR. Similarly, such 
pharmacological evidence fashioned the serotonin hypothesis, also based on the resemblance 
between serotonin receptor agonists that produce psychosis-like effects on humans. These 
molecules exhibit substantial off target occupancy and are considered as “dirty drugs with rich 
pharmacology”310, carrying at the same time, important side effects. They are yet prescribed as 
first line compounds to treat schizophrenia’s positive symptoms, with moderate improvements of 
negative and cognitive ones. A third of subjects do not respond to AAP311,312. Although the classical 
theories on the onset and the etiology of the disorder remain up to date, the scope has yet evolved 
toward other signaling pathways such as glutamate and GABA;  the implication of a combination 
of neurotransmitter systems rather than a single defective gene or pathway could shed light on 
the disorder origin and mechansims309,313,314. Indeed, recent findings propose that a 
heterogeneous genetic network causes distinct clinical syndromes315, as conveyed by years of 
research on the implication of several genes that regulate and express 7TMRs, receptor trafficking 
and neurotransmission, synaptic and structural plasticity316–320. 
The variability of symptoms combined to the diversity of phenotypes resulting from clinical and 
genetic observations conflict with a single disease paradigm, thus single medication are unlikely 
to treat the full spectrum that characterize the disorder321. The absence of a uniform syndrome 
renders difficult the delivery of accurate, specific and reproducible diagnostics322–325, which also 
rely on definitions and clinical practices326. For instance, some criteria can overlap with those of 
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bipolar disorder327 that may affect drug indication and assistance to patients328,329, who eventually 
cope with long term/life lasting treatments, if they find access to them295,296.  
It is nowadays a common concern as to challenge the single disease paradigm297,330, i.e. embrace 
several theories about the disorder to provide novel and more efficient medications. This was the 
case for atypical antipsychotics, who have affinity for both 5-HT2AR and D2R, and together increase 
the beneficial effects on the disorder process and evolution, rather than just on symptoms311,331–
333. The glutamatergic system has also gained in importance with the findings related to altered 
NMDAR-mediated glutamatergic neurotransmission, signaling and trafficking. NMDAR 
dysfunction on GABAergic neurons implicate a hyperglutamatergic stimulation responsible for 
cognitive impairments and other deleterious effects found in schizophrenia. Agonizing the 
mGluR/2/3 pathway potentially rectifies the glutamatergic overstimulation by reducing the 
presynaptic release of glutamate on excitatory neurons, as a compensatory mechanism233. Those 
agonists have been found to relieve all 3 symptoms type in patient with schizophrenia334. It was 
believed that such molecules held a novel and promising mechanism of action that could be 
beneficial to patients226,233. 
Hypothesis 
Investigations in post-mortem schizophrenic prefrontal cortexes suggested that 5-HT2AR specific 
binding is increased yet rectified in treated subjects with AAPs. However, mGluR2 remained 
downregulated in both untreated and treated schizophrenic subjects. We thus hypothesize that 
biosynthesis and endocytosis of interacting 5-HT2AR and mGluR2 may play a role in their common 
and linked dysregulation. Trafficking and signaling being entangled, endocytosis and biosynthesis 
of 7TMR complexes control their cellular localization in time and space. Conversely, trafficking 
failure implies signaling impairments, which eventually result in a host of pathologies. The 
objective of the following study is to elucidate in in vitro and ex vivo models, the maturation and 
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the ligand-dependent trafficking mechanisms regulating the 5-HT2AR-mGluR2 signaling complex 
to further explicit the effect of their imbalance in schizophrenia. 
Aims 
Aim 1: 5-HT2AR modulates mGluR2 post-endocytic sorting. Hypothesis: Pharmacological 
modulation of 5-HT2AR affects mGluR2 sorting and function through Rab-mediated trafficking 
pathways. 
Aim 2: Effects of 5-HT2AR antagonists/inverse agonists (antipsychotic) and hallucinogenic 
agonists (propsychotic) on 5-HT2AR-mediated trafficking of mGluR2. Hypotheses: 5-HT2AR 
and mGluR2 heterocomplex is affected by clozapine, as well as mGluR2 trafficking. Psychedelic 
agents promote Rab5-dependent pathway of mGluR2, while non-psychedelic agents do not. 
Aim 3: 5-HT2AR and mGluR2 are assembled as a GPCR complex in the biosynthetic 
pathway. Hypothesis: 5-HT2AR and mGluR2 structurally associate in the biosynthetic pathway. 




Materials and Methods 
Drugs 
(±)-2,5-Dimethoxy-4-iodoamphetamine hydrochloride (DOI), 5-hydroxytrytamine hydrochloride (5-
HT; serotonin), Lysergic acid diethylamide (LSD), Ergotamine, GDP, and GTPγS were purchased 
from Sigma-Aldrich. (1R,4R,5S,6R)-4-Amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 
(LY379268), (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid 
(LY341495), clozapine, (R)-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-
piperinemethanol (M100907; MDL 100,907; volinanserin), 3-[2-[4-(4-fluorobenzoyl)-1-
piperidinyl]ethyl]-2,3-dihydro-2-thioxo-4(1H)-quinazolinone hydrochloride (altanserin), L-glutamic 
acid, 3-hydroxynaphthalene-2-carboxylic acid (3,4-dihydroxybenzylidene)hydrazide (dynasore), 
[8β(S)]-9,10-didehydro-N-[1-(hydroxymethyl)propyl]-1,6-dimethylergoline-8-carboxamide maleate 
(methysergide) and Lisuride were purchased from Tocris Bioscience. [3H]Ketanserin and 
[35S]GTPγS were obtained from PerkinElmer Life and Analytical Sciences. [3H]LY341495 was 
purchased from American Radiolabeled Chemicals. All other chemicals were obtained from 
standard vendors.  
Plasmid Construction 
All PCR assays were performed with PfuUltra Hotstart Polymerase (Stratagene) in a Mastercycler 
Ep Gradient Auto thermal cycler (Eppendorf). Cycling conditions were 30 cycles of 94C for 30 s, 
55C for 30 s, and 72C for 1 min/kb of amplicon, with an initial denaturation/activation step at 
94C for 2 min and a final extension step of 72C for 7 min. All the constructs were confirmed by 
DNA sequencing. The following constructs have been previously described183,251,252: human 5-
HT2AR N-terminally tagged with the c-Myc epitope (pcDNA3.1-c-Myc-5-HT2AR), human 5-HT2AR 
N-terminally tagged with the c-Myc epitope and C-terminally tagged with enhanced cyan 
fluorescent protein (pcDNA3.1-c-Myc-5-HT2AR-eCFP), human 5-HT2AR N-terminally tagged with 
the c-Myc epitope and C-terminally tagged with mCitrine (pcDNA3.1-c-Myc-5-HT2AR-mCitrine), 
human 5-HT2AR N-terminally tagged with the c-Myc epitope and C-terminally tagged with mCherry 
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(pcDNA3.1-c-Myc-5-HT2AR-mCherry), human 5-HT2AR N-terminally tagged with the c-Myc epitope 
and C-terminally tagged with eYFP (pcDNA3.1-c-Myc 5-HT2AR-eYFP), human mGluR2 C-
terminally tagged with eYFP (pcDNA3.1-mGluR2-eYFP), human mGluR2 C-terminally tagged with 
eCFP (pcDNA3.1-mGluR2-eCFP), human mGluR3 C-terminally tagged with eYFP (pcDNA3.1-
mGluR3-eYFP), human mGluR2 with substitution of residues A6774.40, A6814.44 and A6854.48 in 
mGluR2 for S6864.40, F6904.44 and G6944.48 in mGluR3 C-terminally tagged with eYFP (pcDNA3.1-
mGluR2TM4; formerly named pcDNA3.1-mGluR2TM4N). The construct 5-HT2AR-eCFP was 
subcloned into the vector pcDNA5/FRT/TO (Invitrogen) for the subsequent generation of Flp-In T-
REx HEK293 cells, as we have previously reported335. For BiFC studies, constructs were 
generated by subcloning the sequence encoding the N-terminal 172-amino acid fragment (mCi-
N172) or the C-terminal 67 amino acid fragment of mCitrine (mCi-C76), as we have previously 
described [see 40]. The constructs pcDNA3.1-mCi-N172, pcDNA3.1-mCi-C67, pcDNA3.1-
mGluR2-mCi-N172 and pcDNA3.1-mGluR2-mCi-C67 have been previously described251. The 
form of 5-HT2AR C-terminally tagged with eCFP was digested with NheI and BamHI and subcloned 
into the same restriction sites of pcDNA3.1-mCi-N172 and pcDNA3.1-mCi-C67 to generate 
pcDNA3.1-5-HT2AR-mCi-N172 and pcDNA3.1-5-HT2AR-mCi-C67. The chimeric Gα protein Gαqi9 
has been previously reported336. FRET calibration was performed on parental HEK293 cells 
transfected with either pcDNA3.1-eCFP, pcDNA3.1-eYFP, or the tandem plasmid pcDNA3.1-
eCFP-eYFP. 
Transient Transfection of HEK293 cells 
Human embryonic kidney (HEK293) cells (ATCC: CRL-1573) were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% (v/v) dialyzed fetal bovine serum 
(dFBS) and 1% penicillin/streptomycin (Gibco) in a 5% CO2 humidified atmosphere. Transfection 





Generation of Stable Flp-In T-REx HEK293 cell lines 
Generation Flp-In T-REx HEK293 cells expressing c-Myc-5-HT2AR-eCFP in an inducible manner 
was preformed following standard protocols337. Briefly, Flp-In T-REx HEK293 cells were 
transfected with a mixture containing either c-Myc-5-HT2AR-eCFP cDNA in the pcDNA5/FRT/TO 
vector and pOG44 vector (1:9) using Lipofectamine 2000 reagent (Invitrogen), according to the 
manufacturer’s instructions. When cotransfected with the pcDNA5/FRT/TO plasmid into the Flp-
In mammalian host cell line, the Flp recombinase expressed from pOG44 mediates integration of 
the pcDNA5/FRT/TO vector containing the gene of interest into the genome through Flp 
recombination target (FRT) sites. Clones resistant to blasticidin (5.0 µg/ml; InvivoGen) and 
hygromycin (2.2 µg/ml; InvivoGen) and expressing the Tet repressor (tetR) along with the inserted 
c-Myc-5-HT2AR-eCFP at the FRT site were screened for eCFP expression by standard 
fluorescence microscopy protocols.  
Double stable cell lines expressing mGluR2-eYFP, mGluR3-eYFP or mGluR2TM4 constitutively 
and 5-HT2AR-eCFP in an inducible manner were generated from the Flp-In T-REx HEK293 cells 
described above. Cells were transfected using Lipofectamine 2000 reagent (Invitrogen) with the 
vectors containing mGluR2-eYFP, mGluR3-eYFP or mGluR2TM4. Following transfection, cells 
were selected for resistance to Geneticin (1 mg/ml; Invitrogen), and the resistant clones were 
screened for receptor expression by standard fluorescence microscopy. Flp-In T-REx HEK293 
cells stably expressing -opioid receptor tagged with eYFP and able to express c-Myc-5-HT2AR-
eCFP in an inducible manner have previously been described335. To induce expression of 5-
HT2AR-eCFP, cells were treated with doxycycline (DOX) (1.0 µg/ml; 24 – 48 h). Dialyzed FBS was 
used for cell growth to avoid activation of 5-HT2AR by 5-HT that is routinely present in serum.  
Mice 
5-HT2AR knockout (Htr2a
-/-) mice of 129S6/Sv background have previously been described140. For 
experiments involving 5-HT2AR
-/- mice, wild-type (5-HT2AR
+/+) littermates on a 129S6/Sv 
background were used as controls. Animals were housed at 12 h light/dark cycle at 23C with food 
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and water ad libitum. The Institutional Animal Use and Care Committee at Virginia Commonwealth 
University School of Medicine approved all the experimental procedures.  
Cortical primary cultures 
Fetuses (E17-18.5) from pregnant mothers were removed using aseptic techniques. Cortical 
primary cultures were performed as previously reported140. Cells were maintained for 7 days in 
vitro before use in experiments.  
Immunocytochemistry 
In HEK293 cells or mouse cortical primary cultures, immunocytochemical assays were performed 
as previously reported with minor modifications183,251,252. Briefly, cells were fixed with 4% 
paraformaldehyde (Sigma) supplemented with 100 μM CaCl2 and 100 μM MgCl2 for 10 min at 
room temperature, rinsed with PBS, and washed twice with PBS supplemented with 20 mM 
glycine. Coverslips were incubated with 0.2% Triton X-100 for 10 min at room temperature and 
incubated in the dark for 60 min with PBS containing 5% donkey or goat serum (according to the 
secondary antibody). Primary antibody was added (40 µl on each coverslip) and incubated 
overnight at 4C. Primary antibodies used were rabbit anti-c-Myc (Cell Signaling Technology 
catalog no. 2272; diluted at 1:250), mouse anti-mGluR2 (Abcam catalog no. 15672; diluted at 6.5 
µg/ml), goat anti-Rab5 (SICGEN catalog no. ab1024; diluted at 6.5 µg/ml [HEK293 cells] or 5.0 
µg/ml [primary neurons]), rabbit anti-Rab7 (Cell Signaling Technology catalog no. 9367; diluted at 
1:100), or rabbit anti-GFP (Invitrogen catalog no. A11122; diluted at 1:500) After washing with 
PBS, cells were incubated for 60 min at room temperature in the dark with the secondary 
antibodies Alexa Fluor 488-conjugated goat anti-rabbit (Invitrogen catalog no. A11011; dilution 
1:1000), Alexa Fluor 568 conjugated goat anti-rabbit (Invitrogen catalog no. A11004; dilution 
1:1000), Alexa Fluor 568-conjugated donkey anti-goat (Invitrogen catalog no. A11057; dilution 
1:1000), or Dylight 650-conjugated donkey anti-mouse (Thermofisher catalog no. SA5-10169 
[primary neurons]). For the maturation pathway: ER-Tracker Red (ER-Tr) dying protocol fits mostly 
manufacturer’s recommendations (Thermofisher). Concentration was adjusted to 0.5µM of dye in 
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pre-heated HBSS (Gibco), cells were incubated for 20 minutes in the same conditions as above 
then fixed with 3% PFA during 2 minutes. For Golgi experiments, fixed cells were permeabilized 
in a 0.2% Triton X-100/PBS solution then disposed in a PBS/3%FBS/1%BSA blocking solution. 
Coverslips were then incubated for 60 minutes with 5µg/mL mouse anti-58K primary antibody 
(Abcam), followed by 50 minutes in 0.5µg/mL conjugated AlexaFluor568 goat anti-mouse IgG 
secondary antibody (Invitrogen). Nuclei were stained (5 min) with Hoechst 33342 
(ThermoScientific). After washing (PBS, 6  5 min), the coverslips were mounted on glass slides 
with Prolong Diamond Antifade Mountant (ThermoFisher). 
Confocal microscopy 
Fixed cells and living cells were visualized on a Carl Zeiss Axio Observer LSM 710 laser scanning 
confocal microscope (LSCM) with a Plan-Apochromat 63/1.40 Oil DIC M27 or 40 Cal objective. 
Hoechst 33342 was excited by a 405 nm blue diode, and eCFP with a 440 nm laser-pulse. 
Additionally, 488 nm and 514 nm multi-line Argon lasers were used to excite Alexa Fluor 488, 
mCitrine and eYFP, respectively, whereas a 561 nm green diode laser was used to excite mCherry 
and Alexa Fluor 568. Finally, DyLight 650 was excited with a 633 nm HeNe laser line. Emission 
signals were acquired in the same order using the following Main Beam Splitter/Dichroic Beam 
Splitter (MBS/DBS) and emission filters (EF) sets: InVis 405/Mirror EF: 410-482nm, InVis 
445/Mirror EF: 435-480 nm, 488/Mirror EF: 494-523 nm, 458/514/Mirror EF: 523-543 nm, and 
458/561/633/Mirror EF: 591-661 (mCherry) 573-620 (AF568) 654-700 (DyLight650). Pinhole was 
kept constant and adjusted at 1 airy unit. Living cells (cell cloning) were visualized on a Carl Zeiss 
Cell Axio Observer Z1 spinning disc confocal microscope (SDCM) with an embedded Yokogawa 
CSU-X1 spinning disc and a C-Apochromat 63/1.20 W Korr UV-Vis-IR objective. Illumination 
sources were a 458 nm and 514 nm (multi-Ar) laser for eCFP and eYFP, respectively. Emission 
filters (SD mirror + bypass filters BP) were RTFT457/514/647 + BP485/30 (eCFP) and 
40 
 
RQFF405/488/568/647 + BP525/50 (eYFP). During image acquisition, cells were maintained at 
37°C and 5% CO2 atmosphere by an incubation system. 
Immunoblot Assays 
Western blot experiments were performed as previously reported252, using rabbit anti-c-Myc (Cell 
Signaling, catalog no. 2272; diluted at 1:400) and rabbit anti--actin (Abcam catalog no. 8227; 
diluted at 0.33 µg/ml). 
TAT-fused transmembrane domain interference peptides 
Peptides derived from human mGluR2 TM4 and TM1 were custom synthesized (Genemed 
Synthesis, Inc.). TAT (trans-activating transcriptional activator from human immunodeficiency 
virus; YGRKKRRQRRR) was fused to the N-terminus of the human mGluR2 TM4 
(YGRKKRRQRRRSPASQVAICLALISGQLLIVVAWLVVE) and TM1 (AWAVGPVTIACLGALA- 
TLFVLGVFVRHYGRKKRRQRRR) to obtain the correct orientation for the inserted peptide 
because TAT binds to phosphatidylinosityol-(4,5)-biphosphate found on the inner surface of the 
membrane338. TAT-labelled 38-mer peptide was used as an internal control (YGRKKRRQRRR-
VIAPLYTSCVNWQIF-VISMYRGARVAI). Stock solutions of the TAT-tagged peptides (5.2 mM) 
were prepared in DMSO supplemented with glacial acetic acid (1.93%). For FRET assays, cells 
were incubated with TAT-tagged peptides (10 µM, final concentration) for 60 min (DMSO’s final 
concentration = 0.18%). For studies involving receptor agonists, TAT-tagged peptides were added 
5 minutes before DOI or LY379269, or vehicle administration. For studies involving overnight 
treatment with clozapine, TAT-tagged peptides were added both 5 minutes before clozapine or 
vehicle administration and 65 minutes before cell fixation.  
Proximity Ligation Assay 
Heteromers of c-Myc-5-HT2AR-eCFP and mGluR2-eYFP were detected using the Duolink In Situ 
PLA Detection Reagents Red technology kit (Sigma-Aldrich). Briefly, coverslips with fixed cells 
were incubated with 0.1% Triton X-100 for 10 min at room temperature then in blocking solution 
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according to manufacturer’s instructions. Cells were incubated overnight at 4°C with a mixture of 
the primary antibodies (rabbit anti-c-Myc [Cell Signaling Technology, catalog no. 2272; 1:250], 
and mouse anti-mGluR2 [Abcam, catalog no. 15672; 1:200]). Samples were incubated with 
Duolink In Situ PLA Probe Anti-Rabbit PLUS Affinity purified Donkey anti-Rabbit IgG and Duolink 
In Situ PLA Probe Anti-Mouse MINUS Affinity purified Donkey anti-Mouse IgG. Samples were 
processed for ligation and amplification and were mounted onto glass slides with Prolong Diamond 
Mountant. Z-stack images were acquired in a Carl Zeiss Axio Observer LSM 710 laser scanning 
confocal microscope with a Plan-Apochromat 63/1.40 Oil DIC M27 objective (to obtain a 
representative image) or 40 Cal objective (for quantification purposes). For each field of view, a 
stack of three channels (one per staining) was obtained. Images were processed with Fiji software 
version 2.0.0 (National Institutes of Health, Bethesda, MD). To quantify PLA signal, PLA-red 
channel remained hidden during cell identification process. Automated counting involved selection 
and cropping of each region of interest, Z-Stack projection of the PLA channel, subtraction of 
background with a rolling ball radius of 20 pixels and finding maxima with a noise tolerance value 
of 6000–10000 depending on the experiment and the background. 
Radioligand binding assays 
[3H]Ketanserin, [3H]LY341495 and [35S]GTPS binding assays were performed as previously 
reported183,251,252. The stoichiometry of 5-HT2AR density (as assessed by [3H]ketanserin binding) 
and mGluR2 density (as assessed by [3H]LY341495 binding) is similar to that previously observed 
in native tissue, such as mouse frontal cortex and postmortem human frontal cortex183,251,252 and 
in cross-talk positive clones254. 
[Ca2+]i Mobilization assays 
Two days before the assay, cells were plated onto poly-D-lysine coated 96-well plates (Greiner 
Bio-One GmbH) and, 48 hours later, treated with doxycycline (1 µM) for 40 h. Cells were washed 
with DPBS and loaded with 3 µM Fura 2-AM (Molecular Probes) in imaging solution (5 mM KCl, 
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0.4 mM KH2PO4, 138 mM NaCl, 0.3 mM Na2HPO4, 2 mM CaCl2, 1 mM MgCl2, 6 mM glucose, 20 
mM HEPES, pH 7.4) supplemented with pluronic acid (20% solution in DMSO). After incubation 
for 30 min at 37°C, cells were washed twice with washing buffer before being placed on the 
FlexStation 3 microplate reader (Molecular Devices). The Fura-2 signal was acquired at 510 nm 
by switching the excitation wavelength between 340/380 nm. Intracellular calcium concentration 
was expressed as a 340/380 nm ratio, and values were normalized to the basal 340/380 nm ratio 
recorded during 30 seconds before perfusion of the drug using Softmax Pro (Molecular Devices). 
To allow efficient coupling of Gi/o-coupled mGluRs to the PLC pathway, cells were also 
transfected with the chimeric G protein Gqi9336. Concentrations of LY379268 were selected 
based on our previous findings251. Thus, activation of the canonical Gi/o protein-dependent 
pathway was tested in the presence of LY379268 (0.1 µM), but trans-activation of the Gq/11 
protein-dependent pathway was tested in the presence of LY379268 (10 µM and 100 µM).  
Flow cytometry and immunofluorescence 
Cells were treated with for 60 min with either DOI (1 µM), LY379268 (10 µM), or vehicle, or 
(overnight) with clozapine (10 µM) M100907 (10 µM) or vehicle. Cells were trypsinized, washed 
with PBS, filtered through filter top tubes (35 µm), resuspended in PBS supplemented with 1% 
FBS, and analyzed using a LSRFortessa X-20 Flow cytometer (BD Bioscience). eCFP and eYFP 
were excited with a 405 nm and a 488 nm laser line, respectively. Emission filters were 525/50 
and YFP-A. Quantification was carried out using FCS Express v.5 (De Novo Software). Mean 
intensity values were determined by gating 25.5% or more of the total cell population. Imaging 
flow cytometry (Amnis ImageStreamX) to measure colocalization of mGluR2 or 5-HT2AR with the 
transferrin receptor at the single cell level was performed as previously reported, using an Amnis 
ImageStream flow cytometer254. Cells were considered to present a colocalized signal between 
the receptor constructs and transferrin receptor when their Bright Detail Similarity score was 
greater than 2. To detect cell surface receptors, cells were treated with DOI, LY379268 or vehicle 
43 
 
(60-min treatment), or with clozapine, M100907 or vehicle (overnight treatment). Cells were 
washed with ice-cold imaging buffer (PBS supplemented with 10% FBS) and incubated with 
human mGluR2 Alexa Fluor 647-conjugated antibody (R&D Systems, catalog no. IC4676R; 1:40) 
for 60 min on ice (~11-13°C). After two washes with ice-cold imaging buffer, cells were 
resuspended in ice-cold imaging buffer and loaded into the flow cytometer. 405 nm, 488 nm and 
640 nm lasers were used to excite eCFP, eYFP and AF647, respectively. Data were subsequently 
gated and analyzed using the FCS Express 5 software. For the maturation pathway: IFC assays 
were performed on the Amnis ImageStreamX Mark II flow cytometer (IS). Prior to analysis, probe-
free cells and single color channels controls were made in order to evaluate background 
autofluorescence and to set the compensation matrix parameters required to separate spectral 
overlap of fluorescent probes. For BiFC experiments, cells were transfected 24h before 
experiment on 10 cm plates using scaled up DNA/PEI concentrations. mCitrine and ER-Tr were 
illuminated with a 488 nm and a 561 nm lasers respectively. In-focused cells were acquired with 
a 60x objective and gated by gradients MAX and RMS controlling bright field focus quality, then 
proceeded to similarity analysis. The figure herein displays 
an example of negative control performed on the 5-HT2AR 
BiFC. Cells populations were gated by calculating the 
maximal threshold rendered from irrelevant colocalization 
of each channel with the bright field (>1.5) in ImageStream 
Data Exploration and Analysis Software (IDEAS). The BDS 
score is then determined and set to gate and identify highly colocalized populations254. BDS is a 
log-transformed Pearson Correlation Coefficient. 
SensorFRET 
SensorFRET assays were performed as previously reported339. Briefly, the fluorophores 
associated with uneven expression levels between the donor and acceptor. The fluorophores used 


























Population Count %Gated Median Minimum Maximum
 Colocalized & Focus  89  100  1.009  0.3372  1.524



























Population Count %Gated Median Minimum Maximum
 Colocalized & Focus  89  100  0.8335  0.4356  1.312
 Threshold_ER-Tr_BF & Coloc...  0  0  NaN  NaN  NaN
Colocalized 2AN-2AC_ER-Tr Colocalized 2AN-2AC_ER-Tr 
BDS_ trine_BF BDS_ER- r_BF 
Nomalized requency Nomalized requency 
Figure A: Representative IS histograms 
displaying negative controls to set the 
BDS score. BDS is gated by the max point 
defined by cells population, colocalizing each 
probes with the bright field. 
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0.40 and 0.61, respectively340. This approach also requires knowledge of the fluorophore emission 
shapes (for linear unmixing of the spectra) as well as the relative molar extinction coefficients for 
the fluorophores at each excitation frequency (characterized by the  parameter). The normalized 
emission shapes of both fluorophores as well as the autofluorescence at each excitation frequency 
were determined experimentally. The γ calibration term was also determined experimentally ( = 
0.114), following a previously described procedure339. Imaging was carried out using a Zeiss 710 
confocal LSM at 405nm and 458 nm excitation frequencies and a 32-channel spectral detector 
spanning an emission range of 416nm to 718nm. In unfixed cells, short acquisition times (~ 600 
ms) were necessary to minimize the shift due to vesicle movement during the time needed to 
acquire images at both excitation wavelengths. For assays involving TAT-tagged peptides, cells 
were briefly fixed with PFA (1%) for 5 min to avoid background caused by PFA fixation. A minimum 
of 30 cells were imaged for each experimental group. For the statistical analysis, the measured 
FRET efficiency of each vesicle was considered a single observation. Strict masking was carried 
out to include vesicles that met three criteria. First, only vesicles which remained stationary 
between the 405 and 458 nm images were included because even at short acquisition times, some 
population of vesicles showed appreciable movement. Second, only vesicles with a donor to 
acceptor stoichiometry within the range of 1:10 to 1:1 were included because the sensorFRET 
approach is not applicable when there are excess donor fluorophores339. Thus, below a 1:10 ratio 
the donor signal is so small that it is difficult to reliably distinguish it from auto fluorescence and 
noise. The stoichiometry was estimated by comparing the ratio of the donor and acceptor direct 
excitation in experimental vesicles to a unimolecular construct (both CFP and YFP are encoded 
as part of the same protein) where the stoichiometry is known to be 1:1. Marks were drawn only 
over pixels that showed colocalized eCFP and eYFP signal from both 405 nm and 458 nm images. 
Finally, only vesicles consisting of greater than 5 pixels were included so that mis-localization of 
proteins to small non-vesicle features was excluded, allowing each vesicle observation to be the 




Electron microscopy assays were carried out as previously reported with minor modifications252. 
Briefly, four male mice (8 – 12 weeks old) per genotype were deeply anesthetized and perfused 
transcardially with 2% dextran (MW 70,000) in 0.1 M phosphate buffer (PB, pH 7.4), and then with 
a mixture of 4% paraformaldehyde and 0.125% glutaraldehyde in phosphate buffered saline 
(PBS). Brains were removed and post-fixed in the same perfusate overnight at 4°C. Approximately 
0.5-mm-thick coronal slices were dissected from the regions of interest. Tissue blocks through 
superficial layers of prefrontal cortex were embedded in Lowicryl HM20 resin (Electron Microscopy 
Sciences, Fort Washington, PA) by freeze substitution and low-temperature embedding of the 
specimens using methods previously described341–343. Briefly, slices were cryoprotected by 
immersion in 4% D-glucose, followed with increasing concentrations of glycerol (from 10% to 30% 
PB). Sections were plunged rapidly into liquid propane cooled by liquid nitrogen (−190°C) in a 
Universal Cryofixation System KF80 (Reichert-Jung, Vienna, Austria). The samples were 
immersed in 0.5% uranyl acetate dissolved in anhydrous methanol (−90°C, 24 h) in a 
cryosubstitution AFS unit (Leica, Vienna, Austria). The temperature was raised from −90°C to 
−45°C in steps of 4°C/h. After washing with anhydrous methanol, the samples were infiltrated with 
Lowicryl HM20 resin at −45°C. Polymerization with ultraviolet light (360 nm) was performed for 48 
h at −45°C, followed by 24 h at 0°C. Ultrathin sections (80 nm) were cut using a diamond knife on 
a Leica UC7 ultramicrotome, and mounted on 300 mesh nickel grids (EMS) coated using a Coat-
Quick adhesive pen (EMS). Grids with sections were incubated in 0.1% sodium borohydride and 
50 mM glycine for 6 minutes at room temperature, washed and incubated for 10 min in Tris-
buffered saline with 0.1% Triton X-100 (TBST) containing 2% albumin. For immunolabeling, 
sections were incubated overnight in primary anti-mGluR2 antibody (Abcam, mouse monoclonal 
antibody catalog no. 15672, 10 µg/ml) in the same diluent as above, washed with TBST, and 
incubated with secondary anti-goat 10 nm gold-tagged antibody (EMS; 1:20) in TBST (2% albumin 
and polyethyleneglycol 20,000; 5 mg/ml) for two hours, washed and counter-stained with 1% 
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uranyl acetate (aq.). The specificity of the primary antibody against mGluR2 was previously 
confirmed in experiments with knockout mice252. Grids were viewed on a Hitachi 7000 
transmission electron microscope and imaged at a final captured image magnification of 130K. 
Imaging concentrated on deep layer 2-3 of the prefrontal cortex. Excitatory (asymmetric) 
glutamatergic synapses were identified by the presence of a thickened postsynaptic density, 
synaptic cleft, and clusters of round presynaptic vesicles344. A synapse was scored as 
immunolabel-positive if it contained at least 3 gold particles in the synaptic compartments 
described above, and 25-35 labeled synapses were imaged per animal/group. Overall, ~90% of 
labeled synapses showed gold particles associated within the postsynaptic element, though a 
small population of synapses contained gold particles limited to its presynaptic compartment. Gold 
particle distribution with respect to plasmalemma was scored for each postsynaptic site as 
membrane only, intracellular only, or both. Membrane labelling was defined by gold particles falling 
within 25 n of the plasmalemma (a distance defined by the approximate size of the primary and 
secondary antibodies).  
Data acquisition and statistical analysis 
Statistical analysis was performed with a GraphPad Prism software version 8. 
Immunocytochemical assays were acquired using confocal fluorescence microscopy at identical 
settings for each of the experimental conditions. For colocalization assays, raw 16-bit image files 
(.czi) were imported into the Carl Zeiss ZEN software (Black version) and/or Fiji version 2.0.0 with 
Coloc 2 plugin. To assess colocalization, Pearson’s and/or Manders’ coefficients were calculated 
because these colocalization coefficients are based on pixel-intensity-correlation measurement 
and do not include object-recognition approaches. Pearson’s coefficient, which ranges from +1 
(total positive linear correlation) to -1 (total negative correlation; 0 defines absence of linear 
correlation) is sensitive to both signal cooccurrence and the more rigorous condition of signal 
correlation (pixel-for-pixel proportionality in the signal levels of the two channels). However, unlike 
Pearson’s correlation coefficient, Manders’ fractional overlap coefficients (M1 and M2), which 
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measure the fraction of a probe in a probe-tagged compartment and range from 0 (no overlap) to 
1 (perfect overlap), strictly measures co-occurrence independent of signal proportionality345,346. 
Colocalization of two fluorescently labelled 7TMR constructs (5-HT2AR-eCFP and mGluR2-eYFP) 
was assessed both by Manders’ and Pearson’s coefficients, whereas colocalization of a 
fluorescently labelled 7TMR construct with a marker of endosomal vesicles (Rab5) was assessed 
by Manders’ coefficient. Both Manders’ and Pearson’s coefficients within the region of interest 
were calculated after setting single color thresholds by either colocalizing single probe channels 
or manually defining a threshold mask upon background subtraction in all channels using Rolling 
Ball Radius of the largest object in the image (~ 20 – 30 µm). Colocalization was scored in at least 
25 cells per experimental condition in three independent assays where the experimenter was 
blinded to the experimental conditions. For Manders’ and Pearson’s coefficients, cell regions of 
interest were demarcated according to the eYFP signal located at the plasma membrane as a 
potential cell surface marker. For FRET signal, pixels of interest were demarcated based on their 
intracellular colocalization of eCFP and eYFP signal. For PLA signal, cell regions of interest were 
demarcated according to eYFP signal within previously defined eCFP-positive cells. For 
intracellular eYFP signal, cell regions of interest were randomly demarcated based on eCFP signal 
within intracellular vesicles. Signal intensity for intracellular eYFP was assessed with the Carl 
Zeiss ZEN software (Black version). The laser intensity was kept constant among all experimental 
conditions. Straight-line selections were drawn from the plasma membrane to the nucleus or 
across the cytoplasm, and pixel intensities across the line were measured using plot profile in Fiji. 
Pixels with maximum and minimum intensities were normalized to 100 and 0, respectively. The 
statistical significance of experiments involving three or more groups and two or more treatments 
was assessed by two-way ANOVA followed by Bonferroni’s post hoc test. Statistical analysis of 
experiments involving three or more groups was assessed by one-way ANOVA followed by 
Bonferroni’s post hoc test. Statistical analysis involving two groups was assessed by Student’s t-
test. For FRET analysis, statistical analysis was assessed by Mann-Whitney U test or one-way 
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non-parametric ANOVA (Kruskal-Wallis) with Dunn’s post hoc test because FRET datasets show 
a Cauchy distribution with heavier tails. Normality and homoscedasticity assumptions were 
checked prior to any calculation. Radioligand binding saturation curves were analyzed using a 
nonlinear curve fitting approach. An extra-sum-of-squares (F test) was used to determine 
statistical significance for simultaneous analysis of binding saturation curves and [35S]GTPS 
binding assays. The level of significance was set at P = 0.05. Values included in the figure legends 






I. Cellular distribution of mGluR2 and 5-HT2AR alone and together in HEK293 cells 
1. 5-HT2AR distribution pattern in HEK293 cells 
To first determine and compare expression patterns of human mGlu2 and 5-HT2A receptors in a 
heterologous cellular system and to validate previous findings showing an elevated intracellular 
localization of the 5-HT2AR, we introduced the mCitrine sequence at the C-terminus to generate 
5-HT2AR-mCitrine. As shown before251,347, HEK293 cells transfected with the 5-HT2AR-mCitrine 
exhibit a fluorescent signal mostly localized in intracellular vesicles (Fig. 1A). To rule out a direct 
effect of the C-terminally tagged mCitrine on receptor trafficking, we used a second method where 
the epitope c-Myc was tagged to the N-terminus of the 5-HT2AR construct. Similar to the 
distribution pattern observed with 5-HT2AR-mCitrine, the c-Myc-5-HT2AR construct was primarily 
located intracellularly (Fig. 1B). 
2. Cotransfection of 5-HT2AR and mGluR2 
mGlu2 receptor exhibits a standard surface receptor distribution where most of the expression is 
visible at the plasma membrane area (Fig. 1C). However, when 5-HT2AR and mGluR2 constructs 
were co-transfected, mGluR2 pattern of expression was dramatically changed. In contrast to the 
subcellular localization observed in HEK293 cells transfected with the mGluR2-mCitrine construct 
alone, coexpression of 5-HT2AR-mCherry led to the partial internalization of mGluR2-mCitrine 
(Figs. 1, D and E), which can also be demonstrated by a high level of colocalization of mGluR2-
mCitrine and 5-HT2AR-mCherry in intracellular vesicles (Fig. 1F). Additionally, not all the 
cotransfected cells exhibited the observed relocalization of mGluR2, not in the same proportion. 
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Fig. 1. 5-HT2AR affects localization of mGluR2. (A and B) Representative confocal micrographs 
of HEK293 cells transfected to express 5-HT2AR-mCitrine (A) or c-Myc-5-HT2AR (B). 
Nonpermeabilized cells were imaged to detect mCitrine (A), whereas permeabilized cells were 
stained with anti-c-Myc and secondary antibody, and imaged to detect anti-c-Myc (B). (C to E) 
HEK293 cells were transfected to express mGluR2-mCitrine alone (C), 5-HT2AR-mCherry alone 
(D), or 5-HT2AR-mCherry and mGluR2-mCitrine (E). (F) Representative line scan. (G) BiFC signal 
in HEK293 cells transfected to coexpress 5-HT2AR-mCi-N172 and 5-HT2AR-mCi-C67, mGluR2-
mCi-N172 and mGluR2-mCi-C67, or 5-HT2AR-mCi-N172 and mGluR2-mCi-C67. (H and I) 
Representative micrographs of BiFC controls. HEK293 cells co-transfected to express mCi-N172 
and mCi-C67 (probes only) and submitted to immunofluorescence assay using antibody against 
GFP conjugated to a fluorescent secondary antibody (H). Absence of mCitrine signal when cells 
were cotransfected either with both 5-HT2AR-mCi-N172 and mCi-C67 or with both mGluR2-mCi-
N172 and mCi-C67 (I). Nuclei were stained in blue with Hoechst. Scale bars, 5 µm.  
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II. Intracellular localization of the 5-HT2AR-mGluR2 heterocomplex 
1. Intracellular complementation of 5-HT2A and mGluR2 
The 5-HT2A-mGluR2 receptor heteromer study resembles a niche in the field of 7TMRs oligomers. 
Our laboratory has become an expert in the study of the structure and function of this 
heterocomplex. We thus expected to locate it at the cell boundaries, using several RRI assays. 
To track the intracellular physical interaction between 5-HT2AR and mGluR2 in HEK293 cells, we 
used bimolecular fluorescence complementation (BiFC) as a biophysical technique that allows 
visualization of protein complexes in transfected mammalian cells348,349. BiFC enables generation 
of a single fluorescent signal when each of the constructs fused to a fragment of the mCitrine 
fluorescent protein interact. The recovery of the protein quaternary structure attests the interaction 
between the two proteins. BiFC signal was detected in cells cotransfected with 5-HT2AR fused to 
either the N-terminal 172 amino acid fragment or the C-terminal 67 amino acid fragment of 
mCitrine (mCi-N172 and mCi-C67, respectively) (Fig. 1G), which further corroborates the 
capability of 5-HT2AR to form a family A GPCR homodimer165. Additionally, BiFC signal in cells 
coexpressing 5-HT2AR-mCi-N172 and 5-HT2AR-mCi-C67 was observed intracellularly (Fig. 1G), 
whereas BiFC signal in cells coexpressing mGluR2-mCi-N172 and mGluR2-mCi-C67 was mostly 
detected at the plasma membrane (Fig. 1G). Importantly, this pattern of BiFC signal was 
redistributed in cells coexpressing 5-HT2AR-mCi-N172 and mGluR2-mCi-C67 (Fig. 1G), which 
suggests that physical interaction between 5-HT2AR and mGluR2 can be detected both close to 
the cell surface as well as intracellularly. Internal controls to validate BiFC signal specificity 
included cotransfection of themCi-N172 and mCi-C67 constructs (Fig. 1H), as well as mCi-C67 





III. GPCR heteromerization is necessary for the 5-HT2AR-mediated mGluR2 internal 
relocalization 
The use of stable cellular systems as a reductionist approach to observe trafficking events after 
receptor activation was chosen as a model for this study. This choice has several advantages, 
including overcoming expression variability and transfection efficiency issues – it is easy to 
routinely grow, treat and analyze, and to manage the expression levels. To that purpose, we 
devised an experimental Flp-In T-REx HEK293 cellular system that enables small molecule 
doxycycline (DOX)-inducible expression of the inserted human HTR2A gene construct along with 
the stable expression of mGlu2, mGlu3 or mGlu2ΔTM4 (see below) receptors. The Flp-In T-REx 
system allows expression of the inserted construct into the cell genome via Flp-In recombinase-
mediated DNA recombination at the Flp recombination target (FRT) site, which can be controlled 
by the incorporation DOX to the cell culture medium. This model of stable cell lines has already 
been employed to great advantage in the study of receptor pharmacology, trafficking and 
oligomerization45,335. Here we used Flp-In T-REx HEK293 cells to further explore the effect of 5-
HT2AR on subcellular localization of mGluR2. 
The c-Myc-5-HT2AR-eCFP construct was inserted into the appropriate locus of the Flp-In 
expression system, and pools of positive Flp-In T-REx HEK293 cells were selected. No visible 
expression of the eCFP-tagged construct was observed in the absence of DOX (Fig. 2A). 
However, presence of DOX resulted in expression of the integrated construct as monitored by 
fluorescence corresponding to eCFP (Fig. 2B) and immunoblotting with anti-c-Myc antibody (Fig. 
2C), which also serves as a concentration indicator of receptor expression. Induction of expression 
of c-Myc-5-HT2AR-eCFP was concentration- and time-dependent, reaching maximal levels within 
30 – 40 h upon 1 g/mL [DOX] administration (Figs. 2, B and C), and lasted a couple of days, 
approximately. Additionally, as shown above in HEK293 cells transiently transfected with the 5-























  Fig. 2. Confocal micrographs of Flp-In T-REx HEK293 cells expressing the 5-HT
2A
 receptor. 
(A and B) Representative live-cell confocal micrographs of Flp-In T-REx HEK293 cells harboring c-
Myc-5-HT
2A
R-eCFP at the inducible locus. Cells were left untreated [DOX(-)] (A) or treated for 24h, 
48h, or 72 h with doxycycline [DOX(+)] (B). (C) Membranes from Flp-In T-REx HEK293 cells 
harboring c-Myc-5-HT
2A
R-eCFP at the inducible locus left untreated or treated with doxycycline at 
the indicated concentration were immunoblotted with anti-c-Myc (upper panel) or anti--actin. Scale 
bar, 5 µm. 
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Myc-5-HT2AR-eCFP was located intracellularly (Fig. 2B). Those experiments generated a series 
of parental clones expressing inducible 5-HT2AR. 
In order to demonstrate the involvement of 7TMR heteromerization in the relocalization of mGluR2 
following its coexpression with 5-HT2AR, we first based our negative controls with mGluR3 as well 
as with an mGluR2/mGluR3 chimeric construct that does not form a receptor heteromer with 5-
HT2AR. We selected the mGluR2/mGluR3 chimeric construct mGluR2TM4 because, according 
to previous findings from substitution of residues Ala-6774.40, Ala-6814.44 and Ala-6854.48 in mGluR2 
for Ser-6864.40, Phe-6904.44 and Gly-6944.48 in mGluR3 decreases signal that indicates heteromeric 
assembly. This was demonstrated based on the use of several independent experimental 
approaches, including flow cytometry-based fluorescence energy resonance transfer (FCM-based 
FRET), FRET microscopy, and coimmunoprecipitation in HEK293 cells251,252. 
The parental c-Myc-5-HT2AR-eCFP expressing clones were then transfected with either mGluR2-
eYFP, mGluR3-eYFP or mGluR2TM4-eYFP, and individual clones constitutively eliciting eYFP 
signal were selected. Visual inspection of eYFP fluorescence confirmed that, in the absence of 
DOX, mGluR2-eYFP was localized at the cell boundaries (Fig. 3A). Remarkably, DOX-induced 
expression of 5-HT2AR-eCFP dramatically affected the subcellular distribution of mGluR2-eYFP, 
now partially internalized in vesicles (Fig. 3A). This effect of 5-HT2AR-eCFP expression was not 
observed in cells stably expressing either mGluR3-eYFP (Fig. 3B) or mGluR2TM4-eYFP (Figs. 
3C). Both mGluR3-eYFP and mGluR2TM4-eYFP showed a higher degree of intracellular 
localization as compared to mGluR2-eYFP, yet both quantitative evaluation (Fig. 3D) and 
representative line scans (Figs. 3, E to G) demonstrated significantly less subcellular proximity 
between 5-HT2AR-eCFP and mGluR3-eYFP or mGluR2TM4-eYFP, as compared to the high 
degree of overlap between 5-HT2AR-eCFP and mGluR2-eYFP. The subcellular distribution of the 






Fig. 3. Effect of 5-HT2AR on localization of mGluR2 requires heteromerization. (A to I) Flp-In 
T-REx HEK293 cells stably expressing mGluR2-eYFP (A, D and E), mGluR3-eYFP (B, D and F), 
mGluR2TM4-eYFP (C, D and G), or OR-eYFP (H and I) and harboring 5-HT2AR-eCFP at the 
inducible locus were untreated [DOX(-)] or treated with doxycycline [DOX(+)]. Representative 
confocal micrographs (A to C and H) and corresponding line scans (E to G and I). (D) Manders’ 
and Pearson’s colocalization coefficients analysis of eYFP- and eCFP-tagged constructs (n = 25 
– 33 cell regions of interest in three independent experiments). Data are mean  SEM (D). 
Statistical analysis was performed using the one-way ANOVA (D) with Bonferroni’s post hoc test. 
**P < 0.01, ***P < 0.001. Scale bars, 5 µm.  
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localized 7TMR, was not evidently affected by DOX-induced expression of 5-HT2AR-eCFP (Figs. 
3, H and I), further comforting the specificity of the relation between 5-HT2AR and mGluR2. 
IV. Characterization of the double stable cells lines 
Radioligand binding assays with the 5-HT2AR antagonist [3H]ketanserin confirmed that addition of 
DOX resulted in 5-HT2AR-eCFP expression in cells stably expressing mGluR2-eYFP, mGluR3-
eYFP or mGluR2TM4-eYFP (Figs. 4, A to C, and Table 1). Using the mGluR2/3 antagonist 
[3H]LY341495, we also observed that DOX-induced expression of 5-HT2AR-eCFP led to a 
statistically significant increase in the density of mGluR2-eYFP, an effect that was not observed 
in cells stably expressing mGluR3-eYFP or mGluR2TM4-eYFP (Figs. 4, D to F, and Table 1). 
This effect of DOX-induced 5-HT2AR-eCFP expression on augmentation of mGluR2-eYFP density 
was corroborated by fluorescence flow cytometry assays (Figs. 4, G and H). 
We next assayed the effect of the mGluR2/3 agonist LY379268 on stimulation of [35S]GTPγS 
binding as a functional readout of receptor-Gαi/o protein coupling. Interestingly, DOX-induced 
expression of 5-HT2AR-eCFP reduced the functional properties of LY379268 augmenting 
[35S]GTPγS binding in cells stably expressing mGluR2-eYFP (Fig. 4I), an allosteric event that was 
absent in cells stably expressing mGluR2ΔTM4-eYFP (Fig. 4J). Although activation of mGluR2 
elicited a robust G protein signal after ligand binding, we were unable to test mGluR3 function with 
the [35S]GTPγS assay on clones stably expressing mGluR3. In order to overcome this issue, Gαi/o-
coupled receptors mGluR (i.e., mGluR2, mGluR3 and mGluR2ΔTM4) ability to trigger the 
phospholipase C pathway following activation of the G Protein, we transfect DOX(-) cells with the 
chimeric G protein Gαqi9 and analyzed the fold increase in [Ca2+]i (Fig. 4K) following application of 
0.1 μM of the mGluR2/3 agonist LY379268. Together with the effects of 5-HT2AR on mGluR2 
subcellular redistribution (see above), these findings suggest that, although DOX-induced 
expression of 5-HT2AR results in augmentation of total mGluR2 density, its functional properties 
for agonist-induced Gαi/o protein recruitment are diminished. 
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Activation of 5-HT2AR stimulates the β-isoforms of phospholipase C (PLC-β ) that catalyzes the 
hydrolysis of phosphatidylinositol bisphosphate (PIP2), leading to the production of two second 
messengers, namely inositol triphospate (IP3) and diacylglycerol (DAG). The Gαq-mediated signal 
is then transmitted through to those molecules: IP3 binds to its ER localized receptor and open the 
channel allowing mobilization of the internal store and efflux of calcium in the cytosol. DAG binds 
to the plasma membrane to recruit the protein kinase C that is activated by Ca2+ and mediates 
several other pathways. Our previous results suggested that stimulation of cells coexpressing 
mGluR2 and 5-HT2AR with the mGluR2/3 selective agonist LY379268 leads to a Gαq/11 protein-
dependent increase in the concentration of [Ca2+]I251,253,254, a transactivation mechanism event that 
has been validated by some170,350 but not all studies351. 
Besides physically interacting, 5-HT2AR and mGluR2 have been shown to crosstalk by modulating 
their respective G proteins signaling. The endogenous ligands serotonin and glutamate tend to 
increase the Gαi signaling and reduce the Gαq signaling within the heterocomplex. Intracellular 
calcium mobilization mediated by inositol 1,4,5-triphosphate from endoplasmic reticulum 
compartments can be monitored by calcium-sensitive fluorescent dyes. The highly sensitive 
ratiometric calcium dye Fura-2 was used to assess calcium elevation in our clones expressing 
mGluR2 or mGluR2ΔTM4-eYFP along with the induction of 5-HT2AR expression. Application of 10 
μM of LY379268 was sufficient to increase the intracellular calcium concentration in cells 
expressing mGluR2, with a much lesser signal for the cells expressing the mutant receptor 
mGlu2ΔTM4-eYFP. This effect seemed dose-dependent as with 100 μM an even greater signal 
was observed (Figs. 4, L and M). As expected, neither serotonin (5-hydroxytryptamine, 5-HT) nor 
LY379268 had such an effect on Ca2+ release in DOX(-) Flp-In T-REx HEK293 cells, whereas 5-
HT stimulated an increase in intracellular Ca2+ release in DOX(+) cells (Fig. 4N). An additional 
internal control included absence of effect of 5-HT on Ca2+ release in untransfected HEK293 cells 








Fig. 4. Characterization of the double stable cells lines. (A to C) Density of 5-HT2AR as 
measured by [3H]ketanserin binding in cell membrane preparations of Flp-In T-REx HEK293 cells 
stably expressing mGluR2-eYFP (A), mGluR3-eYFP (B), or mGluR2TM4-eYFP (C) and 
harboring 5-HT2AR-eCFP at the inducible locus. Cells were left untreated [DOX(-)] or treated with 
doxycycline [DOX(+)] (representative results of three independent experiments performed in 
duplicate; see also Table 1). (D to F) Density of mGluR2/3 shown as [3H]LY341495 binding in cell 
membrane preparations of Flp-In T-REx HEK293 cells stably expressing mGluR2-eYFP (D), 
mGluR3-eYFP (E), or mGluR2TM4-eYFP (F) and harboring 5-HT2AR-eCFP at the inducible 
locus. Cells were untreated [DOX(-)] or treated with doxycycline [DOX(+)] (representative results 
of three independent experiments performed in duplicate; see also Table 1). (G and H) Cells were 
untreated [DOX(-)] or treated with doxycycline [DOX(+)], and densities of 5-HT2AR-eCFP and 
mGluR2-eYFP with eCFP (G) and eYFP (H), respectively, were assessed by FACS assays (n = 
10 independent experiments with 8459 – 9710 cells per experimental condition). (I and J) Effect 
of the mGluR2/3 agonist LY379268 on [35S]GTPS binding in membrane preparations of Flp-In T-
REx HEK293 cells stably expressing mGluR2-eYFP (I) or mGluR2TM4-eYFP (J) and harboring 
5-HT2AR-eCFP at the inducible locus. (K) [Ca2+]i mobilization of mGluRs clones by activation of 
the chimeric Gα protein Gαqi9. Flp-In T-REx HEK293 cells stably expressing mGluR2-eYFP, 
mGluR3-eYFP or mGluR2TM4-eYFP and harboring 5-HT2AR-eCFP at the inducible locus were 
untreated [DOX(-)], loaded with Fura-2 and monitored for intracellular calcium concentration after 
administration of LY379269 (0.1 µM), or vehicle. To allow efficient coupling of Gαi/o-coupled 
receptors (mGluR2, mGluR3 and mGluR2TM4) to the PLC pathway, cells were also transfected 
with the chimeric Gα protein Gαqi9. Analysis of the fold increase in [Ca2+]i (n = 4 independent 
experiments, representative results of three independent experiments performed in duplicate). (L 
and M) Flp-In T-REx HEK293 cells stably expressing mGluR2-eYFP or mGluR2TM4-eYFP and 
harboring 5-HT2AR-eCFP at the inducible locus were untreated [DOX(-)] or treated with 
doxycycline [DOX(+)], loaded with Fura-2 and monitored for intracellular calcium concentration 
after sequential administration of LY341495 and/or LY379268, or vehicle. Representative time 
course of Ca2+ release. The arrowhead indicates the time when drugs were added (M). Analysis 
of the fold increase in intracellular calcium concentration (L; n = 4 – 8 independent experiments). 
(N) [Ca2+]i mobilization of mGluRs clones expressing 5-HT2AR only, or untransfected HEK293 
cells.  Flp-In T-REx HEK293 cells stably expressing mGluR2-eYFP and harboring 5-HT2AR-eCFP 
at the inducible locus or untransfected HEK293 cells were treated with doxycycline (or left 
untreated), loaded with Fura-2 and monitored for intracellular calcium concentration after 
administration of 5-HT (1 µM) or LY379268 (100 µM), or vehicle (n = 4 independent experiments). 
Data are mean  SEM (D, I, J, K, L and N). Statistical analysis was performed using the F test (A 
to F), Student’s t-test (G and H) one-way (D, K and N) or two-way (M) ANOVA with Bonferroni’s 
post hoc test, or the F test (A to F). *P < 0.05, **P < 0.01, ***P < 0.001, n.s., not significant.  
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with our cell system and that the receptors stoichiometry allowing the crosstalk between 5-HT2AR 
and mGluR2 is conserved254. 
 
V. mGluR2 and 5-HT2AR interact intracellularly 
Besides attesting of the coupling of mGluR2 and 5-HT2AR assessed by the above-mentioned 
BiFC assay, this experiment also showed that the distribution of the fluorescence produced by the 
complementation of the two mCitrine fluorescent protein moieties held by each receptor is at the 
cell borders but more importantly, intracellular (Fig. 1G). To further explore where the interaction 
between these two receptors is localized, we tested RRI using two different methods: 
sensorFRET, which enables quantitative measurement of FRET efficiency, and proximity ligation 
assay (PLA), which permits direct detection of molecular interactions between two proteins without 
the need of resonance energy transfer assays. Using the sensorFRET approach, we observed a 
significant decrease of FRET efficiency between eCFP and eYFP in DOX(+) cells stably  
expressing mGluR2TM4-eYFP as compared to that observed in cells stably expressing mGluR2-
eYFP (Figs. 5, A to C and Fig. A1). This confirms the impaired ability of the mGluR2/mGluR3 
chimeric construct to physically interact with 5-HT2AR. More importantly, the FRET signal between 
5-HT2AR-eCFP and mGluR2-eYFP was located intracellularly in vesicles positive for both eCFP 
and eYFP fluorescence signal (Fig. 5A). Following DOX-dependent induction of 5-HT2AR-eCFP 
expression, PLA signal between 5-HT2AR and mGluR2 was observed in the form of punctate 
staining (Fig. 5D). Quantification of PLA dots was significantly reduced in cells induced to express 
5-HT2AR-eCFP along with mGluR2TM4-eYFP (Figs. 5, E and F). As anticipated, no PLA signal 
was observed in the absence of doxycycline in cells expressing mGluR2-eYFP only (Fig. 5F). 








Fig. 5. Intracellular localization of the 5-HT2AR-mGluR2 complex. (A to C) SensorFRET 
analysis of Flp-In T-REx HEK293 cells stably expressing mGluR2-eYFP (A and C) or 
mGluR2TM4-eYFP (B and C), harboring 5-HT2AR-eCFP at the inducible locus, and treated with 
doxycycline. Representative live-cell confocal images at 405 nm and 458 nm excitation 
frequencies (A and B), and (C) quantification of FRET efficiencies (n = 249 – 364 regions of 
interest in three independent experiments). (D to F) Flp-In T-REx HEK293 cells stably expressing 
mGluR2-eYFP (D and F) or mGluR2TM4-eYFP (E and F) and harboring c-Myc-5-HT2AR-eCFP 
at the inducible locus were treated with doxycycline, permeabilized and stained with anti-rabbit 
antibody selective for c-Myc and anti-mouse antibody selective for mGluR2, followed by incubation 
with species-specific PLA probes. Representative confocal micrographs of eCFP- or eYFP-tagged 
constructs and PLA signal (cyan dots, Z-stack projection) (D and E). Quantification of PLA dots 
(F). Note that PLA signal was decreased in DOX(-) cells, and when primary antibodies were not 
added (n = 57 – 94 cell regions of interest demarcated according to eYFP signal within previously 
defined eCFP-positive cells in three independent experiments). Data are median with 95% 
confidence interval (C) or mean  SEM (F). Statistical analysis was performed using Mann-
Whitney U test (C) or one-way ANOVA with Bonferroni’s post hoc test (F). ***P < 0.001. Scale 
bars, 5 µm, inserts edge ~ 14.3 μm.  
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VI. Expression of 5-HT2AR augments localization of mGluR2 in endosomal 
compartments  
Our data thus far show that, under steady state conditions, colocalization of mGluR2 with markers 
of endocytic vesicles increased upon coexpression with 5-HT2AR. However, the nature of these 
intracellular compartments remains unknown. It is classically established that agonist binding and 
activation of most 7TMRs usually results in the rapid removal of the receptor from the plasma 
membrane by two complementary mechanisms, desensitization and endocytosis. To evaluate the 
components of the intracellular trafficking pathway in which 5-HT2AR affects subcellular distribution 
of mGluR2, we next tested the effect of DOX-induced expression of 5-HT2AR on colocalization of 
mGluR2 with endosomal markers. Using fixed cell confocal immunofluorescence microscopy, we 
found that colocalization of mGluR2-eYFP with Rab5, which regulates clathrin-mediated 
endocytosis from the plasma membrane to early/sorting endosome pools, showed a modest, yet 
statistically significant, increase in DOX(+) cells as compared to DOX(-) cells (Figs. 6, A to D). 
Additionally, DOX-induced expression of 5-HT2AR substantially augmented localization of 
mGluR2-eYFP with Rab7 as a late endosome maker (Figs. 6, E to H).  
This localization of mGluR2 in Rab7 endosomes was surprising. Are those receptors directed to 
degradation, or Rab7 endosomes serve as storage compartments that are deeper or later used 
after endocytosis? To address that question, colocalization of mGluR2 in Rab7 endosomes was 
assessed following activation of the 5-HT2A receptor. Application of DOI resulted in the reversal of 
the previous pattern; mGluR2 population was now greater in Rab5 than it was in Rab7 endosomes 
(Fig. 6I). This observation suggests that following activation of 5-HT2AR, a Rab transition 
demobilized the Rab5 pool of mGluR2 to Rab7. It is possible that 5-HT2AR activation leads to the 
migration of mGluR2 from Rab7 to Rab5 endosomes. This could explain why at basal state, i.e. 










Fig. 6. Agonist activation of either 5-HT2AR or mGluR2 differentially affects mGluR2 
trafficking and downregulation. (A to L) Flp-In T-REx HEK293 cells stably expressing mGluR2-
eYFP and harboring c-Myc-5-HT2AR-eCFP at the inducible locus were untreated [DOX(-)] or 
treated with doxycycline [DOX(+)], and exposed for 60 min to DOI (1 µM). Cells were then 
permeabilized and stained with anti-Rab5 or anti-Rab7 and secondary antibody, and imaged by 
confocal microscopy to detect eCFP, eYFP, anti-Rab5, or anti-Rab7. Representative confocal 
micrographs (A and E) and corresponding line scans (C and D, G and H), and Manders’ 
colocalization coefficient analysis of anti-Rab5 (A and B; n = 33 – 134 cell regions of interest in 
three independent experiments) or anti-Rab7 (E and F; n = 48 – 49 cell regions of interest in three 
independent experiments) and eYFP-tagged construct. (I) Manders’ colocalization coefficient 
analysis between Rab5 and Rab7 in [DOX(+)] cells and treated with DOI (1 μM) (36 cell regions 
of interest in two independent experiments). (J to L) FACS analysis of internalized mGlu2 
receptors along with the transferrin marker. (J and L) HEK293 cells were transfected to express 
5-HT2AR-mCherry alone, mGluR2-eYFP alone, or 5-HT2AR-mCherry and mGluR2-eYFP together, 
permeabilized, stained with PE-Cy5-tagged anti-transferrin receptor antibody, and imaged with an 
Amnis ImageStream flow cytometer. (J) Representative images. (K) Colocalization of 5-HT2AR-
mCherry and transferrin receptor with or without coexpression of mGluR2-eYFP (n = 4 
independent experiments). (L) Colocalization of mGluR2-eYFP and transferrin receptor with or 
without coexpression of 5-HT2AR-mCherry (n = 4 independent experiments). Data are mean  
SEM (B, F, I, K and L). Statistical analysis was performed using the Student’s t-test (B, F, I, K and 






To pursue quantitative comparison of variant receptor trafficking, and to validate our previous 
findings with an independent marker of clathrin-mediated endosomes, we assessed colocalization 
of 5-HT2AR-mCherry or mGluR2-eYFP with the transferrin receptor, which transits through clathrin-
coated pits and behaves as a marker of early endosomes, using imaging flow cytometry. As above 
with Rab5 and Rab7, our data show that localization between 5-HT2AR-mCherry and the 
transferrin receptor was higher as compared to that observed between mGluR2-eYFP and 
transferrin receptor (Fig. 6J). Additionally, we show that whereas colocalization between 5-HT2AR-
mCherry and transferrin receptor was not affected upon cotransfection of the mGluR2-eYFP 
construct (Fig. 6K), transfection of the 5-HT2AR-mCherry construct led to a significant increase in 
colocalization between mGluR2-eYFP and the transferrin receptor (Fig. 6L). 
VII. DOI and LY379268 differentially affect localization of mGluR2 in Rab5-
positive endosomes 
To gain further insight into how cells control the subcellular localization of a 7TMR complexes, we 
next investigated the effects of different serotonergic and glutamatergic agonists on trafficking 
processes in cells coexpressing 5-HT2AR and mGluR2.  
We first explored the effect of the endogenous neurotransmitter serotonin (5-HT) or the 5-HT2AR 
agonist DOI on localization of mGluR2 within Rab5-positive endosomes. Our data showed that 
colocalization of mGluR2-eYFP and Rab5 was significantly increased after either 5-HT or DOI 
treatment in cells stably expressing mGluR2-eYFP and induced to express 5-HT2AR-eCFP (Figs. 
6A, and 7A, and B). To rule out any effect of DOI on mGluR2 trafficking, we confirmed that 
treatment with DOI does not affect localization of mGluR2-eYFP and Rab5 in cells stably 
expressing mGluR2-eYFP and uninduced (DOX[-]) to express 5-HT2AR-eCFP (Fig. 7C). 
To test whether 5-HT2AR and mGluR2 receptor heteromer is required for this trafficking event, we 
used synthetic peptides with the amino acid sequence of TM4 of mGluR2 fused to the HIV 
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transactivator of transcription (TAT) peptide, which determines the orientation of the peptide when 
inserted in the plasma membrane. To begin with, we wanted to test whether the interfering peptide 
can reduce or even prevent the interaction between 5-HT2A and mGluR2. As expected and based 
on our above findings, incubation with TAT-TM4, but not with TAT-TM1 or TAT-tagged scrambled 
peptide (TAT-SCR), significantly decreased FRET signal in cells coexpressing 5-HT2AR-eCFP and 
mGluR2-eYFP (Fig. 7D). Notably, incubation with TAT-TM4 reduced the effect of DOI on 
colocalization of mGluR2-eYFP and Rab5 (Fig. 7E). Exposure to TAT-TM4, however, did not affect 
colocalization between mGluR2-eYFP and Rab5 in vehicle-treated cells (Fig. 7E). To gain further 
insight into the endocytic process at work, endocytosis was pharmacologically blocked by an 
inhibitor. Dynamin is a GTPase protein that is essential for membrane fission during clathrin-
mediated endocytosis. Dynasore acts as a potent inhibitor of endocytic pathways known to depend 
on dynamin by rapidly blocking coated vesicle formation within seconds of its application. Cells 
coexpressing 5-HT2AR and mGluR2 was submit to dynasore mediated endocytosis inhibition and 
treated with DOI. As a result, a diminution of the effect of DOI on augmentation of colocalization 
between mGluR2-eYFP and Rab5 was observed (Fig. 7F). 
To validate some of above findings with a different approach, and to track mGluR2 internalization 
upon different treatments, we processed the cells to flow cytometry, where cell surface localization 
of mGluR2-eYFP is detected thanks to an Alexa Fluor 647 (AF647)-tagged antibody targeting an 
epitope of the N-terminal of mGluR2. Surprisingly, mGluR2 surface distribution was unaffected by 
DOI in DOX(+) cells (Fig. 7G). As expected, however, cell surface AF647 signal was augmented 
upon dynasore treatment (Fig. 7G). This lack of effect of DOI exposure on cell surface mGluR2-
eYFP was further supported by radioligand binding assays. [3H]LY341495 binding was 
comparable in DOX(+) cells treated with DOI and vehicle (Fig. 7H). Together with the absence of 
effect of DOI treatment on FRET (Fig. 7I) and PLA (Fig. 7J) signal between 5-HT2AR-eCFP and 









Fig. 7. DOI and LY379268 differentially affect localization of mGluR2 in Rab5-positive 
endosomes. (A to C, K and N) Flp-In T-REx HEK293 cells stably expressing mGluR2-eYFP and 
harboring c-Myc-5-HT2AR-eCFP at the inducible locus were untreated [DOX(-)] or treated with 
doxycycline [DOX(+)], and exposed for 60 min to serotonin (5-HT, 1 µM), DOI (1 µM) or LY379268 
(10 µM), or vehicle. Cells were then permeabilized and stained with anti-Rab5 and secondary 
antibody, and imaged by confocal microscopy to detect eCFP, eYFP, anti-Rab5 (Fig. 6A 3rd line). 
Representative line scan of DOI treated cells (B). Cells were incubated (60 min; 10 µM) with TAT-
fused peptide corresponding to TM1 (TAT-TM1) or TM4 (TAT-TM4) of mGluR2, or scrambled 
control peptide and then processed for sensorFRET (n = 248 – 393 regions of interest in three 
independent experiments) (D). (E and Q) Manders’ coefficient colocalization analysis of anti-Rab5 
and eYFP-tagged construct. Cells were exposed for 60 min to DOI (1 µM, E), LY379268 (10 µM, 
Q), or vehicle. TAT-tagged peptides (10 µM) were added 5 min before drug or vehicle 
administration (n = 27 – 103 cell regions of interest in three independent experiments). (F, M and 
O) Manders’ coefficient colocalization analysis of anti-Rab5 and eYFP-tagged construct. Cells 
were exposed for 60 min to DOI (1 µM, F), LY379268 (10 µM, M and O), or vehicle. Dynasore (80 
µM) was added 5 min before drug or vehicle administration (n = 28 – 88 cell regions of interest in 
three independent experiments). (G, L and P) Cell surface localization of mGluR2-eYFP assessed 
by flow cytometry assays with an Alexa Fluor 647 (AF647)-tagged antibody. Cells were exposed 
for 60 min to DOI (1 µM, G), LY379268 (10 µM, L and P), or vehicle. Dynasore (80 µM) was added 
5 min before drug or vehicle administration (n = 3 – 6 independent experiments with 8508 – 10048 
cells per experimental condition). (H, R and S) Density of mGluR2 shown as [3H]LY341495 binding 
in membrane preparations of DOX(+) (H and S) or DOX(-) (R) cells exposed for 60 min to DOI (1 
µM, H), LY379268 (10 µM, R and S), or vehicle. Data are shown as percentage of specific binding 
in DOI- or LY379268-treated cells as compared to vehicle (n = 4 independent groups of membrane 
preparations). (I and J) Cells were exposed for 60 min to DOI (1 µM), LY379268 (10 µM), or 
vehicle. Quantification of FRET efficiencies (I, n = 281 – 536 regions of interest in three 
independent experiments). Quantification of PLA dots (J, n = 82 – 148 cell regions of interest 
demarcated according to eYFP signal within previously defined eCFP-positive cells in three 
independent experiments). Data are mean  SEM (A, C, E to H, K to S) or median with 95% 
confidence interval (D, I and J). Statistical analysis was performed using Student’s t-test (C, H, K, 
N, R, S), one-way ANOVA with Bonferroni’s post hoc test (A, F, G, L, M, O, and P and Q), two-
way ANOVA with Bonferroni’s post hoc test (E), or one-way non-parametric ANOVA (Kruskal-




 localization of mGluR2 within Rab5-positive endosomes through a mechanism that requires 
heteromerization between 5-HT2AR and mGluR2, activation of the 5-HT2AR receptor does not 
affect mGluR2 cell surface density, total density or heteromerization with 5-HT2AR. 
We next tested whether DOX-induced expression of 5-HT2AR-eCFP modulates the effect of the 
mGluR2/3 agonist LY379268 on mGluR2’s subcellular localization and trafficking. Consistent with 
the paradigmatic description of 7TMR endocytosis after ligand binding, in DOX(-) cells, incubation 
with LY379268 led to both an increase of colocalization between mGluR2-eYFP and Rab5 (Fig. 
7K), and reduced cell surface AF647 signal (Fig. 7L), phenotypes that were prevented by dynasore 
(Figs. 7, L and M). Importantly, this effect of LY379268 on subcellular localization of mGluR2 was 
not observed in DOX(+) cells (Figs. 7, N, O and P), although dynasore augmented the surface 
location of mGluR2. This effect was rescued in DOX(+) cells treated with TAT-TM4 (Fig. 7Q). 
Additionally, our radioligand bindings assays with the mGluR2/3 antagonist [3H]LY341495 showed 
that mGluR2 density was reduced in DOX(-) cells treated with LY379268 (Fig. 7R), whereas 
LY379268 treatment did not affect [3H]LY341495 binding in cells stably expressing mGluR2-eYFP 
and induced to express 5-HT2AR-eCFP (Fig. 7S). By contrast, we observed that, in DOX-treated 
cells, molecular proximity between 5-HT2AR-eCFP and mGluR2-eYFP, as assessed by 
sensorFRET (Fig. 7I) and PLA (Fig. 7J), was reduced upon previous exposure to LY379268. 
Together, these data indicate that the 5-HT2AR agonist DOI and the mGluR2/3 agonist LY379268 
differentially affect mGluR2 density as well as localization of mGluR2 with markers of endocytic 
compartments in cells expressing mGluR2 alone, or together with 5-HT2AR. 
VIII. Psychedelic and non-psychedelic compounds have different effects on the 
5-HT2AR-mediated endocytosis of mGluR2 
Our system thus far showed that 5-HT2AR agonists such as DOI and 5-HT displaced mGluR2 to 






Fig. 8. Activation of 5-HT2AR by hallucinogenic or nonhallucinogenic agonists differently 
mediate Rab5-dependent trafficking of mGluR2.  Flp-In T-REx HEK293 cells stably expressing 
mGluR2-eYFP and harboring c-Myc-5-HT2AR-eCFP at the inducible locus were treated with 
doxycycline [DOX(+)], and exposed for 60 min to DOI (1 µM), LSD (1μM), lisuride (1μM) or 
ergotamine (1μM). Cells were then permeabilized and stained with anti-Rab5 and secondary 
antibody, and imaged by confocal microscopy to detect eCFP, eYFP, anti-Rab5. Manders’ 
coefficient colocalization analysis of anti-Rab5 (n = 33 cell regions of interest in one experiment) 
and eYFP-tagged construct. Data are mean  SEM. Statistical analysis was performed using one-
way ANOVA with Bonferroni’s post hoc test. *P < 0.05, n.s., not significant.  
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mGluR2 receptor heterocomplex. Although serotonin is not hallucinogenic at physiological 
concentration, unlike DOI, we wanted to gain more insights into how propsychotic molecules such 
as 5-HT2AR hallucinogens (HAL) can affect mGluR2 trafficking as compared to non-hallucinogenic 
agents (NHAL). Hallucinogenic 5-HT2AR agonists such as LSD and psilocybin have been 
categorized as propsychotic compounds because of their ability to mimic some of the 
schizophrenia positive symptoms. Conversely, molecules that are very close in structure but not 
hallucinogenic, such as lisuride and ergotamine, seem to evoke different internalization and 
signaling mechanism, such as bias agonism114,352 and transphosphorylation350. Given that HAL 
and NHAL have different effects on the internalization of 5-HT2AR and that it can phosphorylate 
mGluR2 to affect its Gαi/o signaling and probably its internalization following exposure to the 
drugs, we hypothesized that similar to those findings, HAL and NHAL would have different effects 
on the internalization of mGluR2 in Rab5 endosomes in cells coexpressing both receptors. 
Consistently with previous findings163,350, and similar to the findings with 5-HT and DOI, cells 
treated with LSD and psilocybin tended to have a greater colocalization index between mGluR2 
and Rab5 (Fig. 8) (Fig. 8). Conversely, no increase was observed with NHAL treatments such as 
lisuride and ergotamine, indicating that only 5-HT2AR hallucinogenic agonists have the potency to 
affect mGluR2 trafficking (Fig. 8).  
IX. Exposure to clozapine down-regulates mGluR2 via GPCR heteromerization with 
5-HT2AR 
1. Effect of 5-HT2AR antagonists on receptor’s subcellular distribution 
Recent reports suggest that presence of 5-HT2AR antagonists/inverse agonists affects intracellular 
localization of 5-HT2AR constructs in living mammalian cell cultures. As an example, upon addition 
of ligands such as mianserin, cells show 5-HT2ARs predominantly at the plasma membrane335. To 
corroborate these findings, we used our Flp-In T-REx system expressing 5-HT2AR-eCFP only (i.e., 
without stable expression of mGluR2-eYFP, mGluR3-eYFP or mGluR2TM4) in an inducible 
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manner. Following addition of DOX, cells were treated overnight with the 5-HT2AR  
antagonist/inverse agonist M100907 (also known as volinanserin or MDL 100,907), or vehicle. 
Our data indicated that, opposite to that observed in vehicle-treated cells, 5-HT2AR-eCFPs were 
essentially localized at the plasma membrane of cells treated with M100907 (Fig. 9A to C). Similar 
results were obtained with the 5-HT2AR antagonist/inverse agonist altanserin (Fig. 9A and D). 
Surprisingly, the clozapine’s analog olanzapine had the same effect on the localization of 5-HT2AR 
(Fig. 9A). Together, these data suggest that, at steady state, the bulk of 5-HT2AR-eCFP is present 
in punctate intracellular vesicles, and that treatment with the 5-HT2AR antagonists/inverse agonists 
enhances the otherwise restricted cell surface localization of the 5-HT2AR. 
2. Effect of clozapine on 5-HT2AR’s subcellular distribution 
Clozapine, however, is an antipsychotic medication that presents peculiar properties as it normally 
behaves as a 5-HT2AR antagonist/inverse agonist, thus blocking or inhibiting 5-HT2AR-dependent 
principal signaling pathways such as activation of Gαq/11 proteins, yet is also able to activate certain 
pathways such as Akt. Additionally, and opposite to what is usually observed with most 
antagonists and inverse agonists (see above), our data showed that following DOX-induced 
expression of 5-HT2AR-eCFP, clozapine exposure did not discernibly affect the subcellular 
distribution of the 5-HT2AR construct (Fig. 9A and E). Nevertheless, our previous findings in whole 
animal models showed that long-lasting exposure to clozapine induces mGluR2 down-regulation 
in brain regions such as the frontal cortex. Consequently, we tested whether clozapine 
affectsmGluR2 localization and density in cells coexpressing 5-HT2AR and mGluR2, as well as the 










Fig. 9. Clozapine treatment affects mGluR2 trafficking and downregulation via 5-HT2AR-
mGluR2. (A) Representative confocal micrographs and representative line scans of Flp-In T-REx 
HEK293 cells harboring 5-HT2AR-eCFP at the inducible locus were treated with doxycycline, and 
then exposed overnight to M100907 (C) (10 µM), altanserin (D) (10 µM) or clozapine (E) (10 µM), 
olanzapine (10 μM) or vehicle (B). (F to H and K, J) Flp-In T-REx HEK293 cells stably expressing 
mGluR2-eYFP (F, G to L, N, P, and U, V, W), mGluR2TM4-eYFP (H, L, R), or mGluR3-eYFP 
(O, Q) and harboring 5-HT2AR-eCFP at the inducible locus were treated with doxycycline and then 
exposed overnight to clozapine (10 µM or 50 µM) or M100907 (10 µM), or vehicle. Representative 
confocal micrographs and line scans (F, G, J, K). (H) Manders’ coefficient colocalization analysis 
of eYFP- and eCFP-tagged constructs (n = 30 – 74 cell regions of interest in three independent 
experiments). (I) Manders’ coefficient colocalization analysis of eYFP- and eCFP-tagged 
constructs in cells stably expressing mGluR2-eYFP and harboring 5-HT2AR-eCFP at the inducible 
locus. Cells were treated with doxycycline, and then exposed overnight to clozapine (10 µM) or 
M100907 (10 µM), or vehicle. TAT-tagged peptides were added both 5 minutes before clozapine 
or vehicle administration and 65 minutes before cell fixation (n = 44 – 98 cell regions of interest in 
three independent experiments). (M to O, U, V, W) Cell surface localization of mGluR2-eYFP with 
an Alexa Fluor 647 (AF647)-tagged antibody (U, V, W) and mGluR2-eYFP (M, N) or mGluR3-
eYFP (O) density with eYFP were assessed by flow cytometry assays (n = 3 – 5 independent 
experiments with 8148 – 10418 cells per experimental condition). (P to R) Density of mGluR2 (P), 
mGluR3 (Q) or mGluR2TM4 (R) shown as [3H]LY341495 binding in membrane preparations of 
cells exposed overnight to clozapine (10 µM), or vehicle (n = 4 independent groups of membrane 
preparations). (S) Quantification of FRET efficiencies (n = 315 – 364 regions of interest in three 
independent experiments). (T) Quantification of PLA dots (n = 160 – 253 cell regions of interest 
demarcated according to eYFP signal within previously defined eCFP-positive cells in three 
independent experiments). (W) Intracellular eYFP signal in cells stably expressing mGluR2-eYFP 
and harboring 5-HT2AR-eCFP at the inducible locus. Cells were treated with doxycycline, and then 
exposed overnight to clozapine (10 µM), or vehicle (n = 73 – 68 cell regions of interest demarcated 
based on eCFP signal within intracellular vesicles in three independent experiments). Data are 
mean  SEM (H, and I, L to R, and T to W) or median with 95% confidence interval (S). Statistical 
analysis was performed using Student’s t-test (N to R, S, T, and W), one-way ANOVA with 
Bonferroni’s post hoc test (M and U), two-way ANOVA with Bonferroni’s post hoc test (H, I, L), or 
Mann-Whitney U test (S). **P < 0.01, ***P < 0.001, n.s., not significant. Scale bars, 5 µm.  
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3. Effect of clozapine on mGluR2’s subcellular distribution 
Cells induced to express 5-HT2AR-eCFP and stably expressing mGluR2-eYFP were incubated 
with clozapine or vehicle. As before (see Fig. 3A, above), induction of 5-HT2AR-eCFP corroborated 
a high level of colocalization between 5-HT2AR-eCFP and mGluR2-eYFP in intracellular vesicles 
of vehicle-treated cells (Fig. 9F, G and L). Importantly, addition of clozapine resulted in an 
observable reduction of colocalization between mGluR2-eYFP and 5-HT2AR-eCFP (Figs. 9, F and 
Hand L). This effect was not observed after addition of M100907 (Figs. 9, F and I), and was 
prevented by TAT-TM4 (Fig. 9I). Interestingly, and opposite to the effect observed in cells 
expressing 5-HT2AR-eCFP alone (see Fig. 9A, above), both 5-HT2AR-eCFP and mGluR2-eYFP 
remained intracellularly colocalized upon exposure to M100907 (Fig. 9F and J). As expected (see 
Fig. 3C, above), colocalization was less observable in cells coexpressing 5-HT2AR-eCFP and 
mGluR2TM4-eYFP (Figs. 9H, K, L), yet this low degree of colocalization was unaffected upon 
clozapine exposure (Figs. 9F, H and L)). Together, these data suggest that clozapine, and not 
M100907, reduces subcellular colocalization of 5-HT2AR-eCFP and mGluR2-eYFP through a 
mechanism that requires their molecular proximity.  
4. Effect of clozapine on mGluR2 density and expression and its heteromeric 
association with 5-HT2AR  
We next tested whether clozapine treatment affects mGluR2’s density via the 5-HT2AR-mGluR2 
heteromer. Our flow cytometry analysis shows that, in DOX(+) cells stably expressing mGluR2-
eYFP, clozapine treatment reduced intensity of eYFP (Fig. 9F), an effect that was not observed 
upon M100907 treatment (Fig. 9N) or in cells stably expressing mGluR3-eYFP (Fig. 9O). Similarly, 
density of mGluR2-eYFP, as determined by binding saturation curves with [3H]LY341495, was 
reduced upon clozapine treatment in cells induced to express 5-HT2AR-eCFP and stably 
expressing mGluR2-eYFP (Fig. 9P and Fig. A2 A). This clozapine-dependent effect, however, was 
not observed in cells induced to express 5-HT2AR-eCFP and stably expressing either mGluR3-
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eYFP (Fig. 9Q and Fig. A2 B) or mGluR2TM4-eYFP (Fig. 9R and Fig. A2 C). Treatment with 
clozapine also diminished both FRET efficiency (Fig. 9S) and PLA signal (Fig. 9T) between 5-
HT2AR-eCFP and mGluR2-eYFP. Most importantly, although clozapine (Fig. 9U), but not M100907 
(Fig. 9V), decreased cell surface immunoreactivity of mGluR2-eYFP, this effect was more evident 
on the subpopulation of mGluR2 located intracellularly (Fig. 9W). Additional controls included 
absence of effect of clozapine on cell surface mGluR2-eYFP immunoreactivity (Fig. A2 D5Q) and 
eYFP signal (Fig. A2 E) in DOX(-) cells.  
 
X. Absence of 5-HT2AR expression affects mGluR2 localization in cortical 
pyramidal neurons 
1. Colocalization of mGluR2 and Rab5 in mouse cortical primary neurons 
Previous neuroanatomical studies showed that 5-HT2AR and mGluR2 colocalize in frontal cortex 
pyramidal neurons. Our current data so far suggest that expression of 5-HT2AR modulates mGluR2 
trafficking and localization in a mammalian tissue culture model. To ensure that this phenomenon 
occurs in a primary cell culture system, we examined whether localization of mGluR2 in Rab5-
positive endosomes is affected in cortical neuron cultures of 5-HT2AR knockout (5-HT2AR
-/-) mice 
and wild-type (5-HT2AR
+/+) littermates. Notably, colocalization of anti-mGluR2 immunoreactivity 
and Rab5 was significantly reduced in cortical primary neuron cultures of 5-HT2AR
-/- mice, as 
compared to 5-HT2AR
+/+ animals (Figs. 10, A and B).  
2. Effect of 5-HT2AR expression on mGluR2 subcellular localization in mouse frontal 
cortex synapses 
To assess whether the subcellular localization of mGluR2 is regulated by its interactions with 5-
HT2AR in native tissue, we examined the distribution of anti-mGluR2 immunoreactivity relative to 
the plasmalemma in the frontal cortex of 5-HT2AR
+/+ and 5-HT2AR







Fig. 10. Localization of mGluR2 is dysregulated in the frontal cortex of 5-HT2AR−/− mice. (A 
and B) Colocalization analysis of anti-mGluR2 and anti-Rab5 immunoreactivity in cortical primary 
cultures of 5-HT2AR
+/+ and 5-HT2AR
−/− mice. Representative confocal micrographs (A). Manders’ 
coefficient colocalization analysis (B) (n = 30 to 74 cell regions of interest in two independent 
experiments). Nuclei were stained in blue with Hoechst 33342. (C and D) Immunogold labeling for 
anti-mGluR2 immunoreactivity in the frontal cortex of 5-HT2AR
+/+ and 5-HT2AR
−/− mice (n = 4 mice 
per genotype and 25 to 35 synapses per mouse). Representative photomicrographs showing 
excitatory synapses in mouse frontal cortex (C). Quantification of relative distribution of gold 
particles within postsynaptic spines (D). Data are means ± SEM (B and D). Statistical analysis 
was performed using Student’s t test (B) or two-way ANOVA with Bonferroni’s post hoc test (D). 
*P < 0.05 and ***P < 0.001. Scale bars, 5 μm (A) and 100 nm (C). n.s., not significant.  
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labeling. We focused our analysis solely on excitatory postsynaptic dendritic spines which in the 
frontal cortex region are the principal sites of glutamatergic input onto pyramidal neurons, and our 
previous data showed that 5-HT2AR and mGluR2 crosstalk in this population of cortical cells. 
Within postsynaptic dendritic spines, particle clusters were observed at plasma membrane, inside 
the cytoplasm, or distributed on both plasmalemma and intracellularly (Fig. A3). For each synapse, 
distribution was scored based on these three categories. In neurons from 5-HT2AR
+/+ mice, the 
largest proportion of synapses showed both plasma membrane and intracellular labeling (Figs. 
10, C and D). Additionally, there was a significantly greater proportion of gold particle clusters at 
the plasma membrane alone in neurons from 5-HT2AR
-/- mice relative to 5-HT2AR
+/+ littermates 
(Figs. 10, C and D). Together, these findings indicate that subcellular localization of mGluR2 is 
affected by expression of 5-HT2AR in mouse cortical pyramidal neurons. 
 
XI. 5-HT2AR-mGluR2 fluorescence complementation in the HEK293 maturation 
pathway 
1. In the endoplasmic reticulum 
To address whether homo or heterodimeric receptor’s complexes can be matured in the ER, we 
assessed by confocal microscopy the colocalization and the codistribution of the BiFC signal with 
the ER dye ER-Tracker, using the same quantitative colocalization analyses. 5-HT2A, mGlu2 and 
mGlu3 homodimers complementation signals overlapped with the red dye, suggesting post-
translational assembling in this organelle (Fig.11A, B, C, E and F). More importantly, 5-HT2A-
mGlu2 BiFC signal colocalized with the reticulum (Fig. 11D). 5-HT2AR homodimer exhibited a 
significantly higher index of colocalization index (Manders p<0.001), accounting for ±80% of 
probes co-occurrence (Fig. 11E). No significant variation of mCitrine amount was measured (±0.6) 









Fig. 11. 5-HT2AR-mGluR2 fluorescence complementation in the maturation pathway of 
HEK293. (A) Quantitative colocalization analysis of BiFC signals and the endoplasmic reticulum. 
(A to D) Single channel confocal micrographs of BiFC signal in HEK293 cells transfected to 
coexpress 5-HT2AR-mCi-N172 and 5-HT2AR-mCi-C67 (2AN-2AC), mGluR2-mCi-N172 and 
mGluR2-mCi-C67 (G2N-G2C), mGluR3-mCi-N172 and mGluR3-mCi-C67 (G3N-G3C), or 5-
HT2AR-mCi-N172 and mGluR2-mCi-C67 (2AN-G2C)and treated with the ER dye ER-Tracker. (E 
and F) Manders’ and Pearson’s coefficient colocalization analysis of BiFC mCitrine (yellow) and 
ER-Tracker (red) signal. (G) Colocalization between BiFC of 5-HT2AR-mCi-N172 and 5-HT2AR-
mCi-C67, mGluR2-mCi-N172 and mGluR2-mCi-C67, mGluR3-mCi-N172 and mGluR3-mCi-C67, 
or 5-HT2AR-mCi-N172 and mGluR2-mCi-C67 and the Golgi apparatus 58K. Immnunofluorescence 
using a primary antibody against 58K protein and secondary AF568. Arrows point white pixels 
indicating positive signals for both probes. (H) Intensities distributions line scans from the 
membrane to the nucleus areas. Fluorescence intensity profiles illustrate the spatial codistribution 
of the two probes, BiFC and ER-Tracker. The relative similarity probes profiles in the case of 5-
HT2AR are consistent with relatively high and concentrated yellow pixels, as depicted by the 
image. mGluRs absence of paired profiles was reflected by absence of correlation. (I) 
ImageStream IFC-based BiFC of dual positive cell populations gated according to their Bright 
Details Similarity scores (BDS). Orange areas represent gated colocalized cell populations after 
indicated BDS calculation. Percentages of colocalized cells are shown. Images represent flowed 
cells and fluorescence profiles in each population acquired with a 60x objective. n=: 5-HT2A: 579; 
mGlu2: 811; mGlu3: 281; 5-HT2A-mGlu2: 974. Data are means ± SEM for 2 experiments (A to D, 
and I), one experiment (G). Statistical analysis was performed using one-way ANOVA with 
Bonferroni’s post hoc test (E and F) and a Pearson logarithm transformation for the BDS score 
calculation (I). ***p<0.001, n.s. not significant. Scale bar is 10 μm.  
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homodimer elicited a high fractional overlap with the ER dye (Fig. 11E). Probes intensity 
codistribution analysis by Pearson correlation index (PCC) confirmed a relatively high index of 
codistribution between the signals, suggesting a linear correlation of their intensity in the organelle 
(Fig. 11F). This was supported by the intensity profiles plotted by line scans crossing the 
intracellular cell’s area from the membrane to the nucleus (Fig. 11G). There was no such 
correlation in the case of the mGluRs (Fig. 11F). The PCC value of the 5-HT2A-mGlu2 receptor 
heteromer with the ER dye was significantly higher than the mGluR homodimers but lower than 
the 5-HT2AR homodimer, suggesting a partial overlap with the ER (Fig. 11F). Noticeably, the 
expression pattern of the heterocomplex was both plasma membranous and intracellular (Fig. 
11D). Together, these colocalization analyses suggest that 5-HT2A and mGluR2, come in close 
proximity within the ER.  
2. In the Golgi apparatus 
We used an immunofluorescence approach to detect the presence of the 5-HT2A-mGlu2 receptor 
heteromer in the Golgi apparatus (GA) with an anti-58k antibodies targeting the resident protein 
58K, conjugated to AlexaFluor568 secondary antibody. Due to the reduced area covered by the 
Golgi apparatus within cells compared to that of the ER, we qualitatively assessed the presence 
of the BiFC signal attesting the formation of the 5-HT2AR-mGlu2 heterocomplex (Fig. 11H). 
Homomeric 5-HT2A mGluR2 and mGlu3 receptors were found is small proportion in the Golgi 
apparatus, consistent with the upward flow of the protein biosynthesis (Fig. 11H). 5-HT2A-mGlu2 
heterocomplex colocalized with the GA. This suggests that the heterodimer may also be matured 
in the GA in relatively same proportion as the homomeric structures.  
3. Image Flow Cytometry-based BiFC colocalization of 5-HT2A-mGlu2 heterocomplex 
with the ER 
In order to confirm previous findings in a larger cell populations, we combined IFC with BiFC in 
cells transfected with paired constructs. Double fluorescent populations were analyzed by the 
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Bright Details Similarity score (BDS). Negative gates were set for each complementation 
experiment by colocalizing each probe with the bright field. As previously described, a BDS score 
of >1.5 indicates highly colocalized cell populations254. All calculated control gates provided BDS 
scores ≥ 1.5 (Fig. 11G). This score delineate the gate over which cell population can be interpreted 
as highly colocalized. BDS score of 1.5 showed that 44,6% of 5-HT2A BIFC-positive population 
were highly colocalizing with the ER. Scores of 1.593 and 1.594 gated mGluR2 and mGluR3 
populations accounting for 12.3% and 11%, respectively. The heterodimer scored 1.532 with 
60.4% of colocalized cells. Thus, this experiment distinguished consistent amount of highly 
colocalized cells populations and provided a similar trend between the BiFC constructs, although 




It has long been known that coexpression of multiple 7TMRs by individual cells can affect 
processes related to agonist-promoted receptor signaling, endocytosis and down-
regulation58,64,353–357. The taste receptors provide a typical example. The finding that the class C 
heterodimer formed by T1R1 and T1R3 are sensors for the glutamate and aspartate amino-acid, 
commonly termed umami taste, while T1R2 and T1R3 associate to sense the sweet molecules, 
indicates that heteromerization is required for the perception of different taste stimuli. A change in 
the ligand binding domain (LBD) conformation relays an immediate restructuration of the dimeric 
interface, allowing to switch on downstream signals, which finally results in cell responses as 
diverse as taste perception can be358–360. Previous studies also suggested that for many 
documented 7TMRs heterocomplexes, such as -opioid-2-adrenergic361, 2A adrenergic-1-
adrenergic57, and adenosine A2A-dopamine D2 receptor362, stimulation of only one of the 
components was sufficient to promote co-trafficking of the complex. Thus, the concept of 7TMRs 
co-trafficking in heterologous systems is not new. Pioneer observations suspected the co-
internalization of two opioid receptors as a 7TMRs heterodimer, which were intensively studied for 
their pharmacology and their signaling as oligomers. The authors suggested that, etorphine 
treatment leads to internalization of δ-opioid receptor (δOR) when expressed alone, but not when 
it is coexpressed with κ-opioid receptor (κOR). However, they demonstrated that 30% of the 
surface fluorescence diminished indicating that δOR homodimer can be internalized in cells 
expressing both δOR and κOR. It was then proposed that heterodimerization may participate in 
mGluR2 co-internalization64.  
In the present study, our data suggest that expression of 5-HT2AR affects the subcellular 
distribution of mGluR2 through a molecular mechanism that involves a physical interaction of the 
two protomers. We further show that in the same cells, mGluR2 responds differently to processes 
related to agonist-induced trafficking through endosomal compartments when expressed with 5-
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HT2AR. In addition, in glutamatergic excitatory postsynaptic elements of HTR2A-/- mouse frontal 
cortex, mGluR2 subcellular distribution is maintained close to the plasmalemma, similar to the 
prototypical localization observed in Flp-In T-REx stable HEK293 cells not induced to express 5-
HT2AR. Moreover, in cortical primary culture of 5-HT2AR-deficient mice, the colocalization of 
mGluR2 and Rab5 is diminished, supporting the finding that 5-HT2AR expression favors Rab5-
mediated internalization mGluR2. 
Under basal state experimental conditions (i.e., the dialyzed FBS used in the culture media is free 
of the endogenous neurotransmitter 5-HT) our data validate the intriguing observation that 5-
HT2AR shows an elevated level of localization in intracellular vesicles, which could appear as an 
anomalous localization compared to most 7TMRs that are primarily addressed to the surface. This 
singular phenotype had previously been observed in several experimental systems, including 
HEK293 and CHO-K1 cells40,88,363. By assessing, in intact COS-7 cells, the interaction between 5-
HT2AR and 5-HT2CR’s PSD-95/Disc-large/Zonula occludens-1 (PDZ) domains and co-transfected 
pre or postsynaptic PDZ resident proteins, it was reported a prominent intracellular presence of 5-
HT2AR when transfected alone, as a consequence of its interaction with specific sets of intracellular 
PDZ proteins364. Additionally, those protein sites together with PSD-95, being resident of the 
postsynaptic element, are in accordance with the main localization of 5-HT2AR in this compartment 
(see below). Although not mutually exclusive, the physical interaction of 5-HT2AR and PSD-95, 
besides providing structural localization, has also a functional role: PSD-95 enhances 5-HT2AR-
mediated activation of Gαq signaling as measured by IP accumulation in HEK 293 cells365. 
However, the direct interaction of 5-HT2AR and PSD-95 accounting for this phenotype was 
interpreted in two ways: PSD-95 would anchor 5-HT2AR in clusters to the cell surface, suggesting 
that its constitutive activity can be modulated by this postsynapytic proteins; and second, that this 
localization would favor interactions between 5-HT2AR and other downstream effectors to elicit 
agonist-induced signaling yet restricting agonist-dependent internalization of 5-HT2AR365; here, 
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PSD-95 inhibits agonist-induced internalization of 5-HT2AR in order to maintain the receptor near 
cell surface pools. This process is also thought to participate, through the recognition by PSD-95 
of specific PDZ motifs borne by 5-HT2AR, in its proper targeting to dendrites of pyramidal 
neurons366. In support of such cellular organization, it was also proposed that, similar to the 
agonist-independent G protein activation of 5-HT2CR, 5-HT2AR may also have constitutive activity 
in heterologous systems, although to a much lesser extent than the former receptor, hence its 
intracellular localization367. Later, the constitutive activity of the 5-HT2AR has been reevaluated: 
using a cell-based functional assay, a stronger turnover was measured, that could be modulated 
by mutating residues in the helices 6 and 3 (interaction model) of the WT receptor18,368. Together, 
these reports in heterologous cellular systems addressed the nonstandard localization of 5-HT2AR 
by providing functional and structural plausible explanations. Nonetheless, the 5-HT2AR 
intracellular distribution is not restricted to such systems. Some of these regions contain neurons 
that express both 5-HT2AR and mGluR2. While testing the subcellular distribution following the 
dendritic targeting mediated by the PDZ-binding domain of 5-HT2AR, SFV-induced exogenous 
expression of 5-HT2AR was found intracellularly, within dendrites of cortical primary neurons, in 
accordance with its endogenous distribution in culture366. 
Immunocytochemistry studies on rat cerebellar cortex and olfactory bulb demonstrated both 
intracellular and membranous expression of the 5-HT2AR protein using two different antibodies, 
targeting either the receptor N-terminus or the C-terminus (both tested and exhibiting an 
intracellular presence in form of puncta in S2 cells)369. In the rat spinal cord and ganglia, the 
immuno-targeted 5-HT2AR was observed in small and large neurons and also interpreted as 
intracellular, i.e. in “dot-like” cytoplasmic distribution370. The receptor was also immuno-reactive in 
the somata and dendrites of Purkinje cells and in neural bodies of deep cellular nuclei, where 
again, we could observed dot-like cytosolic patterns133. 
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In the rat VTA, another study showed the prominent cytoplasmic localization of 5-HT2AR-like 
immunoreactivity colocalizing with the enzyme tyrosine hydroxylase, marker of dopaminergic 
neurons in this region, where 92% of the immunogold particles was detected. Neurons where TH 
was not detected also displayed this intracellular pattern, and was interpreted as membrane 
recycling of surface receptors, with all the caution attributed to immunogold assays127. Given the 
highly probable constitutive activity of 5-HT2AR (see above), it is possible to interpret this presence 
as agonist-independent activated receptor trafficking. Additionally, 5-HT2AR immunoperoxidase 
stained other organelles such as the endoplasmic reticulum, Golgi apparatus, mitochondria and 
microtubules. This has also been observed in a study providing similar results in the rat cerebral 
cortex, using immunogold counterstaining and colocalization with the Microtubule Associated 
Protein 1A (MAP-1A)371. The authors validated previous findings addressing the large intracellular 
presence of 5-HT2AR in the rat CNS123, and specified the possible link between the intracellular 
enrichment of 5-HT2AR in small dendrites of pyramidal neurons and the microtubule network, as a 
likely interaction with MAP-1A. This interaction could potentially generate more interactions with 
intracellular signaling molecules, and could also suggest an intracellular signaling role or a 
dynamic association between surface and cytosolic 5-HT2AR371. A study focused on the caudate-
putamen nucleus and the nucleus accumbens shell, attested that 5-HT2AR and NMDAR 
colocalized in neuron’s somata and dendrites. Interestingly, the intracellular presence of 5-HT2AR 
was associated with cytoplasmic organelles rather than synaptic or extra-synaptic plasma 
membranes. Those neurons, assumed to be spiny striatal in the CPN and the NAc, were localized 
in dendrites and immuno-reacted with the endoplasmic reticulum and mitochondria. In the 
dorsolateral part of the CPN, labeling was more sharply localized in restricted areas between the 
plasma membrane and along mitochondria membranes, as well as in axon terminal endosomes, 
MVB, and small synaptic vesilcles372. In nociceptive neurons of rat lumbar dorsal root ganglia, 5-
HT2AR appeared in the cytoplasm, and at the junction of sensory and satellite cells, though also 
found at the plasma membrane of larger cell bodies373. While demonstrating the putative 
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interaction of 5-HT2CR with 5-HT2AR in the mPFC of rats, confocal images showed that in this 
critical region, 5-HT2AR immunoreactivity was mostly intracellular374. In a study aiming to 
differentiate the anti-aversive action of serotonin inputs through activation of the 5-HT2AR in the 
aversive system held within the midbrain periaqueductal grey matter, immunoreactivity was 
observed in both soma and dendrites of GABAergic interneurons375. The cytoplasmic localization 
of the 5-HT2AR can also be found in unexpected cell types. Besides being observed in cell bodies 
and dendrites of pyramidal neurons in the cortex, the receptor was detected in Schwann cells 
using a newly developed monoclonal antibody targeting an epitope on the receptor N-terminal376. 
In rat hippocampus, 5-HT2AR was detected in mossy fibers, indicating a presynaptic function of 
serotonin on glutamate axons. Additionally, the staining suggested that the receptor could be 
found on both excitatory and inhibitory neurons. Similar to the above findings, its intracellular 
presence was also recognized377. The approaches using immunoreactivity depends on the 
antibodies used, especially their reliability in terms of specificity378. It is possible, and often 
considered as a limitation, that several antibodies raised against different epitopes of the 5-HT2AR 
receptor could lead to variable labelings of different cell types and subcellular localizations. 
However, the use of several antibodies at the same time followed by analysis of the matching 
profiles, allowed to validate and comfort the intracellular presence of the 5-HT2AR379. The 
discrepancies could be attributed to the different conformations adopted by the receptor, i.e. 
different activation states that could reflect different levels of subcellular distribution: an antibody 
raised against the N-terminal end of the receptor would be likely inefficient to localized internalized 
vesicular receptors, because the N-terminal  is in its lumen126,380. 
Conversely, the 5-HT2AR was reported to be mostly located at the plasma membrane, in 
heterologous cell systems261,381, or both intracellularly and at the cell surface137. In mouse cortical 
neurons, both the dendritic plasma membrane and the axon cytoplasm were positive for the 
serotonin receptor252. It is possible that the antibodies, used or the system itself, may contribute 
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to such variations in the distribution pattern of 5-HT2AR. Another possibility is that, when the rat 5-
HT2AR is transfected in human cells, the trafficking proteins could not recognize its PDZ motif, 
which is different among species382. In vivo, ultrastructural studies of the rat spinal cord 
demonstrated a major localization of the 5-HT2AR at the plasma membrane in many subregions383. 
However, the same study found substantial staining in intracellular organelles, such as 
endosomes and MVB. Moreover, 5-HT2AR may take distinct functions whether localize in the 
spinal cord, as opposed to the cerebral cortex or the midbrain.  This could explain such differences 
in its expression. In a more recent review, it was proposed and admitted that the 5-HT2AR can 
actually function and traffic differently, in pre or post synaptic terminals, as well as in different cell 
types384. The mixed plasma membrane/cytoplasm distribution pattern of 5-HT2AR was also 
observed in the intestine385. In non-human primates, similar findings have been reported124.  
Together, this collection of studies indicates that the 5-HT2AR may be found in multiple brain 
regions where it adopts mixed distribution patterns, and more importantly, corroborates the 
intracellular distribution of the receptor. In heterologous cell systems, either the plasma 
membranous or the cytoplasmic pattern can be due to the absence of specific trafficking and 
signaling interacting partners that are present endogenously in vivo386. The presence or absence 
of ligand could also cause discrepancies. Moreover, the specific localization of a brain region 
and/or or cell type, determines the receptor’s function; this is another point that could explain its 
mixed distribution pattern. Lastly, the technique in use and how it is carried out could also affect 
the results. Several hypotheses have been proposed to explain such atypical behavior for a class 
A 7TMR, such as constitutive activity, intracellular signaling and as a sensor for serotonin 
concentration. In accordance with our findings herein, another possibility may be explored in future 
work. The basal activity of the 5-HT2AR was substancial in the stable cell line used, and this 
seemed to relocalize mGluR2, in absence of agonist. While the activation of 5-HT2AR implicated 
Rab5-mediated internalization of mGluR2, it is possible that the serotonin receptor plays a role in 
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the internalization of unbound interacting receptors and promote their agonist-independent 
internalization. This is consistent with the observation that in presence of mGluR2 agonist 
LY379268, its colocalization with Rab5 is reversed. This mechanism is mediated by its 
heteromerization with 5-HT2AR. Another possibility is that the heteromeric formation would signal 
from intracellular compartments, offering a novel functionally never observed previously. 
Most 7TMRs are trafficked through the endocytic pathway after internalization263,387. We showed 
that, in the absence of 5-HT2AR or mGluR2 agonists, the glutamate receptor colocalization indexes 
with endosome markers were higher when coexpressed with 5-HT2AR, as compared to that 
obtained in HEK293 cells expressing mGluR2 alone. Our data also suggest that the presence of 
5-HT2AR in cells stably expressing mGluR2 increased mGluR2 colocalization with different 
markers of the endocytic pathway such as Rab5, Rab7, and the transferrin receptor. Considering 
that colocalization of mGluR2 and Rab5 was also reduced in 5-HT2AR
−/− mouse cortical primary 
cultures, these data provide evidence that 5-HT2AR’s constitutive activity affects the localization of 
mGluR2 within individual components of the endocytic pathway. 
Although an important proportion of the 5-HT2AR population is located intracellularly, we and 
others have validated the expected finding that addition of 5-HT2AR agonists, including 5-HT or 
DOI, leads to activation of Gαq/11 protein-dependent pathways, such as stimulation of 
phospholipase C (PLC) activity, which increases intracellular inositol triphosphate (IP3), 
diacylglycerol (DAG) and intracellular Ca2+ levels251,254,388. 
When HEK293 cells were transfected with both 5-HT2AR-mCherry and mGluR2-mCitrine 
construct, we observed that mGluR2 is relocalized intracellularly like it is partially adopting the 
pattern of the serotonin receptor. However, this was not the case for all cells cotransfected with 
both constructs; while the 5-HT2AR-mCherry was localized inside all the observed cells, mGluR2-
eYFP was still maintained at the plasma membrane for some of them. It is likely that not all the 
cells express the same exact ratio of 5-HT2AR/mGluR2 receptors. The relative stoichiometry, or 
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the amount of transfected DNA penetrating the cells in terms of copies, has been shown to affect 
the crosstalk between 5-HT2AR and mGluR2, responsible for the mobilization of GIRK1/GIRK4 
currents as a reporter of Gαi and Gαq activation. It has been already reported that in HEK 293 
cells, the relative stoichiometry between the two cotransfected receptors is critical to elicit a robust 
crosstalk251,254. Because the functional crosstalk has been validated by several functional assays 
(GIRK current and Ca2+ mobilization), in this study we selected clones that elicited a robust cross-
signaling in addition to their intracellular colocalization. In transfected cells that express 5-HT2AR-
mCherry and mGluR2-eYFP, the exact number of inserted genes was not assessed, and it is 
possible that the relative stoichiometry between the two receptors was not conserved. Together, 
these observations provide an interesting conclusion, suggesting that, in cells, a characteristic 
stoichiometry is necessary to elicit both the functional crosstalk and the co-trafficking of 5-HT2AR 
and mGluR2. Further work would be required to determine what is the exact relative stoichiometry 
in neurons co-expressing the two receptors and likely prone to cross-signal, and compare the 
findings to the number of exogenous DNA copies inserted into the cell genome of crosstalk 
positive clones. 
These above considerations incline to speculate that a critical stoichiometry between 5-HT2AR and 
mGluR2 can either be beneficial (i.e. physiologic) or detrimental (over/under-expressed) for the 
neuron and its neurotransmission, and that the intracellular localization of 5-HT2AR is an important 
factor of regulation. This is relevant to schizophrenia. Following the simplest hypothesis that 
trafficking controls proteins’ subcellular spatial and temporal distribution, it is then possible that a 
defect in this synchronicity may lead to unbalanced ratio of receptors, which, if maintained for a 
substantial amount of time and because of the entanglement of receptor trafficking and signaling, 
increase the likelihood to generate a global failure, in a form of a neuropsychiatric disorder. 
The implication of subcellular trafficking in schizophrenia was the topic of several symposia where, 
for the first time, to our knowledge, links were made between gene association and molecular 
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mechanisms389. In particular, several themes were related to endosomal trafficking and clathrin-
coated dependent endocytosis, as well as the DTBNP1 gene390. In post mortem tissues extracted 
from subjects with psychotic disorders, altered levels of several proteins interacting with clathrin, 
AP-2 and dynamin-1, among others, have been found391. These proteins regulate lysosome 
positioning and expression, endosomal trafficking and cell division (this review article lists several 
other proteins implicated in trafficking and detected in genetic or GWAS association studies). The 
DTNBP1 gene is cited among several other primary candidates associated or altered in 
schizophrenia, such as COMT, NRG1, RGS4, GRM3, and DISC1143,392,393. 
Emerging hypotheses shedded light on a possible genetic dysregulation of the trafficking 
machinery and more specifically, the endosomal system, resulting in neurochemical and signaling 
abnormalities390,391. It is supported by genome wide analyses that detected several genes 
implicated in schizophrenia related to the endosomal trafficking, and in particular to the potential 
defects of the Biogenesis of Lysosome-related Organelles Complex-1 (BLOC-1). The 
dystrobrevin-binding protein 1 (DTNBP1) gene that encodes the dysbindin-1 protein, together with 
MUTED, are essential components of the BLOC-1 protein complex, and has become a highly 
scrutinized gene for its implication in schizophrenia317,394, as well as in cognition in healthy 
subjects395. Dysbindin is widely expressed in neurons, in both presynaptic terminal and 
postsynaptic densities throughout the brain395,396. It is expressed in regions known to contain both 
5-HT2AR and mGluR2, such as the frontal and temporal cortexes, certain nuclei of the basal 
ganglia, the hippocampus, the thalamus, the amygdala, as well as the midbrain, which receives 
inputs from the claustrum that may control conditioning and sleep397, a region that also receives 
main serotoninergic innervation from the DR398. Dysbindin mRNA is reduced in the dorsal 
prefrontal cortex and in the midbrain of patients with schizophrenia399. In the hippocampus of those 
patients, both mRNA and dysbindin protein are reduced. More importantly, this reduction in the 
contribution of dysbindin in the proper functioning of BLOC-1 has been shown to affect the surface 
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localization of D2R, one of the main class A 7TMRs involved in both schizophrenia 
physiopathology and its treatment. The dopamine hypothesis indeed postulates that, within the 
PFC, the D2R-D1R ratio is imbalanced in favor of D2R, resulting in a reduction of the cortical 
excitability concomitant with a reduction of the inhibitory strength of GABA interneurons400. In 
human SH-SY5Y neuroblastoma cells and in cultured cortical neurons, the reduction in dysbindin 
expression has been shown to augment the cell surface presence of D2R, but not D1R401. siRNA-
induced downregulation of dysbindin decreased levels of SNAP25 and synapsin I, together with a 
reduction of glutamate release, suggesting that dysbindin plays a role in exocytosis of glutamate 
containing synaptic vesicles402. Similar findings have also been reported in the sandy mouse (a 
natural occurring null mutation of DTNBP1)403. Other components of the BLOC-1, such as snapin 
and pallidin, can respectively interact with SNAP25 and syntaxin 13401, two members of the 
SNARE family, master regulators of membrane fusion404,405. It has also been proposed that, under 
elevated synaptic activity, pallidin interacts with Rab5 to recycle synaptic vesicles more efficiently 
in pools within early endosomes. Interestingly, in yeast, BLOC-1 may also regulate and participate 
to the early endosome maturation by interacting with Rab5 homolog406. These interactions, if 
altered, can also affect the dynamic and the spatial distribution of endosomes by disturbing the 
actin/microtubule cytoskeleton structure407. In the case of dysbindin, it has also been shown that 
the protein does not primarily regulate the endocytic trafficking, but rather influences later steps 
that lead to degradation. The overcharge of D2R at the cell surface is a consequence of an 
inefficient degradation capacity. Additionally, the authors also suggest that this role of dysbindin 
is perhaps not strictly specific to D2R but also to other 7TMRs, in various cell types408. The 
presynaptic reduction of dysbindin was also correlated with an augmentation of VGLUT-1 in the 
hippocampus of more than 75% of the studied schizophrenia population. It has thus been 
suspected that, because altered DTNBP1 in presynaptic glutamatergic terminals can cause 
BLOC-1 to dysfunction, the augmentation of VGLUT-1 can result from a lesser degradative 
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function of BLOC-1, thus providing a plausible cause of glutamate dysfunction in 
schizophrenia399,409,410. 
It is then tempting to speculate that a defect in receptor stoichiometry, for instance 5-HT2AR and 
mGluR2, due to a defect in protein trafficking/signaling, and/or vice-versa, is a plausible 
explanation for the dysregulation observed in patients with schizophrenia syndrome183. What could 
be at the origin of such a breakdown of the trafficking system is beyond the scope of this study; it 
is possible that persistent epigenetic alterations can cause such deleterious effects in the core 
machinery of protein synthesis and recycling411,412.  
Many neuropsychiatric disorders, including schizophrenia, could be caused by alterations of the 
dopaminergic neurotransmission and related subcellular signaling413. Hyperdopaminergic 
activation in the prefrontal cortex (i.e., increased D2/D1 ratio) associated with a lack of dopamine 
tone in the striatum, may account for both positive and negative symptoms of the schizophrenia 
syndrome414–416. The actual mechanism is complex but one model described that in dysbindin-
deficient primary cortical neurons of sandy mice, BLOC-1-mediated trafficking of D2R toward its 
degradation following ligand binding, corresponded to a reduction of dopamine-induced 
subcellular internalization of D2R. As a result, abundant D2R receptors at the cell surface seemed 
to traffic much faster than D1R400. This excess of signaling has deleterious effects on the 
GABAergic neurons by reducing their excitability in the PFC and in the striatum, and more 
precisely, in the layer V of the PFC pyramidal neurons400. These defects could be the results of 
the dopamine neurotransmission imbalance observed in schizophrenia400. First generation 
antipsychotics have high affinity for the D2R, although atypical antipsychotics target the receptor 
as well309,314,415,417,418.  
In the case of a defect in the 5-HT2AR trafficking in the PFC, similar to the effects described above 
on D2R, it is possible that a disruption of the constitutive activity of 5-HT2AR, either by a defect of 
the endocytosis or the degradation processes, could lead to receptor overexpression and because 
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5-HT2AR seemed to co-internalize mGluR2, the latter would also be downregulated, resulting in 
the loss of inhibition of glutamatergic transmission by the PFC neurons. This is consistent with the 
fact that agonists of mGluR2 have a potential antipsychotic activity. Thus, it would be interesting 
to search into the relationship between 5-HT2AR mGluR2 and DTNBP1, although a study has 
implicated 5-HT2AR and dysbindin in humans419. This is supported by the fact that the involvement 
of the HTR2A gene in the physiopathology of schizophrenia is not clear. Since neither apparent 
gene mutations, nor alteration of the receptor binding properties have been clearly demonstrated, 
it is possible to speculate that the regulation of the receptor is involved, rather than structural 
impairments of the peptide420. 
The potential role of heteromerization as the mechanism underlying the effect of 5-HT2AR on 
subcellular localization of mGluR2 is supported by our findings demonstrating intracellular 
localization of the heterocomplex by BiFC, PLA and FRET. Surprisingly, we could not detect any 
FRET signal nor PLA association near the plasma membrane. As above-mentioned, most of the 
5-HT2AR seems located intracellularly, and despite being able to elicit a fast calcium mobilization, 
validating the fact that 5-HT2AR can signal from the plasma membrane (as it is difficult to imagine 
that a monoamine like 5-HT crosses the plasma membrane and binds intracellular receptors), 
there was low to no interactions in this area. There was though a very faint eCFP fluorescence at 
the plasma membrane. This is puzzling and somewhat not consistent with the standard 
localization of most 7TMRs. If these findings are consistent, it will be necessary to further examine 
the role of receptor heteromers in the intracellular trafficking and signaling or 7TMRs. 
Recent findings point towards instability of a family A 7TMR oligomeric interface47,48,81. Our current 
data demonstrating that the assembly of 5-HT2AR and mGluR2 is able to modulate and affect 
dramatically the distribution of one of them can hardly be explained by a transient interaction 
lasting fractions of seconds as it has been demonstrated for other class A 7TMRs (kiss-and-fly 
model)31,421–423. Here, the interclass 7TMR heteromeric assembly supports the concept that 5-
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HT2AR and mGluR2 are part of a stable receptor complex structure that is co-trafficked and can 
cross-signal consistently along different experiments251,253,254,424. Our findings in the maturation 
pathway, suggesting that 5-HT2AR and mGluR2 can come together in close enough proximity to 
be detected by BiFC confocal microcopy support that, at least in these compartments, the 
existence of a stable heteromer is conceivable. Further work, however, will be necessary to fully 
characterize the dynamics of this structural assembly. Given the active and structurally preferential 
TM domain involved in the homodimerization of mGluR2/3 and 5-HT2AR, a recent 
photocrosslinking study addressed with high accuracy the potential TM domain at the interface of 
the heterocomplex formed by 5-HT2AR and mGluR289. This indicates a potential site of stabilization 
that would explain herein results especially in the surprising case of DOI activating 5-HT2AR-
dependent trafficking of mGluR2 in Rab5 endosomes. Although previously thought as stable, the 
μ-opioid receptor dimer has recently been observed as a minor and negligible entity51. Whether 5-
HT2AR association with mGluR2 it is stable or not, and whether this is a limitation, has to be 
addressed by additional experiments, such as single-molecule pull-down assay (SiMPull) 
assay425–427. 
An interesting observation was that whereas DOX-induced expression of 5-HT2AR augments the 
density of mGluR2, but not that of mGluR3 or mGluR2ΔTM4, Gαi/o protein coupling induced upon 
activation of mGluR2 was substantially reduced in DOX(+) cells as compared to DOX(−) cells. 
Although this finding further supports specificity of the cross-talk between 5-HT2AR and mGluR2, 
the exact mechanism remains to be investigated. Nevertheless, a potential explanation to 
reconcile these results is the existence of a compensatory pathway to rescue mGluR2-dependent 
function due to the higher degree of mGluR2 intracellular localization upon DOX-induced 5-HT2AR 
expression.  
Acting through 5-HT2AR, LY379268 and DOI differently affected the distribution of mGluR2 within 
Rab5-positive endocytic vesicles, as well as the physical interaction between 5-HT2AR and 
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mGluR2. Thus, we found that whereas coexpression of 5-HT2AR prevented the effect of mGluR2 
agonists on both mGluR2 endocytosis and down-regulation, agonist-induced activation of mGluR2 
decreased its physical proximity with 5-HT2AR. Our data also support the conclusion that agonist 
activation of 5-HT2AR increased the colocalization between mGluR2 and Rab5. This effect 
required 5-HT2AR–mGluR2 heteromeric assembly because it was reduced by the interfering 
peptide TAT-TM4. However, under the same experimental conditions, and opposite to the effects 
of LY379268, both mGluR2 density and 5-HT2AR–mGluR2 heteromerization remained 
unchanged. These data suggest that whereas DOI augments intracellular distribution of mGluR2 
within Rab5-positive and clathrin-dependent endosomes coexpressing 5-HT2AR and mGluR2, 
internalized mGluR2 is not degraded after entering the late endosomal/lysosomal pathway. 
Sorting of mGluR2 into the recycling pathway could provide a potential explanation. Additional 
work will be necessary to determine the population of intracellular vesicles downstream of Rab5-
positive endosomes responsible for increased endocytic uptake of mGluR2 without receptor 
down-regulation. 
In the absence of DOI, colocalization of mGluR2 and Rab5 was comparable between cells 
exposed to either TAT-TM4 or the TAT-tagged scrambled peptide. This absence of effect of TAT-
TM4 on colocalization of mGluR2 and Rab5 at steady-state conditions does not call into question 
the capability of the TAT-tagged peptide to reduce 5-HT2AR–mGluR2 complex assembly. Instead, 
together with the effect of TAT-TM4 preventing DOI-induced augmentation of mGluR2 localization 
within Rab5-positive endosomes, these findings suggest that, in the absence of exogenous 
agonists such as DOI, disruption of 5-HT2AR–mGluR2 heteromerization does not imply rapid 
mGluR2 trafficking from Rab5-positive endosomes to alternative endocytic compartments. 
Although discovered in the late 1950’s428, clozapine still remains the gold standard for 
schizophrenia treatment429. It binds with relatively low affinity to dopamine D2R and other 
monoaminergic neurotransmitter receptors, but similarly to other atypical antipsychotics, clozapine 
108 
 
shows a particularly high affinity for 5-HT2AR430,431. Activation of mGluR2 by mGluR2/3 agonists, 
including pomaglumetad or LY2140023 (an oral prodrug of LY404039), has been proposed to 
treat tripartite symptoms in patients with schizophrenia226, but pomaglumetad did not show enough 
clinical utility432. We previously proposed that chronic treatment with clozapine and other atypical 
antipsychotics induces a selective down-regulation of mGluR2 expression through an epigenetic 
mechanism involving repressive histone modifications at the promoter region of the mGluR2 
(GRM2) gene in mouse and human frontal cortex433,434. These preclinical findings were validated 
by clinical work showing the absence of therapeutic effects of pomaglumetad in patients with 
schizophrenia previously treated with atypical antipsychotic medications435. Our current findings 
here propose an alternative, although not mutually exclusive, explanation by which long-lasting 
exposure to clozapine down-regulates mGluR2 density through a mechanism that requires its 
heteromerization with the 5-HT2AR. We observed that subcellular colocalization between 5-HT2AR 
and mGluR2 was reduced upon clozapine exposure. This effect was not induced by overnight 
exposure to M100907, was not observed in cells stably expressing mGluR2ΔTM4 and induced to 
express 5-HT2AR, and was prevented by a TAT-tagged peptide that disrupts 5-HT2AR–mGluR2 
heteromerization. Similarly, clozapine, but not M100907, reduced total mGluR2 density and 
mGluR2 localization at both cell surface and in intracellular compartments. Thus, continued 
exposure to clozapine, but not M100907, affects mGluR2’s subcellular distribution and density 
through a mechanism that requires 5-HT2AR–mGluR2 complex formation. Further work will be 
necessary to better understand the trafficking pathway responsible for alterations in mGluR2 
cellular distribution among 5-HT2AR–positive intracellular vesicles and plasma membrane. 
In the perspective of studying repressive epigenetic mechanisms at the mGlu2 promoter, our lab 
showed that in mouse frontal cortex lacking the HTR2A gene, the mRNA level of mGlu2 are also 
decreased, whereas 5-HT2C and mGlu2 levels are not affected. Although these findings 
demonstrate in animal model an effect of 5-HT2AR affecting mGlu2 at the transcription level, our 
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results in a cellular system showed that expression of 5-HT2AR have a tendency to upregulate 
mGluR2 at the protein level. Although these two observations are distant to the mechanism of 
action, both seem to be consistent, although there is no evidence yet to prove it. 
Exposure of GF-62 cells to 5-HT2AR antagonists, including clozapine, has been shown to 
internalize the receptor which decreased its cell surface density. Similarly, an increase in the 
intracellular concentration of 5-HT2AR in apical dendrites of rat pyramidal cells has been reported, 
following exposure to such drugs. An alternative mechanism to ligand-induced dynamin 
dependent endocytosis has been proposed, involving caveolae436. In the present study, we 
observed that in HEK293 cells induced to express 5-HT2AR, several inverse agonists/antagonists 
relocated the receptor intracellular distribution to the plasma membrane area. Although it is not 
clear whether the receptor is actually spanning the membrane or stationing underneath in 
endosomes, only clozapine treatments seemingly failed to relocate the receptor. Even more 
surprising was that olanzapine, a clozapine analog, did affect 5-HT2AR localization. Such puzzling 
finding would require fine investigations on how antagonists or inverse agonists affect the 
constitutive activity of 5-HT2AR. The constitutive activity of 5-HT2AR can affect ritanserin potency18. 
It is also a property of inverse agonists to affect the basal activity of 5-HT2AR, while antagonist 
compounds should remain “inactive”22. A study in vivo provided more insights into this particular 
mode of action typical to 5-HT2AR437. 
We were unable to characterize the function of our mGluR3 clones with the GTPγS assay. This is 
the reason why HEK293 were transfected with the chimeric G protein qi9, in order to test 
intracellular calcium release. The positive signal elicited by mGlu3 clones suggested that the cell 
line held a functional receptor. To note, we observed a large presence of intracellular eYFP-
positive vesicles, attesting of a constitutive activity of the mGlu3 receptor. In the second step, we 
recently addressed the reason why mGluR3 was not able to efficiently mobilize Gαi protein 
signaling. In several brain tissues, GTPγS assays were performed in presence of the NAM 
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mGluR3. Robust signal was elicited accounting for the presence of mGluR2 and mGluR3 
composite signals. Application of NAM reduced the signal elicited by LY379268 binding in the 
GTPγS readout (data not shown, in progress). Together, this indicates that mGluR3 can efficiently 
couple to G proteins, but for an unknown reason, this was not the case in our cell line. A consistent 
analogy is provided by a study that was able to distinguish mGluR2 signaling from mGluR3230. 
Considering our findings in this heterologous cellular system, the fact that over expression or 
overactivation of the 5-HT2AR may as well induce over internalization of mGluR2 into more 
internalized compartment is consistent with a defect of activity. It would reduce the surface 
availability and the overall density of mGluR2, and likely damped the effect of antipsychotic 
glutamate agonists such as pomaglumetad. Our findings showed that coexpression of 5-HT2AR 
and mGluR2 elicited some populations of more internal glutamate receptors, whereas as in 
average, unlike WT, 5-HT2AR-/- mice postsynaptic area, mGluR2 tends to be nearby the 
plasmalemma. 
Concluding remarks 
Although some reported examples may reflect data overinterpretation or ambiguity due to the 
system in use, the concept that class A 7TMRs form receptor complexes is supported by 
numerous experimental approaches. As of yet, the functional importance of 7TMRs 
oligomerization remains controversial. Our data obtained with stable expression of mGluR2 or 
mGluR2/mGluR3 chimeric constructs and TAT-tagged peptides to disrupt 5-HT2AR–mGluR2 
complex formation support the conclusion that 5-HT2AR affects the subcellular localization of 
mGluR2 through 7TMR heteromerization. The validity of this concept is further advanced by our 
findings showing alterations in mGluR2 cellular distribution in frontal cortex pyramidal neurons of 
5-HT2AR
−/− mice as compared to control littermates. In short, these findings illuminate the 






The relatively low percentage of FRET efficiency is also consistent with the relative proportion but 
also the orientation of the fluorescent proteins. As we cannot establish a positive control to detect 
what is the maximum efficiency of this system, we could not compare our signal to a standard 
maximum FRETe. However, we showed that the mGluR2TM4-eYFP chimera FRETe was 
reduced by 2 folds. This indicates that the interaction is less stable with the mutant or alternatively, 
we cannot rule out that the mutant’s fluorescent protein is orientated differently. Orientation of the 
fluorescent protein is critical for the FRET to occur and its efficiency. Another possibility is that, as 
the KD of the mutant is higher than the WT (Table 1), the function of this receptor is affected and 
could not change its conformation as the WT does. 
Another important question was the origin of mGluR2 trafficked by 5-HT2AR. We showed that the 
application of the dynamin inhibitor dynasore prevented endocytosis of mGluR2 when 5-HT2AR 
was coexpressed. Additionally, BiFC and FACS experiments suggested that the 5-HT2A-mGlu2 
receptor heteromer could be synthesized in the ER, and also detected in the Golgi apparatus. 
Several hypotheses can be provided: the heterocomplex is stable from it biosynthesis in the ER 
to the plasma membrane and it is trafficked as a stable entity; partially synthesized in the ER and 
partially assembled later at the cell surface or in endosomes; or mGlu2 provides an ER exit routes 
for 5-HT2AR, similar to the GABABR or β2AR, and the association is dynamic during the trafficking 
or upon ligand-induced G protein activation. An known limitation to those findings using the BiFC 
assay, is that complements of the fluorescent protein can be covalently fused and therefore, the 
heteromeric association is irreversible438,439. This has limited our studies to the maturation 
pathway, which suggested, even if the association is irreversible, that a close contact occurred. 
Additional work would be necessary to delineate and ascertain the directionality and the timeline 
of this association, for example by tracking 5-HT2AR biosynthesis and trafficking in mGluR2-/- mice. 
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Although the HEK293 cells have been used extensively and reliably over the past decades as a 
neuronal model subrogate, they are not neurons. If they do not express mGluR2 and 5-HT2AR, 
they still translate 7TMR interacting proteins, scaffolds and chaperones necessary for endogenous 
cellular operations and contain the basic machinery to robustly allow and maintain the structure 
and the function of overexpressed 7TMRs, or other transfected or stable receptors and 
transporters. It is interesting to have in mind the native receptor expressed by this cell line and 
control the expression of close and studied receptors to avoid any interference440. There is no 
serotonin in our DMEM, although serotonin is an important neurotransmitter and a hormone for 
the kidney function. GRM2 and GRM3 are also absent though it seems that GRM2 has traces as 
assessed by a microarray study440. 
The question about the affinity of the mGlu2 chimera compared to the WT mGluR2 has not been 
addressed in this study. Whether the difference in affinity comes from the impaired association 
with 5-HT2AR or the mutant by itself, constitutes a point to address.  
Colocalization analyses sometime yielded high variances among and within experiments. This is 
perhaps due to the fact that not all cells elicit the same amount of 5-HT2AR-eCFP after being 
induced, and because stoichiometry seems important, this can lead to a differential internalization 
of mGluR2 consistent with the level of 5-HT2AR in Rab5 or Rab7. 
The primary cortical cultured neurons were extracted from embryonic mice. Because we used the 
total cortical area, the exact nature of the neurons analyzed by immunofluorescence is not known, 
although we favored pyramidal shaped neurons in our collection. 
The Pearson correlation coefficient is sensitive to the fluorescence intensity because the 
correlation is maximal when intensities are linearly associated. The use of Manders coefficient 
was more appropriate in those cases, and explains why the tandem was not systematically used 





[3H]LY341495 binding saturation curves in Flp-In T-REx HEK293 cells 
 
 DOX(-) DOX(+) 
 KD Bmax (pmol/mg prot) KD Bmax (pmol/mg prot) 
mGluR2-eYFP 1.59 ± 0.21 36.94 ± 1.43 2.27 ± 0.15 51.81 ± 1.11 
mGluR3-eYFP 1.16 ± 0.24 5.47 ± 0.30 0.68 ± 0.08 5.56 ± 0.16 
mGluR2TM4-eYFP 89.4 ± 4.84 2.33 ± 0.38 105.4 ± 4.03 3.77 ± 0.38 
 
[3H]LY341495 binding saturation curves in Flp-In T-REx HEK293 cells stably expressing mGluR2-
eYFP, mGluR3-eYFP or mGluR2TM40-eYFP and harboring 5-HT2AR-eCFP at the inducible locus. 
Cells were untreated [DOX(-)] or treated with doxycycline [DOX(+)] (n = 2). The data are presented 
as the mean  s.e. 
 
 
[3H]ketanserin binding saturation curves in Flp-In T-REx HEK293 cells 
 
 DOX(-) DOX(+) 
 KD Bmax (fmol/mg prot) KD Bmax (fmol/mg prot) 
mGluR2-eYFP n/a n/a 0.65 ± 0.07 3211 ± 115.9 
mGluR3-eYFP n/a n/a 0.64 ± 0.09 3343 ± 153.7 
mGluR2TM4-eYFP n/a n/a 0.74 ± 0.12 7923 ± 416.0 
 
[3H]Ketanserin binding saturation curves in Flp-In T-REx HEK293 cells stably expressing mGluR2-
eYFP, mGluR3-eYFP or mGluR2TM40-eYFP and harboring 5-HT2AR-eCFP at the inducible locus. 
Cells were untreated [DOX(-)] or treated with doxycycline [DOX(+)] (n = 2). The data are presented 
as the mean  s.e. n/a, not applicable.   
114 
 
 REFERENCE CITED 
1. Cvicek, V., Goddard, W. A. & Abrol, R. Structure-Based Sequence Alignment of the 
Transmembrane Domains of All Human GPCRs: Phylogenetic, Structural and Functional 
Implications. PLOS Comput. Biol. 12, e1004805 (2016). 
2. JC Venter, M. A. E. M. P. L. R. M. G. S. et al. The sequence of the human genome. Science 
(80-. ). 291, 1304–1351 (2001). 
3. Willyard, C. Expanded human gene tally reignites debate. Nature 558, 334–335 (2018). 
4. Gurevich, V. V. & Gurevich, E. V. GPCRs and Signal Transducers: Interaction 
Stoichiometry. Trends Pharmacol. Sci. 39, 672–684 (2018). 
5. Robinson, D. R., Wu, Y. M. & Lin, S. F. The protein tyrosine kinase family of the human 
genome. Oncogene 19, 5548–5557 (2000). 
6. Hauser, A. S., Attwood, M. M., Rask-andersen, M. & Schiöth, H. B. Trends in GPCR drug 
discovery: new agents, targets and indications Alexander. Nat. Rev. Drug Discov. 16, 829–
842 (2019). 
7. Garland, S. L. Are GPCRs still a source of new targets? Journal of Biomolecular Screening 
18, 947–966 (2013). 
8. Wei, H. et al. Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II 
activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. U. S. A. 
100, 10782–10787 (2003). 
9. Gesty-Palmer, D. et al. A β-arrestin-biased agonist of the parathyroid hormone receptor 
(PTH1R) promotes bone formation independent of G protein activation. Sci. Transl. Med. 
1, (2009). 
10. Brzostowski, J. A. & Kimmel, A. R. Signaling at zero G: G-protein-independent functions for 
7-TM receptors. Trends Biochem. Sci. 26, 291–297 (2001). 
11. Schöneberg, T., Hofreiter, M., Schulz, A. & Römpler, H. Learning from the past: evolution 
of GPCR functions. Trends Pharmacol. Sci. 28, 117–121 (2007). 
12. King, N., Hittinger, C. T. & Carroll, S. B. Evolution of key cell signaling and adhesion protein 
families predates animal origins. Science (80-. ). 301, 361–363 (2003). 
13. Peroutka, S. J. & Howell, T. A. The molecular evolution of G protein-coupled receptors: 
Focus on 5-hydroxytryptamine receptors. Neuropharmacology 33, 319–324 (1994). 
14. Kolakowski, L. F. GCRDb: A G-protein-coupled receptor database. Receptors and 
Channels 2, 1–7 (1994). 
15. Pin, J. P., Bockaert, J. J. L. Molecular tinkering of G protein-coupled receptors : an 
evolutionary success. EMBO J. 18, 1723–1729 (1999). 
16. Fredriksson, R., Lagerström, M. C., Lundin, L.-G. G. & Schiöth, H. B. The G-protein-coupled 
receptors in the human genome form five main families. Phylogenetic analysis, paralogon 
groups, and fingerprints. Mol. Pharmacol. 63, 1256–1272 (2003). 
17. Massotte, D. & Kieffer, B. L. Structure—Function Relationships in G Protein-Coupled 
Receptors. in The G Protein-Coupled Receptors Handbook 3–31 (Humana Press, 2008). 
doi:10.1007/978-1-59259-919-6_1 
18. Shapiro, D. A., Kristiansen, K., Weiner, D. M., Kroeze, W. K. & Roth, B. L. Evidence for a 
model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that 
115 
 
involves the disruption of a strong ionic interaction between helices 3 and 6. J. Biol. Chem. 
277, 11441–11449 (2002). 
19. Hu, G. M., Mai, T. L. & Chen, C. M. Visualizing the GPCR Network: Classification and 
Evolution. Sci. Rep. 7, 1–15 (2017). 
20. Mustafa, A. K., Gadalla, M. M. & Snyder, S. H. Signaling by Gasotransmitters. Sci. Signal. 
2, re2 (2009). 
21. Hilger, D., Masureel, M. & Kobilka, B. K. Structure and dynamics of GPCR signaling 
complexes. Nat. Struct. Mol. Biol. 25, 4–12 (2018). 
22. Sullivan, L., Clarke, W. & Berg, K. Atypical antipsychotics and inverse agonism at 5-HT2 
receptors. Curr. Pharm. Des. 21, 3732–3738 (2015). 
23. Heuss, C., Scanziani, M., Gähwiler, B. H. & Gerber, U. G-protein-independent signaling 
mediated by metabotropic glutamate receptors. Nat. Neurosci. 2, 1070–1077 (1999). 
24. Heuss, C. & Gerber, U. G-protein-independent signaling by G-protein-coupled receptors. 
Trends Neurosci. 23, 469–475 (2000). 
25. Shenoy, S. K. et al. β-Arrestin-dependent, G Protein-independent ERK1/2 Activation by the 
β2 Adrenergic Receptor. J. Biol. Chem. 281, 1261–1273 (2006). 
26. Sun, Y. et al. Dosage-dependent switch from G protein-coupled to G protein-independent 
signaling by a GPCR. EMBO J. 26, 53–64 (2007). 
27. Cong, X., Topin, J. & Golebiowski, J. Class A GPCRs: Structure, Function, Modeling and 
Structure-based Ligand Design. Curr. Pharm. Des. 23, 4390–4409 (2017). 
28. Muto, T., Tsuchiya, D., Morikawa, K. & Jingami, H. Structures of the extracellular regions 
of the group II/III metabotropic glutamate receptors. Proc. Natl. Acad. Sci. U. S. A. 104, 
3759–3764 (2007). 
29. Fonseca, J. M. & Lambert, N. A. Instability of a class A G protein-coupled receptor oligomer 
interface. Mol. Pharmacol. 75, 1296–1299 (2009). 
30. Kasai, R. S. et al. Full characterization of GPCR monomer-dimer dynamic equilibrium by 
single molecule imaging. J. Cell Biol. 192, 463–480 (2011). 
31. Kasai, R. S., Ito, S. V., Awane, R. M., Fujiwara, T. K. & Kusumi, A. The Class-A GPCR 
Dopamine D2 Receptor Forms Transient Dimers Stabilized by Agonists: Detection by 
Single-Molecule Tracking. Cell Biochem. Biophys. 76, 29–37 (2018). 
32. Hebert, T. E. et al. A peptide derived from a β 2-adrenergic receptor transmembrane domain 
inhibits both receptor dimerization and activation. J. Biol. Chem. 271, 16384–16392 (1996). 
33. González-Maeso, J. GPCR oligomers in pharmacology and signaling. Mol. Brain 4, 20 
(2011). 
34. Gaitonde, S. A. & González-Maeso, J. Contribution of heteromerization to G protein-
coupled receptor function. Curr. Opin. Pharmacol. 32, 23–31 (2017). 
35. Lan, T. H. et al. BRET evidence that β2 adrenergic receptors do not oligomerize in cells. 
Sci. Rep. 5, 1–12 (2015). 
36. Milligan, G. & Bouvier, M. Methods to monitor the quaternary structure of G protein-coupled 
receptors. FEBS Journal 272, 2914–2925 (John Wiley & Sons, Ltd (10.1111), 2005). 
37. Han, Y., Moreira, I. S., Urizar, E., Weinstein, H. & Javitch, J. A. Allosteric communication 
between protomers of dopamine class a GPCR dimers modulates activation. Nat. Chem. 
116 
 
Biol. 5, 688–695 (2009). 
38. Whorton, M. R. et al. Efficient coupling of transducin to monomeric rhodopsin in a 
phospholipid bilayer. J. Biol. Chem. 283, 4387–4394 (2008). 
39. Sartania, N., Appelbe, S., Pediani, J. D. & Milligan, G. Agonist occupancy of a single 
monomeric element is sufficient to cause internalization of the dimeric β2-adrenoceptor. 
Cell. Signal. 19, 1928–1938 (2007). 
40. Lopez-Gimenez, J. F., Canals, M., Pediani, J. D. & Milligan, G. The α1b-adrenoceptor exists 
as a higher-order oligomer: Effective oligomerization is required for receptor maturation, 
surface delivery, and function. Mol. Pharmacol. 71, 1015–1029 (2007). 
41. Ge, B. et al. Single-molecule imaging reveals dimerization/oligomerization of CXCR4 on 
plasma membrane closely related to its function. Sci. Rep. 7, 1–9 (2017). 
42. Smith, T. H., Li, J. G., Dores, M. R. & Trejo, J. A. Protease-activated receptor-4 and 
purinergic receptor P2Y12 dimerize, co-internalize, and activate Akt signaling via 
endosomal recruitment of -arrestin. J. Biol. Chem. 292, 13867–13878 (2017). 
43. Jin, J. et al. CCR5 adopts three homodimeric conformations that control cell surface 
delivery. Sci. Signal. 11, 2869 (2018). 
44. Dorsch, S., Klotz, K.-N., Engelhardt, S., Lohse, M. J. & Bünemann, M. Analysis of receptor 
oligomerization by FRAP microscopy. Nat. Methods 6, 225–230 (2009). 
45. Marsango, S. et al. A molecular basis for selective antagonist destabilization of dopamine 
D3 receptor quaternary organization. Sci. Rep. 7, 1–17 (2017). 
46. Dijkman, P. M. et al. Dynamic tuneable G protein-coupled receptor monomer-dimer 
populations. Nat. Commun. 9, 1710 (2018). 
47. Hern, J. A. et al. Formation and dissociation of M1 muscarinic receptor dimers seen by total 
internal reflection fluorescence imaging of single molecules. Proc. Natl. Acad. Sci. U. S. A. 
107, 2693–2698 (2010). 
48. Pediani, J. D., Ward, R. J., Godin, A. G., Marsango, S. & Milligan, G. Dynamic regulation 
of quaternary organization of the m1 muscarinic receptor by subtype-selective antagonist 
drugs. J. Biol. Chem. 291, 13132–13146 (2016). 
49. Gavalas, A. et al. Segregation of family A G protein-coupled receptor protomers in the 
plasma membrane. Mol. Pharmacol. 84, 346–352 (2013). 
50. Felce, J. H. et al. Receptor Quaternary Organization Explains G Protein-Coupled Receptor 
Family Structure. Cell Rep. 20, 2654–2665 (2017). 
51. Meral, D. et al. Molecular details of dimerization kinetics reveal negligible populations of 
transient µ-opioid receptor homodimers at physiological concentrations. Sci. Rep. 8, 7705 
(2018). 
52. Lavoie, C. et al. Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-
adrenergic receptor internalization and ERK signaling efficacy. J. Biol. Chem. 277, 35402–
35410 (2002). 
53. Lavoie, C. & Hébert, T. E. Pharmacological characterization of putative β 1 -β 2 -adrenergic 
receptor heterodimers. Can. J. Physiol. Pharmacol. 81, 186–195 (2003). 
54. Mercier, J.-F., Salahpour, A., Angers, S., Breit, A. & Bouvier, M. Quantitative assessment 
of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by 
bioluminescence resonance energy transfer. J. Biol. Chem. 277, 44925–31 (2002). 
117 
 
55. Breit, A., Lagacé, M. & Bouvier, M. Hetero-oligomerization between beta2- and beta3-
adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional 
properties. J. Biol. Chem. 279, 28756–65 (2004). 
56. Stanasila, L., Perez, J.-B., Vogel, H. & Cotecchia, S. Oligomerization of the alpha 1a- and 
alpha 1b-adrenergic receptor subtypes. Potential implications in receptor internalization. J. 
Biol. Chem. 278, 40239–51 (2003). 
57. Xu, J. et al. Heterodimerization of alpha 2A- and beta 1-adrenergic receptors. J. Biol. Chem. 
278, 10770–10777 (2003). 
58. Cvejic, S. & Devi, L. A. Dimerization of the δ opioid receptor: Implication for a role in receptor 
internalization. J. Biol. Chem. 272, 26959–26964 (1997). 
59. McVey, M. et al. Monitoring receptor oligomerization using time-resolved fluorescence 
resonance energy transfer and bioluminescence resonance energy transfer. The human 
delta -opioid receptor displays constitutive oligomerization at the cell surface, which is not 
regulate. J. Biol. Chem. 276, 14092–9 (2001). 
60. Perron, A. A. et al. Agonist-independent desensitization and internalization of the human 
platelet-activating factor receptor by coumermycin-gyrase B-induced dimerization. J. Biol. 
Chem. 278, 27956–27965 (2003). 
61. George, S. R. et al. Oligomerization of μ- and δ-opioid receptors: Generation of novel 
functional properties. J. Biol. Chem. 275, 26128–26135 (2000). 
62. Pfeiffer, M. et al. Heterodimerization of somatostatin and opioid receptors cross-modulates 
phosphorylation, internalization, and desensitization. J. Biol. Chem. 277, 19762–19772 
(2002). 
63. Gomes, I. et al. Heterodimerization of mu and delta opioid receptors: A role in opiate 
synergy. J. Neurosci. 20, RC110–RC110 (2000). 
64. Jordan, B. A. & Devi, L. A. G-protein-coupled receptor heterodimerization modulates 
receptor function. Nature 399, 697–700 (1999). 
65. Jones, K. A. et al. GABA(B) receptors function as a heteromeric assembly of the subunits 
GABA(B)R1 and GABA(B)R2. Nature 396, 674–679 (1998). 
66. Margeta-Mitrovic, M., Jan, Y. N. & Jan, L. Y. A trafficking checkpoint controls GABA(B) 
receptor heterodimerization. Neuron 27, 97–106 (2000). 
67. Bouvier, M. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci. 
2, 274–286 (2001). 
68. Doly, S. et al. GABA B receptor cell-surface export is controlled by an endoplasmic 
reticulum gatekeeper. Mol. Psychiatry 21, 480–490 (2016). 
69. Milligan, G. Oligomerisation of G-protein-coupled receptors. J. Cell Sci. 114, 1265–1271 
(2001). 
70. Bulenger, S., Marullo, S. & Bouvier, M. Emerging role of homo- and heterodimerization in 
G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. 26, 131–
137 (2005). 
71. Doly, S. & Marullo, S. Gatekeepers Controlling GPCR Export and Function. Trends 
Pharmacol. Sci. 36, 636–644 (2015). 
72. El Moustaine, D. et al. Distinct roles of metabotropic glutamate receptor dimerization in 




73. Goudett, C. et al. Heptahelical domain of metabotropic glutamate receptor 5 behaves like 
rhodopsin-like receptors. Proc. Natl. Acad. Sci. U. S. A. 101, 378–383 (2004). 
74. Milligan, G., Ward, R. J. & Marsango, S. GPCR homo-oligomerization. Curr. Opin. Cell Biol. 
57, 40–47 (2019). 
75. Romano, C., Yang, W. L. & O’Malley, K. L. Metabotropic glutamate receptor 5 is a disulfide-
linked dimer. J. Biol. Chem. 271, 28612–28616 (1996). 
76. Lohse, M. J. Dimerization in GPCR mobility and signaling. Curr. Opin. Pharmacol. 10, 53–
58 (2010). 
77. Gurevich, V. V. & Gurevich, E. V. How and why do GPCRs dimerize? Trends Pharmacol. 
Sci. 29, 234–240 (2008). 
78. Guidolin, D., Marcoli, M., Tortorella, C., Maura, G. & Agnati, L. F. G protein-coupled 
receptor-receptor interactions give integrative dynamics to intercellular communication. 
Reviews in the Neurosciences 29, 703–726 (De Gruyter, 2018). 
79. Rasmussen, S. G. F. et al. Crystal structure of the β 2 adrenergic receptor-Gs protein 
complex. Nature 477, 549–557 (2011). 
80. Seven, A. B. et al. G-protein activation by a metabotropic glutamate receptor. Nature 
(2021). doi:10.1038/s41586-021-03680-3 
81. Calebiro, D. et al. Single-molecule analysis of fluorescently labeled G-protein-coupled 
receptors reveals complexes with distinct dynamics and organization. Proc. Natl. Acad. Sci. 
U. S. A. 110, 743–748 (2013). 
82. Fung, J. J. et al. Ligand-regulated oligomerization of Β 2-adrenoceptors in a model lipid 
bilayer. EMBO J. 28, 3315–3328 (2009). 
83. Herrick-Davis, K., Grinde, E., Cowan, A. & Mazurkiewicz, J. E. Fluorescence correlation 
spectroscopy analysis of serotonin, adrenergic, muscarinic, and dopamine receptor 
dimerization: the oligomer number puzzle. Mol. Pharmacol. 84, 630–42 (2013). 
84. Milligan, G. The Prevalence, Maintenance, and Relevance of G Protein–Coupled Receptor 
Oligomerization. Mol. Pharmacol. 84, 158–169 (2013). 
85. Ferré, S. et al. Building a new conceptual framework for receptor heteromers. Nat. Chem. 
Biol. 5, 131–134 (2009). 
86. Gomes, I. et al. G Protein–Coupled Receptor Heteromers. Annu. Rev. Pharmacol. Toxicol. 
56, 403–425 (2016). 
87. Porzionato, A. et al. Receptor–Receptor Interactions of G Protein-Coupled Receptors in the 
Carotid Body: A Working Hypothesis. Front. Physiol. 9, 697 (2018). 
88. Magalhaes, A. C. C. et al. CRF receptor 1 regulates anxiety behavior via sensitization of 5-
HT2 receptor signaling. Nat. Neurosci. 13, 622–629 (2010). 
89. Shah, U. H. H., Toneatti, R., Gaitonde, S. A. A., Shin, J. M. M. & González-Maeso, J. Site-
Specific Incorporation of Genetically Encoded Photo-Crosslinkers Locates the Heteromeric 
Interface of a GPCR Complex in Living Cells. Cell Chem. Biol. 27, 1308-1317.e4 (2020). 
90. Fotiadis, D. et al. Rhodopsin dimers in native disc membranes. Nature 421, 127–128 
(2003). 
91. Fuxe, K. et al. Moonlighting proteins and protein-protein interactions as neurotherapeutic 
119 
 
targets in the G protein-coupled receptor field. Neuropsychopharmacology 39, 131–155 
(2014). 
92. Jeffery, C. J. Protein moonlighting: what is it, and why is it important? Philos. Trans. R. Soc. 
B Biol. Sci. 373, 20160523 (2018). 
93. Jeffery, C. J. Moonlighting proteins: old proteins learning new tricks. Trends Genet. 19, 
415–417 (2003). 
94. Turlejski, K. Evolutionary ancient roles of serotonin: Long-lasting regulation of activity and 
development. Acta Neurobiol. Exp. (Wars). 56, 619–636 (1996). 
95. Azmitia, E. C. Evolution of Serotonin: Sunlight to Suicide. in 21, 3–22 (Elsevier, 2010). 
96. Azmitia, E. C. & York, N. Serotonin. eLS. (2012).  
97. Jayamohanan, H., Kumar, M. K. M. & Aneesh, T. P. 5-HIAA as a potential biological marker 
for neurological and psychiatric disorders. Advanced Pharmaceutical Bulletin 9, 374–381 
(2019). 
98. Fairbanks, L. A., Melega, W. P., Jorgensen, M. J., Kaplan, J. R. & McGuire, M. T. Social 
impulsivity inversely associated with CSF 5-HIAA and fluoxetine exposure in vervet 
monkeys. Neuropsychopharmacology 24, 370–378 (2001). 
99. Bourgeois, M. Serotonin, impulsivity and suicide. Hum. Psychopharmacol. Clin. Exp. 6, 
S31–S36 (1991). 
100. Coccaro, E. F. Central serotonin and impulsive aggression. Br. J. Psychiatry. Suppl. 52–62 
(1989). 
101. Coccaro, E. F., Lee, R. & Kavoussi, R. J. Aggression, suicidality, and intermittent explosive 
disorder: serotonergic correlates in personality disorder and healthy control subjects. 
Neuropsychopharmacology 35, 435–44 (2010). 
102. Coccaro, E. F., Fanning, J. R., Phan, K. L. & Lee, R. Serotonin and impulsive aggression. 
CNS Spectr. 20, 295–302 (2015). 
103. Moberg, T. et al. CSF 5-HIAA and exposure to and expression of interpersonal violence in 
suicide attempters. J. Affect. Disord. 132, 173–178 (2011). 
104. Musshoff, F., Menting, T. & Madea, B. Postmortem serotonin (5-HT) concentrations in the 
cerebrospinal fluid of medicolegal cases. Forensic Sci. Int. 142, 211–219 (2004). 
105. Nordström, P. et al. CSF 5‐HIAA Predicts Suicide Risk After Attempted Suicide. Suicide 
Life‐Threatening Behav. 24, 1–9 (1994). 
106. Ninan, P. T. et al. CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. 
Am. J. Psychiatry 141, 566–569 (1984). 
107. Croonenberghs, J. et al. Peripheral markers of serotonergic and noradrenergic function in 
post- pubertal, caucasian males with autistic disorder. Neuropsychopharmacology 22, 275–
283 (2000). 
108. Hérault, J. et al. Serotonin and autism: Biochemical and molecular biology features. 
Psychiatry Res. 65, 33–43 (1996). 
109. Launay, J. M. et al. Serotonin Metabolism and Other Biochemical Parameters in Infantile 
Autism. Neuropsychobiology 20, 1–11 (1988). 
110. Hoshino, Y. et al. Blood Serotonin and Free Tryptophan Concentration in Autistic Children. 
Neuropsychobiology 11, 22–27 (1984). 
120 
 
111. Chakraborti, B. et al. Gender-Specific Effect of 5-HT and 5-HIAA on Threshold Level of 
Behavioral Symptoms and Sex-Bias in Prevalence of Autism Spectrum Disorder. Front. 
Neurosci. 13, 1375 (2020). 
112. Carlborg, A., Jokinen, J., Nordström, A. L., Jönsson, E. G. & Nordström, P. CSF 5-HIAA, 
attempted suicide and suicide risk in schizophrenia spectrum psychosis. Schizophr. Res. 
112, 80–85 (2009). 
113. Berger, M., Gray, J. A. & Roth, B. L. The expanded biology of serotonin. Annu. Rev. Med. 
60, 355–366 (2009). 
114. López-Giménez, J. F. & González-Maeso, J. Hallucinogens and Serotonin 5-HT2A 
Receptor-Mediated Signaling Pathways. in Behavioral Neurobiology of Psychedelic Drugs 
45–73 (Springer Berlin Heidelberg, 2017).  
115. Steinbusch, H. W. M., Dolatkhah, M. A. & Hopkins, D. A. Anatomical and neurochemical 
organization of the serotonergic system in the mammalian brain and in particular the 
involvement of the dorsal raphe nucleus in relation to neurological diseases. in Progress in 
Brain Research 261, 41–81 (Elsevier B.V., 2021). 
116. Römpler, H. et al. G protein-coupled time travel: Evolutionary aspects of GPCR research. 
Molecular Interventions 7, 17–25 (2007). 
117. A. J. Thompson and S.C.R.Lummis. 5-HT-3 Receptor. in Curr Pharm Des 12, 1–7 (Elsevier, 
2006). 
118. Lummis, S.  5-HT 3 Receptors . eLS 1–7 (2018).  
119. Hannon, J. & Hoyer, D. Molecular biology of 5-HT receptors. Behav. Brain Res. 195, 198–
213 (2008). 
120. Garnovskaya, M. N., Nebigil, C. G., Arthur, J. M., Spurney, R. F. & Raymond, J. R. 5-
Hydroxytryptamine(2A) receptors expressed in rat renal mesangial cells inhibit cyclic AMP 
accumulation. Mol. Pharmacol. 48, 230–237 (1995). 
121. McCorvy, J. D. & Roth, B. L. Structure and function of serotonin G protein-coupled 
receptors. Pharmacol. Ther. 150, 129–142 (2015). 
122. Johansen, A. et al. Human biodistribution and radiation dosimetry of the 5-HT2A receptor 
agonist Cimbi-36 labeled with carbon-11 in two positions. EJNMMI Res. 9, 71 (2019). 
123. Cornea-Hébert, V., Riad, M., Wu, C., Singh, S. K. & Descarries, L. Cellular and subcellular 
distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J. 
Comp. Neurol. 409, 187–209 (1999). 
124. Jakab, R. L. et al. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral 
cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell 
apical dendrites. Proc. Natl. Acad. Sci. U. S. A. 95, 735–740 (1998). 
125. Marek, G. J., Wright, R. A., Schoepp, D. D., Monn, J. A. & Aghajanian, G. K. Physiological 
antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate 
receptors in prefrontal cortex. J. Pharmacol. Exp. Ther. 292, 76–87 (2000). 
126. Miner, L. A. H., Backstrom, J. R., Sanders-Bush, E. & Sesack, S. R. Ultrastructural 
localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal 
cortex. Neuroscience 116, 107–117 (2003). 
127. Doherty, M. D. & Pickel, V. M. Ultrastructural localization of the serotonin 2A receptor in 
dopaminergic neurons in the ventral tegmental area. Brain Res. 864, 176–185 (2000). 
121 
 
128. Barre, A. et al. Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and 
associative learning. Proc. Natl. Acad. Sci. 113, E1382–E1391 (2016). 
129. Xu, T. & Pandey, S. C. Cellular localization of serotonin2A (5HT2A) receptors in the rat 
brain. Brain Res. Bull. 51, 499–505 (2000). 
130. López-Giménez, J. F., Mengod, G., Palacios, J. M. & Vilaró, M. T. Selective visualization of 
rat brain 5-HT(2A) receptors by autoradiography with [3H]MDL 100,907. Naunyn. 
Schmiedebergs. Arch. Pharmacol. 356, 446–454 (1997). 
131. Erritzoe, D. et al. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-
episode schizophrenic patients. Neuropsychopharmacology 33, 2435–2441 (2008). 
132. Burnet, P. W. J., Eastwood, S. L. & Harrison, P. J. 5-HT(1A) 5-HT(2A) receptor mRNAs and 
binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 
15, 442–455 (1996). 
133. Geurts, F. J., De Schutter, E. & Timmermans, J. P. Localization of 5-HT2A, 5-HT3, 5-HT5A 
and 5-HT7 receptor-like immunoreactivity in the rat cerebellum. J. Chem. Neuroanat. 24, 
65–74 (2002). 
134. Eastwood, S. L., Burnet, P. W. J., Gittins, R., Baker, K. & Harrison, P. J. Expression of 
serotonin 5-HT2A receptors in the human cerebellum and alterations in schizophrenia. 
Synapse 42, 104–114 (2001). 
135. Paterson, L. M., Kornum, B. R., Nutt, D. J., Pike, V. W. & Knudsen, G. M. 5-HT radioligands 
for human brain imaging with PET and SPECT. Med. Res. Rev. 33, 54–111 (2013). 
136. Ettrup, A. et al. Serotonin 2A receptor agonist binding in the human brain with [ 11 C]Cimbi-
36. J. Cereb. Blood Flow Metab. 34, 1188–1196 (2014). 
137. Willins, D. L., Deutch, A. Y. & Roth, B. L. Serotonin 5-HT(2A) receptors are expressed on 
pyramidal cells and interneurons in the rat cortex. Synapse 27, 79–82 (1997). 
138. Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H. & Hell, 
D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist 
action. Neuroreport 9, 3897–3902 (1998). 
139. Nichols, D. E. Hallucinogens. Pharmacol. Ther. 101, 131–181 (2004). 
140. González-Maeso, J. et al. Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-
Mediated Signaling Pathways to Affect Behavior. Neuron 53, 439–452 (2007). 
141. Roth, B. L., Willins, D. L., Kristiansen, K. & Kroeze, W. K. Activation is hallucinogenic and 
antagonism is therapeutic: Role of 5- HT(2A) receptors in atypical antipsychotic drug 
actions. Neuroscientist 5, 254–262 (1999). 
142. Aghajanian, G. K. & Marek, G. J. Serotonin and hallucinogens. Neuropsychopharmacology 
21, 16S-23S (1999). 
143. González-Maeso, J. & Sealfon, S. C. Psychedelics and schizophrenia. Trends Neurosci. 
32, 225–232 (2009). 
144. Nichols, D. E. Psychedelics. 264–355 (2016). 
145. Halberstadt, A. L. & Geyer, M. A. Serotonergic hallucinogens as translational models 
relevant to schizophrenia. Int. J. Neuropsychopharmacol. 16, 2165–2180 (2013). 
146. Leptourgos, P. et al. Hallucinations under Psychedelics and in the Schizophrenia Spectrum: 
An Interdisciplinary and Multiscale Comparison. Schizophr. Bull. 46, 1396–1408 (2020). 
122 
 
147. Vollenweider, F. X. & Kometer, M. The neurobiology of psychedelic drugs: Implications for 
the treatment of mood disorders. Nat. Rev. Neurosci. 11, 642–651 (2010). 
148. Genís Ona, J. C. B. Can psychedelics be the treatment for the crisis in 
psychopharmacology. Russ. Union Cat. Sci. Lit. 6, 1–6 (2013). 
149. Gasser, P., Kirchner, K. & Passie, T. LSD-assisted psychotherapy for anxiety associated 
with a life-threatening disease: A qualitative study of acute and sustained subjective effects. 
J. Psychopharmacol. 29, 57–68 (2015). 
150. Szabo, A. Psychedelics and immunomodulation: Novel approaches and therapeutic 
opportunities. Front. Immunol. 6, 1–11 (2015). 
151. Palhano-Fontes, F. et al. Rapid antidepressant effects of the psychedelic ayahuasca in 
treatment-resistant depression: A randomized placebo-controlled trial. Psychol. Med. 49, 
655–663 (2019). 
152. Kelly, J. R. et al. Psychedelic science in post-COVID-19 psychiatry. Irish Journal of 
Psychological Medicine 38, 93–98 (2021). 
153. Nutt, D., Erritzoe, D. & Carhart-Harris, R. Psychedelic Psychiatry’s Brave New World. Cell 
181, 24–28 (2020). 
154. Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant 
depression: an open-label feasibility study. The Lancet Psychiatry 3, 619–627 (2016). 
155. Rucker, J. J. H., Iliff, J. & Nutt, D. J. Psychiatry &amp; the psychedelic drugs. Past, present 
&amp; future. Neuropharmacology 142, 200–218 (2018). 
156. Young, J. W., Powell, S. B. & Geyer, M. A. Mouse pharmacological models of cognitive 
disruption relevant to schizophrenia. Neuropharmacology 62, 1381–90 (2012). 
157. Meyerhoefer, M. M. Serotonergic Hallucinogens. in Addiction Medicine 585–602 (Springer 
New York, 2010). doi:10.1007/978-1-4419-0338-9_27 
158. Raote, I., Bhattacharya, A. & Panicker, M. M. Serotonin 2A (5-HT2A) Receptor Function: 
Ligand-Dependent Mechanisms and Pathways. Serotonin Receptors in Neurobiology (CRC 
Press/Taylor & Francis, 2007). 
159. WILLINS, D. L. et al. Serotonergic Antagonist Effects on Trafficking of Serotonin 5-HT2A 
Receptors in Vitro and in Vivoa. Ann. N. Y. Acad. Sci. 861, 121–127 (1998). 
160. Gray, J. A. & Roth, B. L. Paradoxical trafficking and regulation of 5-HT2A receptors by 
agonists and antagonists. Brain Res. Bull. 56, 441–451 (2001). 
161. Berg, KA (Berg, KA); Maayani, S (Maayani, S); Goldfarb, J (Goldfarb, J); Clarke, WP 
(Clarke, W. Pleiotropic Behavior of 5-HT2A and 5-HT2C Receptor Agonists. Ann. N. Y. 
Acad. Sci. 861, 104–110 (1998). 
162. González-Maeso, J. et al. Transcriptome fingerprints distinguish hallucinogenic and 
nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse 
somatosensory cortex. J. Neurosci. 23, 8836–8843 (2003). 
163. Karaki, S. et al. Quantitative phosphoproteomics unravels biased phosphorylation of 
serotonin 2A Receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists. Mol. 
Cell. Proteomics 13, 1273–1285 (2014). 
164. Canal, C. E. & Morgan, D. Head-twitch response in rodents induced by the hallucinogen 
2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of 
mechanisms, and its utility as a model. Drug Test. Anal. 4, 556 (2012). 
123 
 
165. Brea, J. et al. Evidence for Distinct Antagonist-Revealed Functional States of 5HT2A 
Homodimers. Mol. Pharmacol. 75, 1380–1391 (2009). 
166. Bruno, A., Beato, C. & Costantino, G. Molecular dynamics simulations and docking studies 
on 3D models of the heterodimeric and homodimeric 5-HT(2A) receptor subtype. Futur. 
Med Chem. 3, 665–81 (2011). 
167. Shashack, M. J. et al. Synthesis and Evaluation of Dimeric Derivatives of 5-HT 2A Receptor 
(5-HT 2A R) Antagonist M-100907. ACS Chem. Neurosci 2, 640–644 (2011). 
168. Iglesias, A., Cimadevila, M., Cadavid, M. I., Loza, M. I. & Brea, J. Serotonin-2A homodimers 
are needed for signalling via both phospholipase A2 and phospholipase C in transfected 
CHO cells. Eur. J. Pharmacol. 800, 63–69 (2017). 
169. Moutkine, I., Quentin, E., Guiard, B. P., Maroteaux, L. & Doly, S. Heterodimers of serotonin 
receptor subtypes 2 are driven by 5-HT2C protomers. J. Biol. Chem. 292, 6352–6368 
(2017). 
170. Poulie, C. B. M., Liu, N., Jensen, A. A. & Bunch, L. Design, Synthesis, and Pharmacological 
Characterization of Heterobivalent Ligands for the Putative 5-HT 2A /mGlu 2 Receptor 
Complex. J. Med. Chem. acs.jmedchem.0c01058 (2020).  
171. Łukasiewicz, S. et al. Hetero-dimerization of serotonin 5-HT2A and dopamine D2 receptors. 
Biochim. Biophys. Acta - Mol. Cell Res. 1803, 1347–1358 (2010). 
172. Albizu, L., Holloway, T., González-Maeso, J. & Sealfon, S. C. Functional crosstalk and 
heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharmacology 
61, 770–777 (2011). 
173. Galindo, L. et al. Cannabis Users Show Enhanced Expression of CB1-5HT2A Receptor 
Heteromers in Olfactory Neuroepithelium Cells. Mol. Neurobiol. 55, 6347–6361 (2018). 
174. Maroteaux, L., Béchade, C. & Roumier, A. Dimers of serotonin receptors: Impact on ligand 
affinity and signaling. Biochimie 161, 23–33 (2019). 
175. Guinart, D. et al. Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory 
Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use. Schizophr. 
Bull. 46, 1547–1557 (2020). 
176. Borroto-Escuela, D. O. et al. Dopamine D2 and 5-hydroxytryptamine 5-HT2A receptors 
assemble into functionally interacting heteromers. Biochemical and Biophysical Research 
Communications 401, (2010). 
177. Van Heeringen, C. et al. Prefrontal 5-HT2a receptor binding index, hopelessness and 
personality characteristics in attempted suicide. J. Affect. Disord. 74, 149–158 (2003). 
178. Bryson, A., Carter, O., Norman, T. & Kanaan, R. 5-HT2A agonists: A novel therapy for 
functional neurological disorders? International Journal of Neuropsychopharmacology 20, 
422–427 (2017). 
179. Camile, B. 5-HT2A mediated plasticity as a target in major depression : a narrative review 
connecting the dots from neurobiology to cognition and psychology. 1–35 (2020). 
180. Akin, D., Manier, D. H., Sanders-Bush, E. & Shelton, R. C. Decreased serotonin 5-HT2A 
receptor-stimulated phosphoinositide signalling in fibroblasts from melancholic deppresed 
patients. Neuropsychopharmacology 29, 2081–2087 (2004). 
181. Benedetti, F. et al. Serotonin 5-HT2A receptor gene variants influence antidepressant 
response to repeated total sleep deprivation in bipolar depression. Prog. Neuro-
124 
 
Psychopharmacology Biol. Psychiatry 32, 1863–1866 (2008). 
182. Yu, B. et al. Serotonin 5-hydroxytryptamine2A receptor activation suppresses tumor 
necrosis factor-α-induced inflammation with extraordinary potency. J. Pharmacol. Exp. 
Ther. 327, 316–323 (2008). 
183. González-Maeso, J. et al. Identification of a serotonin/glutamate receptor complex 
implicated in psychosis. Nature 452, 93–97 (2008). 
184. Huot, P. et al. Increased 5-HT2A receptors in the temporal cortex of Parkinsonian patients 
with visual hallucinations. Mov. Disord. 25, 1399–1408 (2010). 
185. Muguruza, C. et al. Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of 
schizophrenic subjects. Eur. Neuropsychopharmacol. 23, 852–864 (2013). 
186. Guiard, B. P. & Giovanni, G. Di. Central serotonin-2A (5-HT2A) receptor dysfunction in 
depression and epilepsy: the missing link? Front. Pharmacol. 6, 46 (2015). 
187. Aznar, S. & Hervig, M. E. S. The 5-HT2A serotonin receptor in executive function: 
Implications for neuropsychiatric and neurodegenerative diseases. Neuroscience and 
Biobehavioral Reviews 64, 63–82 (2016). 
188. Vollenweiderl, F. X. et al. S54.04 A system model of altered consciousness: Integrating 
natural and drug-induced psychoses. Eur. Psychiatry 15, 318s-318s (2000). 
189. Muguruza, C. et al. Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal 
cortex of subjects with major depressive disorder: Effect of antidepressant treatment. 
Neuropharmacology 86, 311–318 (2014). 
190. Hayashi, T. Effects of sodium glutamate on the nervous system. keio j. med. 3, 183–192 
(1954). 
191. Curtis, D. R. & Watkins, J. C. The excitation and depression of spinal neurones by 
structurally related amino acids. j. neurochem. 6, 117–141 (1960). 
192. Danbolt, N. C. Glutamate uptake. Progress in Neurobiology 65, 1–105 (2001). 
193. Greenamyre, J. T. The Role of Glutamate in Neurotransmission and in Neurologic Disease. 
Arch. Neurol. 43, 1058–1063 (1986). 
194. Schousboe, A., Bak, L. K. & Waagepetersen, H. S. Astrocytic control of biosynthesis and 
turnover of the neurotransmitters glutamate and GABA. Frontiers in Endocrinology 4, 102 
(2013). 
195. Murphy-Royal, C., Dupuis, J., Groc, L. & Oliet, S. H. R. Astroglial glutamate transporters in 
the brain: Regulating neurotransmitter homeostasis and synaptic transmission. J. Neurosci. 
Res. 95, 2140–2151 (2017). 
196. Zhou, Y. & Danbolt, N. C. Glutamate as a neurotransmitter in the healthy brain. Journal of 
Neural Transmission 121, 799–817 (2014). 
197. Yao, H.-H. et al. Enhancement of glutamate uptake mediates the neuroprotection exerted 
by activating group II or III metabotropic glutamate receptors on astrocytes. J. Neurochem. 
92, 948–961 (2005). 
198. Pinheiro, P. S. & Mulle, C. Presynaptic glutamate receptors: physiological functions and 
mechanisms of action. Nature reviews. Neuroscience 9, 423–436 (2008). 
199. Pin, J. P., De Colle, C., Bessis, A. S. & Acher, F. New perspectives for the development of 




200. Pin, J. P. & Duvoisin, R. The metabotropic glutamate receptors: Structure and functions. 
Neuropharmacology 34, 1–26 (1995). 
201. Yasumatsu, K. et al. Multiple receptors underlie glutamate taste responses in mice. in 
American Journal of Clinical Nutrition 90, (Am J Clin Nutr, 2009). 
202. Tanabe, Y., Masu, M., Ishii, T., Shigemoto, R. & Nakanishi, S. A family of metabotropic 
glutamate receptors. Neuron 8, 169–179 (1992). 
203. Petralia, R. S., Wang, Y. X., Niedzielski, A. S. & Wenthold, R. J. The metabotropic 
glutamate receptors, MGLUR2 and MGLUR3, show unique postsynaptic, presynaptic and 
glial localizations. Neuroscience 71, 949–976 (1996). 
204. Wright, R. A. et al. CNS distribution of metabotropic glutamate 2 and 3 receptors: 
Transgenic mice and [3H]LY459477 autoradiography. Neuropharmacology 66, 89–98 
(2013). 
205. Ohishi, H., Neki, A. & Mizuno, N. Distribution of a metabotropic glutamate receptor, 
mGluR2, in the central nervous system of the rat and mouse: an immunohistochemical 
study with a monoclonal antibody. Neurosci. Res. 30, 65–82 (1998). 
206. Tamaru, Y., Nomura, S., Mizuno, N. & Shigemoto, R. Distribution of metabotropic glutamate 
receptor mGluR3 in the mouse CNS: Differential location relative to pre- and postsynaptic 
sites. Neuroscience 106, 481–503 (2001). 
207. Jin, L. E. et al. mGluR2/3 mechanisms in primate dorsolateral prefrontal cortex: evidence 
for both presynaptic and postsynaptic actions LE. Mol. Psychiatry 22, 1615–1625 (2017). 
208. Scanziani, M., Salin, P. A., Vogt, K. E., Malenka, R. C. & Nicoll, R. A. Use-dependent 
increases in glutamate concentration activate presynaptic metabotropic glutamate 
receptors. Nature 385, 630–634 (1997). 
209. Forsythe, I. D. & Clements, J. D. Presynaptic glutamate receptors depress excitatory 
monosynaptic transmission between mouse hippocampal neurones. J. Physiol. 429, 1–16 
(1990). 
210. Ozawa, S., Kamiya, H. & Tsuzuki, K. Glutamate receptors in the mammalian central 
nervous system. Prog. Neurobiol. 54, 581–618 (1998). 
211. Durand, D., Carniglia, L., Caruso, C. & Lasaga, M. mGlu3 receptor and astrocytes: Partners 
in neuroprotection. Neuropharmacology 66, 1–11 (2013). 
212. Jin, L. E. et al. mGluR2 versus mGluR3 Metabotropic Glutamate Receptors in Primate 
Dorsolateral Prefrontal Cortex: Postsynaptic mGluR3 Strengthen Working Memory 
Networks. Cereb. Cortex 28, 974–987 (2017). 
213. Cochilla, A. J. & Alford, S. Metabotropic glutamate receptor-mediated control of 
neurotransmitter release. Neuron 20, 1007–1016 (1998). 
214. Choi, S. & Lovinger, D. M. Metabotropic glutamate receptor modulation of voltage-gated 
Ca2+ channels involves multiple receptor subtypes in cortical neurons. J. Neurosci. 16, 36–
45 (1996). 
215. Hanna, L. et al. Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, 
an mGlu2 agonist/mGlu3 antagonist. Neuropharmacology 66, 114–121 (2013). 
216. Wroblewska, B. et al. N-acetylaspartylglutamate selectively activates mGluR3 receptors in 
transfected cells. J. Neurochem. 69, 174–181 (1997). 
126 
 
217. Neale, J. H., Bzdega, T. & Wroblewska, B. N-Acetylaspartylglutamate. J. Neurochem. 75, 
443–452 (2002). 
218. Cid, J. M., Trabanco, A. A. & Lavreysen, H. Metabotropic glutamate receptor 2 activators. 
Top. Med. Chem. 13, 101–142 (2015). 
219. Muguruza, C., Meana, J. J. & Callado, L. F. Group II Metabotropic Glutamate Receptors as 
Targets for Novel Antipsychotic Drugs. Front. Pharmacol. 7, 130 (2016). 
220. González-Maeso, J. Metabotropic Glutamate 2 (mGlu2) Receptors and Schizophrenia 
Treatment. in 59–78 (Humana Press, Cham, 2017).  
221. Sanger, H. et al. Pharmacological profiling of native group II metabotropic glutamate 
receptors in primary cortical neuronal cultures using a FLIPR. Neuropharmacology 66, 264–
273 (2013). 
222. Kingston, A. E. et al. Neuroprotection by metabotropic glutamate receptor agonists: 
LY354740, LY379268 and LY389795. Eur. J. Pharmacol. 377, 155–165 (1999). 
223. Rorick-Kehn, L. M. et al. In vivo pharmacological characterization of the structurally novel, 
potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric 
disorders. Psychopharmacology (Berl). 193, 121–136 (2007). 
224. Niswender, C. M. & Conn, P. J. Metabotropic glutamate receptors: Physiology, 
pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50, 295–322 (2010). 
225. Kinon, B. J. et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-
ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J. Clin. 
Psychopharmacol. 31, 349–355 (2011). 
226. Patil S.T. et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: 
A randomized Phase 2 clinical trial. Nat. Med. 13, 1102–1107 (2007). 
227. Simmons, R. M. A., Webster, A. A., Kalra, A. B. & Iyengar, S. Group II mGluR receptor 
agonists are effective in persistent and neuropathic pain models in rats. Pharmacol. 
Biochem. Behav. 73, 419–427 (2002). 
228. Swanson C.J. et al. Metabotropic glutamate receptors as novel targets for anxiety and 
stress disorders. Nature Reviews Drug Discovery 4, 131–144 (Nature Publishing Group, 
2005). 
229. Schiefer, J. et al. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 
agonist LY379268 modify disease progression in a transgenic mouse model of Huntington’s 
disease. Brain Res. 1019, 246–254 (2004). 
230. Woolley, M. L., Pemberton, D. J., Bate, S., Corti, C. & Jones, D. N. C. The mGlu2 but not 
the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse 
models predictive of antipsychotic activity. Psychopharmacology (Berl). 196, 431–440 
(2008). 
231. Kufahl, P. R. et al. Attenuation of methamphetamine seeking by the mGluR2/3 agonist 
LY379268 in rats with histories of restricted and escalated self-Administration. 
Neuropharmacology 66, 290–301 (2013). 
232. Menezes, M. M. et al. The mGlu2/3 Receptor Agonists LY354740 and LY379268 
Differentially Regulate Restraint-Stress-Induced Expression of c-Fos in Rat Cerebral 
Cortex. Neurosci. J. 2013, 1–8 (2013). 
233. Li, M. L., Hu, X. Q., Li, F. & Gao, W. J. Perspectives on the mGluR2/3 agonists as a 
127 
 
therapeutic target for schizophrenia: Still promising or a dead end? Prog. Neuro-
Psychopharmacology Biol. Psychiatry 60, 66–76 (2015). 
234. Highland, J. N., Zanos, P., Georgiou, P. & Gould, T. D. Group II metabotropic glutamate 
receptor blockade promotes stress resilience in mice. Neuropsychopharmacology 1 (2019). 
doi:10.1038/s41386-019-0380-1 
235. Fell, M. J., Svensson, K. A., Johnson, B. G. & Schoepp, D. D. Evidence for the role of 
metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic 
pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-
sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 
326, 209–217 (2008). 
236. Di Prisco, S. et al. Presynaptic, release-regulating mGlu 2 -preferring and mGlu 3 -preferring 
autoreceptors in CNS: pharmacological profiles and functional roles in demyelinating 
disease. Br. J. Pharmacol. 173, 1465–1477 (2016). 
237. Witkin, J., Marek, G., Johnson, B. & Schoepp, D. Metabotropic Glutamate Receptors in the 
Control of Mood Disorders. CNS Neurol. Disord. - Drug Targets 6, 87–100 (2008). 
238. Chaki, S. Group II metabotropic glutamate receptor agonists as a potential drug for 
schizophrenia. European Journal of Pharmacology 639, 59–66 (2010). 
239. De Filippis, B. et al. The role of group II metabotropic glutamate receptors in cognition and 
anxiety: Comparative studies in GRM2-/-, GRM3-/- and GRM2/3-/- knockout mice. 
Neuropharmacology 89, 19–32 (2015). 
240. Maksymetz, J., Moran, S. P. & Conn, P. J. Targeting metabotropic glutamate receptors for 
novel treatments of schizophrenia. Mol. Brain 10, 15 (2017). 
241. Ferraguti, F., Baldani-Guerra, B., Corsi, M., Nakanishi, S. & Corti, C. Activation of the 
extracellular signal-regulated kinase 2 by metabotropic glutamate receptors. Eur. J. 
Neurosci. 11, 2073-2082X (1999). 
242. Zammataro, M. et al. MGlu2 metabotropic glutamate receptors restrain inflammatory pain 
and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonists. Mol. Pain 7, 
(2011). 
243. Lyon, L. et al. Fractionation of Spatial Memory in GRM2/3 (mGlu2/mGlu3) Double Knockout 
Mice Reveals a Role for Group II Metabotropic Glutamate Receptors at the Interface 
Between Arousal and Cognition. 36, (2011). 
244. Pritchett, D. et al. Deletion of metabotropic glutamate receptors 2 and 3 (mGlu2 & mGlu3) 
in mice disrupts sleep and wheel-running activity, and increases the sensitivity of the 
circadian system to light. PLoS One 10, e0125523 (2015). 
245. Cohrs, S. Sleep disturbances in patients with schizophrenia: Impact and effect of 
antipsychotics. CNS Drugs 22, 939–962 (2008). 
246. Pritchett, D. et al. Evaluating the links between schizophrenia and sleep and circadian 
rhythm disruption. Journal of Neural Transmission 119, 1061–1075 (2012). 
247. Liu, J. J. et al. Allosteric control of an asymmetric transduction in a g protein-coupled 
receptor heterodimer. Elife 6, (2017). 
248. Moreno Delgado, D. et al. Pharmacological evidence for a metabotropic glutamate receptor 
heterodimer in neuronal cells. Elife 6, (2017). 
249. Lee, J. et al. Defining the Homo- and Heterodimerization Propensities of Metabotropic 
128 
 
Glutamate Receptors. Cell Rep. 31, 107605 (2020). 
250. Corti, C. et al. Altered Dimerization of Metabotropic Glutamate Receptor 3 in Schizophrenia. 
Biol. Psychiatry 62, 747–755 (2007). 
251. Moreno, J. L. et al. Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor 
complex and its potential contribution to schizophrenia. Sci. Signal. 9, 1–19 (2016). 
252. Moreno, J. L. et al. Identification of three residues essential for 5-hydroxytryptamine 2A-
metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive 
behavioral function. J. Biol. Chem. 287, 44301–44319 (2012). 
253. Fribourg, M. et al. Decoding the signaling of a GPCR heteromeric complex reveals a 
unifying mechanism of action of antipsychotic drugs. Cell 147, 1011–1023 (2011). 
254. Baki, L. et al. Cross-signaling in metabotropic glutamate 2 and serotonin 2A receptor 
heteromers in mammalian cells. Pflugers Arch. Eur. J. Physiol. 468, 775–793 (2016). 
255. Wischhof, L., Hollensteiner, K. J. & Koch, M. Impulsive behaviour in rats induced by 
intracortical DOI infusions is antagonized by co-administration of an mGlu2/3 receptor 
agonist. Behav. Pharmacol. 22, 805–13 (2011). 
256. Wischhof, L. & Koch, M. 5-HT2A and mGlu2/3 receptor interactions. Behav. Pharmacol. 27, 
1–11 (2016). 
257. Kurita, M. et al. Repressive Epigenetic Changes at the mGlu2 Promoter in Frontal Cortex 
of 5-HT2A Knockout Mice. 1166–1175 (2013). 
258. Scott, M. G. H. H. et al. An escort for GPCRs: implications for regulation of receptor density 
at the cell surface. Trends Pharmacol. Sci. 29, 528–535 (2008). 
259. Irannejad, R. & Von Zastrow, M. GPCR signaling along the endocytic pathway. Curr. Opin. 
Cell Biol. 27, 109–116 (2014). 
260. Irannejad, R. et al. Conformational biosensors reveal GPCR signalling from endosomes. 
Nature 495, 534–538 (2013). 
261. Bhatnagar, A. et al. The Dynamin-dependent, Arrestin-independent Internalization of 5-
Hydroxytryptamine 2A (5-HT 2A ) Serotonin Receptors Reveals Differential Sorting of 
Arrestins and 5-HT 2A Receptors during Endocytosis. J. Biol. Chem. 276, 8269–8277 
(2001). 
262. Raote, I., Bhattacharyya, S. & Panicker, M. M. Functional selectivity in serotonin receptor 
2A (5-HT2A) endocytosis, recycling, and phosphorylation. Mol. Pharmacol. 83, 42–50 
(2013). 
263. Magalhaes, A. C., Dunn, H., Ferguson, S. S. G. S., Taylor, J. A. & Ferguson, S. S. G. S. 
Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br. 
J. Pharmacol. 165, 1717–1736 (2012). 
264. Pfeffer, S. R. Rab GTPases: specifying and deciphering organelle identity and function. 
Trends Cell Biol. 11, 487–491 (2001). 
265. Kjos, I., Vestre, K., Guadagno, N. A., Borg Distefano, M. & Progida, C. Rab and Arf proteins 
at the crossroad between membrane transport and cytoskeleton dynamics. Biochimica et 
Biophysica Acta - Molecular Cell Research 1865, 1397–1409 (2018). 
266. Horgan, C. P. & McCaffrey, M. W. Rab GTPases and microtubule motors. Biochem. Soc. 
Trans. 39, 1202–1206 (2011). 
129 
 
267. Jordens, I. et al. The Rab7 effector protein RILP controls lysosomal transport by inducing 
the recruitment of dynein-dynactin motors. Curr. Biol. 11, 1680–1685 (2001). 
268. Zerial, M. & McBride, H. Rab proteins as membrane organizers. Nat. Rev. Mol. Cell Biol. 2, 
107–117 (2001). 
269. Bucci, C. et al. The small GTPase rab5 functions as a regulatory factor in the early endocytic 
pathway. Cell 70, 715–728 (1992). 
270. Poteryaev, D., Datta, S., Ackema, K., Zerial, M. & Spang, A. Identification of the switch in 
early-to-late endosome transition. Cell 141, 497–508 (2010). 
271. Pfeffer, S. R. Rab GTPase regulation of membrane identity. Curr. Opin. Cell Biol. 25, 414–
419 (2013). 
272. Pfeffer, S. R. Rab GTPases: master regulators that establish the secretory and endocytic 
pathways. (2017). doi:10.1091/mbc.E16-10-0737 
273. Seachrist, J. L. & Ferguson, S. S. G. Regulation of G protein-coupled receptor endocytosis 
and trafficking by Rab GTPases. Life Sci. 74, 225–235 (2003). 
274. Oakley, R. H., Laporte, S. A., Holt, J. A., Caron, M. G. & Barak, L. S. Differential affinities 
of visual arrestin, βarrestin1, and βarrestin2 for G protein-coupled receptors delineate two 
major classes of receptors. J. Biol. Chem. 275, 17201–17210 (2000). 
275. Seachrist, J. L., Anborgh, P. H. & Ferguson, S. S. G. β2-Adrenergic Receptor 
Internalization, Endosomal Sorting, and Plasma Membrane Recycling Are Regulated by 
Rab GTPases. J. Biol. Chem. 275, 27221–27228 (2000). 
276. Iwata, K., Ito, K., Fukuzaki, A., Inaki, K. & Haga, T. Dynamin and Rab5 regulate GRK2-
dependent internalization of dopamine D2 receptors. Eur. J. Biochem. 263, 596–602 
(1999). 
277. Seachrist, J. L. et al. Rab5 association with the angiotensin II type 1A receptor promotes 
Rab5 GTP binding and vesicular fusion. J. Biol. Chem. 277, 679–685 (2002). 
278. Murphy, J. E., Padilla, B. E., Hasdemir, B., Cottrell, G. S. & Bunnett, N. W. Endosomes: A 
legitimate platform for the signaling train. Proc. Natl. Acad. Sci. U. S. A. 106, 17615–17622 
(2009). 
279. Thomsen, A. R. B., Jensen, D. D., Hicks, G. A. & Bunnett, N. W. Therapeutic Targeting of 
Endosomal G-Protein-Coupled Receptors. Trends Pharmacol. Sci. 39, 879–891 (2018). 
280. Naslavsky, N. & Caplan, S. The enigmatic endosome - Sorting the ins and outs of endocytic 
trafficking. Journal of Cell Science 131, (2018). 
281. Gruenberg, J., Griffiths, G. & Howell, K. E. Characterization of the early endosome and 
putative endocytic carrier vesicles in vivo and with an assay of vesicle fusion in vitro. J. Cell 
Biol. 108, 1301–1316 (1989). 
282. Dunn, K. W., McGraw, T. E. & Maxfield, F. R. Iterative fractionation of recycling receptors 
from lysosomally destined ligands in an early sorting endosome. J. Cell Biol. 109, 3303–
3314 (1989). 
283. Gruenberg, J. The endocytic pathway: a mosaic of domains. Nat. Rev. Mol. Cell Biol. 2, 
721–730 (2001). 
284. Yamashiro, D. J. & Maxfield, F. R. Acidification of morphologically distinct endosomes in 
mutant and wild-type Chinese hamster ovary cells. J. Cell Biol. 105, 2723–2733 (1987). 
130 
 
285. Jovic, M., Sharma, M., Rahajeng, J. & Caplan, S. The early endosome: A busy sorting 
station for proteins at the crossroads. Histology and Histopathology 25, 99–112 (2010). 
286. Gorvel, J. P., Chavrier, P., Zerial, M. & Gruenberg, J. rab5 controls early endosome fusion 
in vitro. Cell 64, 915–925 (1991). 
287. Bucci, C. et al. Rab5a is a common component of the apical and basolateral endocytic 
machinery in polarized epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 91, 5061–5065 (1994). 
288. Mayor, S., Presley, J. F. & Maxfield, F. R. Sorting of membrane components from 
endosomes and subsequent recycling to the cell surface occurs by a bulk flow process. J. 
Cell Biol. 121, 1257–1269 (1993). 
289. Van Weering, J. R. T. & Cullen, P. J. Membrane-associated cargo recycling by tubule-based 
endosomal sorting. Semin. Cell Dev. Biol. 31, 40–47 (2014). 
290. Cullen, P. J. & Steinberg, F. To degrade or not to degrade: mechanisms and significance 
of endocytic recycling. Nature Reviews Molecular Cell Biology 19, 679–696 (2018). 
291. Bright, N. A., Davis, L. J. & Luzio, J. P. Endolysosomes Are the Principal Intracellular Sites 
of Acid Hydrolase Activity. Curr. Biol. 26, 2233–2245 (2016). 
292. Ferguson, S. S. G. Evolving concepts in G protein-coupled receptor endocytosis: The role 
in receptor desensitization and signaling. Pharmacol. Rev. 53, 1–24 (2001). 
293. Sönnichsen, B., De Renzis, S., Nielsen, E., Rietdorf, J. & Zerial, M. Distinct membrane 
domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, 
Rab5, and Rab11. J. Cell Biol. 149, 901–913 (2000). 
294. James, S. L. et al. Global, regional, and national incidence, prevalence, and years lived 
with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A 
systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1789–1858 
(2018). 
295. National Institute of Mental Health. NIMH » Schizophrenia. National Institutes of Health 
(2016). Available at: https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml. 
(Accessed: 21st January 2021) 
296. Castañé, A. & Adell, A. Schizophrenia. 5-HT2A Receptors in the Central Nervous System 
191–204 (Springer International Publishing, 2018). doi:10.1007/978-3-319-70474-6_8 
297. Wong, A. H. C. & Van Tol, H. H. M. Schizophrenia: From phenomenology to neurobiology. 
Neurosci. Biobehav. Rev. 27, 269–306 (2003). 
298. Rössler, W., Joachim Salize, H., Van Os, J. & Riecher-Rössler, A. Size of burden of 
schizophrenia and psychotic disorders. Eur. Neuropsychopharmacol. 15, 399–409 (2005). 
299. Fleischhacker, W. W. Schizophrenia—Time to Commit to Policy Change. (2014). 
300. Wander, C. Schizophrenia: Opportunities to improve outcomes and reduce economic 
burden through managed care. Am. J. Manag. Care 26, S62–S68 (2020). 
301. Desai, P. R., Lawson, K. A., Barner, J. C. & Rascati, K. L. Estimating the direct and indirect 
costs for community-dwelling patients with schizophrenia. J. Pharm. Heal. Serv. Res. 4, 
187–194 (2013). 
302. Miller, G. Is pharma running out of brainy ideas? Science (80-. ). 329, 502–504 (2010). 
303. Cressey, D. Psychopharmacology in crisis. Nature (2011). doi:10.1038/news.2011.367 




(Accessed: 19th October 2020) 
305. O’Brien, P. L., Thomas, C. P., Hodgkin, D., Levit, K. R. & Mark, T. L. The Diminished 
Pipeline for Medications to Treat Mental Health and Substance Use Disorders. Psychiatr. 
Serv. 65, 1433–1438 (2014). 
306. Nicoletti, F., Bruno, V., Ngomba, R. T., Gradini, R. & Battaglia, G. Metabotropic glutamate 
receptors as drug targets: What’s new? Curr. Opin. Pharmacol. 20, 89–94 (2015). 
307. Duncan, M. O. and P. Why ‘big pharma’ stopped searching for the next Prozac | Society | 
The Guardian. (2016). Available at: 
https://www.theguardian.com/society/2016/jan/27/prozac-next-psychiatric-wonder-drug-
research-medicine-mental-illness. (Accessed: 19 October 2020) 
308. Dakić, T. Mental health burden and unmet needs for treatment: A call for justice. Br. J. 
Psychiatry 216, 241–242 (2020). 
309. Yang, A. & Tsai, S.-J. New Targets for Schizophrenia Treatment beyond the Dopamine 
Hypothesis. Int. J. Mol. Sci. 18, 1689 (2017). 
310. Meltzer, H. Y. What’s atypical about atypical antipsychotic drugs? Curr. Opin. Pharmacol. 
4, 53–57 (2004). 
311. Lieberman, J. A. et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic 
Schizophrenia. N. Engl. J. Med. 353, 1209–1223 (2005). 
312. Lally, J., Gaughran, F., Timms, P. & Curran, S. R. Pharmacogenomics and Personalized 
Medicine Dovepress Treatment-resistant schizophrenia: current insights on the 
pharmacogenomics of antipsychotics. Pharmgenomics. Pers. Med. 2016, 9–117 (2016). 
313. Stępnicki, P., Kondej, M. & Kaczor, A. A. Current concepts and treatments of schizophrenia. 
Molecules 23, (2018). 
314. Stahl, S. M. Beyond the dopamine hypothesis of schizophrenia to three neural networks of 
psychosis: Dopamine, serotonin, and glutamate. CNS Spectr. 23, 187–191 (2018). 
315. Arnedo, J. et al. Uncovering the hidden risk architecture of the schizophrenias: Confirmation 
in three independent genome-wide association studies. Am. J. Psychiatry 172, 139–153 
(2015). 
316. Allen, N. C. et al. Systematic meta-analyses and field synopsis of genetic association 
studies in schizophrenia: The SzGene database. Nat. Genet. 40, 827–834 (2008). 
317. Ryder, P. V. & Faundez, V. Schizophrenia: The ‘BLOC’ may be in the endosomes. Sci. 
Signal. 2, 1–6 (2009). 
318. Consortium, S. W. G. of the P. G. et al. Biological insights from 108 schizophrenia-
associated genetic loci. Nature 511, 421–427 (2014). 
319. Hall, J. et al. Genetic risk for schizophrenia: Convergence on synaptic pathways involved 
in plasticity. Biol. Psychiatry 77, 52–58 (2015). 
320. Fries, G. R. et al. Genome-wide expression in veterans with schizophrenia further validates 
the immune hypothesis for schizophrenia. Schizophr. Res. 192, 255–261 (2018). 
321. Carpenter, W. T., Kirkpatrick, B. & Buchanan, R. W. Schizophrenia: Syndromes and 
diseases. J. Psychiatr. Res. 33, 473–475 (1999). 




323. Kambeitz, J. et al. Detecting Neuroimaging Biomarkers for Schizophrenia: A Meta-Analysis 
of Multivariate Pattern Recognition Studies. Neuropsychopharmacology 40, 1742–1751 
(2015). 
324. Gao, S., Calhoun, V. D. & Sui, J. Machine learning in major depression: From classification 
to treatment outcome prediction. CNS Neurosci. Ther. 24, 1037–1052 (2018). 
325. Ebdrup, B. H. et al. Accuracy of diagnostic classification algorithms using cognitive-, 
electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia 
patients. Psychol. Med. 49, 2754–2763 (2019). 
326. Strauss, J. Reconceptualizing schizophrenia. Schizophr. Bull. 40, 97–100 (2014). 
327. Thibaut, F. Schizophrenia: an example of complex genetic disease. World J. Biol. 
Psychiatry 7, 194–197 (2006). 
328. Kendler, K. S. Phenomenology of schizophrenia and the representativeness of modern 
diagnostic criteria. JAMA Psychiatry 73, 1082–1092 (2016). 
329. Cuesta, M. J. & Peralta, V. Going beyond classic descriptions to future phenomenology of 
schizophrenia. JAMA Psychiatry 73, 1010–1012 (2016). 
330. van Os, J. &quot;Schizophrenia&quot; does not exist. BMJ 352, i375 (2016). 
331. Eggers, A. E. A serotonin hypothesis of schizophrenia. Med. Hypotheses 80, 791–794 
(2013). 
332. Marder, S. R. et al. Advancing drug discovery for schizophrenia. Ann. N. Y. Acad. Sci. 1236, 
30–43 (2011). 
333. Meltzer, H. Y. & Huang, M. In vivo actions of atypical antipsychotic drug on serotonergic 
and dopaminergic systems. Prog. Brain Res. 172, 177–197 (2008). 
334. Jeffrey Conn, P., Christopoulos, A. & Lindsley, C. W. Allosteric modulators of GPCRs: A 
novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8, 41–54 (2009). 
335. Lopez-Gimenez, J. F., Vilaró, M. T. & Milligan, G. Morphine desensitization, internalization, 
and down-regulation of the μ opioid receptor is facilitated by serotonin 5-
hydroxytryptamine2A receptor coactivation. Mol. Pharmacol. 74, 1278–1291 (2008). 
336. Xue, L., Rovira, X., Zhao, H., Liu, J. & Pin, J.-P. major ligand-induced rearrangement of the 
heptahelical domain interface in a gpcr dimer. Nat. Chem. Biol. (2014). 
doi:10.1038/nchembio.1711 
337. Ward, R. J., Alvarez-Curto, E. & Milligan, G. Using the Flp-InTM T-RexTM system to regulate 
GPCR expression. Methods Mol. Biol. 746, 21–37 (2011). 
338. Wagstaff, K. M. & Jans, D. A. Protein transduction: cell penetrating peptides and their 
therapeutic applications. Curr. Med. Chem. 13, 1371–87 (2006). 
339. Arsenovic, P. T., Mayer, C. R. & Conway, D. E. SensorFRET: A Standardless Approach to 
Measuring Pixel-based Spectral Bleed-through and FRET Efficiency using Spectral 
Imaging. Sci. Rep. 7, 15609 (2017). 
340. Bajar, B. et al. A Guide to Fluorescent Protein FRET Pairs. Sensors 16, 1488 (2016). 
341. Chaudhry, F. A. et al. Glutamate transporters in glial plasma membranes: Highly 
differentiated localizations revealed by quantitative ultrastructural immunocytochemistry. 
Neuron 15, 711–720 (1995). 
133 
 
342. Hjelle, O. P., Chaudhry, F. A. & Ottersen, O. P. Antisera to Glutathione: Characterization 
and Immunocytochemical Application to the Rat Cerebellum. Eur. J. Neurosci. 6, 793–804 
(1994). 
343. Van Lookeren Campagne, M., Oestreicher, A. B., Van der Krift, T. P., Gispen, W. H. & 
Verkleij, A. J. Freeze-substitution and Lowicryl HM20 embedding of fixed rat brain: 
Suitability for immunogold ultrastructural localization of neural antigens. J. Histochem. 
Cytochem. 39, 1267–1279 (1991). 
344. A. Peters, S. L. Palay, H. Webster,  deF. The Fine Structure of the Nervous System. 
Neurons and their Supporting Cells. 3rd edition. J. Neuropathol. Exp. Neurol. 50, 282.1-282 
(1991). 
345. Dunn, K. W., Kamocka, M. M. & McDonald, J. H. A practical guide to evaluating 
colocalization in biological microscopy. American Journal of Physiology - Cell Physiology 
300, (2011). 
346. Adler, J. & Parmryd, I. Quantifying colocalization by correlation: The Pearson correlation 
coefficient is superior to the Mander’s overlap coefficient. Cytom. Part A 77A, 733–742 
(2010). 
347. Ibi, D. et al. Antipsychotic-induced Hdac2 transcription via NF-Î° B leads to synaptic and 
cognitive side effects. Nat. Neurosci. 20, 1247–1259 (2017). 
348. Kerppola, T. K. Design and implementation of bimolecular fluorescence complementation 
(BiFC) assays for the visualization of protein interactions in living cells. Nat. Protoc. 1, 
1278–1286 (2006). 
349. Kerppola, T. K. Visualization of molecular interactions by fluorescence complementation. 
Nat. Rev. Mol. Cell Biol. 7, 449–456 (2006). 
350. Murat, S. et al. 5-HT2A receptor-dependent phosphorylation of mGlu2 receptor at Serine 
843 promotes mGlu2 receptor-operated Gi/o signaling. Mol. Psychiatry 1 (2018). 
doi:10.1038/s41380-018-0069-6 
351. Delille, H. K. et al. Heterocomplex formation of 5-HT 2A -mGlu 2 and its relevance for 
cellular signaling cascades. Neuropharmacology 62, 2184–2191 (2012). 
352. Rankovic, Z., Brust, T. F. & Bohn, L. M. Biased agonism: An emerging paradigm in GPCR 
drug discovery. Bioorganic Med. Chem. Lett. 26, 241–250 (2016). 
353. Canals, M., Lopez-Gimenez, J. F. & Milligan, G. Cell surface delivery and structural re-
organization by pharmacological chaperones of an oligomerization-defective α 1b-
adrenoceptor mutant demonstrates membrane targeting of GPCR oligomers. Biochem. J. 
417, 161–172 (2009). 
354. Lopez-Gimenez, J. F., Alvarez-Curto, E. & Milligan, G. M3 muscarinic acetylcholine 
receptor facilitates the endocytosis of mu opioid receptor mediated by morphine 
independently of the formation of heteromeric complexes. Cell. Signal. 35, 208–222 (2017). 
355. Devi, L. A. Heterodimerization of G-protein-coupled receptors: Pharmacology, signaling 
and trafficking. Trends Pharmacol. Sci. 22, 532–537 (2001). 
356. Milligan, G. The role of dimerisation in the cellular trafficking of G-protein-coupled receptors. 
Current Opinion in Pharmacology 10, 23–29 (Elsevier, 2010). 
357. Bunnett W., Cottrell G. Trafficking and Signaling of G Protein-Coupled Receptors in the 
Nervous System: Implications for Disease and Therapy. CNS Neurol. Disord. - Drug 
Targets 9, 539–556 (2012). 
134 
 
358. Nelson, G. et al. Mammalian sweet taste receptors. Cell 106, 381–390 (2001). 
359. Zhao, G. Q. et al. The receptors for mammalian sweet and umami taste. Cell 115, 255–266 
(2003). 
360. Nango, E. et al. Taste substance binding elicits conformational change of taste receptor T1r 
heterodimer extracellular domains. Sci. Rep. 6, 1–8 (2016). 
361. Jordan, B. A., Trapaidze, N., Gomes, I., Nivarthi, R. & Devi, L. A. Oligomerization of opioid 
receptors with 2-adrenergic receptors: A role in trafficking and mitogen-activated protein 
kinase activation. Proc. Natl. Acad. Sci. 98, 343–348 (2001). 
362. Hillion, J. et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A 
receptors and dopamine D2 receptors. J. Biol. Chem. 277, 18091–18097 (2002). 
363. Schmid, C. L., Raehal, K. M., Bohn, L. M. & Lefkowitz, R. J. Agonist-directed signaling of 
the serotonin 2A receptor depends on-arrestin-2 interactions in vivo. (2008). 
364. Bécamel, C. et al. The Serotonin 5-HT2A and 5-HT2C Receptors Interact with Specific Sets 
of PDZ Proteins. J. Biol. Chem. 279, 20257–20266 (2004). 
365. Xia, Z., Gray, J. A., Compton-Toth, B. A. & Roth, B. L. A direct interaction of PSD-95 with 
5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. J. Biol. 
Chem. 278, 21901–21908 (2003). 
366. Xia, Z., Hufeisen, S. J., Gray, J. A. & Roth, B. L. The PDZ-binding domain is essential for 
the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro. 
Neuroscience 122, 907–920 (2003). 
367. Grotewiel, M. S. & Sanders-Bush, E. Differences in agonist-independent activity of 5-
HT(2A) and 5-HT(2C) receptors revealed by heterologous expression. Naunyn. 
Schmiedebergs. Arch. Pharmacol. 359, 21–27 (1999). 
368. Egan, C., Herrick-Davis, K. & Teitler, M. Creation of a constitutively activated state of the 
5-HT(2A) receptor by site-directed mutagenesis: Revelation of inverse agonist activity of 
antagonists. in Annals of the New York Academy of Sciences 861, 136–139 (1998). 
369. Hamada, S. et al. Localization of 5-HT2A receptor in rat cerebral cortex and olfactory 
system revealed by immunohistochemistry using two antibodies raised in rabbit and 
chicken. Mol. Brain Res. 54, 199–211 (1998). 
370. Maeshima, T. et al. The cellular localization of 5-HT(2A) receptors in the spinal cord and 
spinal ganglia of the adult rat. Brain Res. 797, 118–124 (1998). 
371. Cornea-Hébert, V. et al. Similar ultrastructural distribution of the 5-HT2A serotonin receptor 
and microtubule-associated protein MAP1A in cortical dendrites of adult rat. Neuroscience 
113, 23–35 (2002). 
372. Rodríguez, J. J., Garcia, D. R. & Pickel, V. M. Subcellular distribution of 5-
hydroxytryptamine(2A) and N-methyl-D- aspartate receptors within single neurons in rat 
motor and limbic striatum. J. Comp. Neurol. 413, 219–231 (1999). 
373. Van Steenwinckel, J. et al. The 5-HT2A receptor is mainly expressed in nociceptive sensory 
neurons in rat lumbar dorsal root ganglia. Neuroscience 161, 838–846 (2009). 
374. Price, A. E., Sholler, D. J., Stutz, S. J., Anastasio, N. C. & Cunningham, K. A. Endogenous 
Serotonin 5-HT2A and 5-HT2C Receptors Associate in the Medial Prefrontal Cortex. ACS 
Chem. Neurosci. 10, 3241–3248 (2019). 
375. Griffiths, J. L. & Lovick, T. A. Co-localization of 5-HT2A-receptor- and GABA-
135 
 
immunoreactivity in neurones in the periaqueductal grey matter of the rat. Neurosci. Lett. 
326, 151–154 (2002). 
376. Wu, C. et al. Development and Characterization of Monoclonal Antibodies Specific to the 
Serotonin 5-HT 2A Receptor. The Journal of Histochemistry & Cytochemistry 46, (1998). 
377. Bombardi, C. Neuronal localization of 5-HT2A receptor immunoreactivity in the rat 
hippocampal region. Brain Res. Bull. 87, 259–273 (2012). 
378. Michel, M. C., Wieland, T. & Tsujimoto, G. How reliable are G-protein-coupled receptor 
antibodies? Naunyn. Schmiedebergs. Arch. Pharmacol. 379, 385–388 (2009). 
379. McDonald, A. J. & Mascagni, F. Neuronal localization of 5-HT type 2A receptor 
immunoreactivity in the rat basolateral amygdala. Neuroscience 146, 306–320 (2007). 
380. Nocjar, C., Roth, B. L. & Pehek, E. Localization of 5-HT2A receptors on dopamine cells in 
subnuclei of the midbrain A10 cell group. Neuroscience 111, 163–176 (2002). 
381. Gray, J. A. et al. Cell-Type Specific Effects of Endocytosis Inhibitors on 5-
Hydroxytryptamine2A Receptor Desensitization and Resensitization Reveal an Arrestin-, 
GRK2-, and GRK5-Independent Mode of Regulation in Human Embryonic Kidney 293 Cells 
Vol. 60, No. 5 22/936816 Pri. 60, (American Society for Pharmacology and Experimental 
Therapy, 2001). 
382. Bhattacharya, A., Sankar, S. & Panicker, M. M. Differences in the C-terminus contribute to 
variations in trafficking between rat and human 5-HT2A receptor isoforms: Identification of 
a primate-specific tripeptide ASK motif that confers GRK-2 and β arrestin-2 interactions. J. 
Neurochem. 112, 723–732 (2010). 
383. Doly, S. et al. The 5-HT2A Receptor Is Widely Distributed in the Rat Spinal Cord and Mainly 
Localized at the Plasma Membrane of Postsynaptic Neurons. J. Comp. Neurol. 472, 496–
511 (2004). 
384. Bécamel, C., Berthoux, C., Barre, A. & Marin, P. Growing Evidence for Heterogeneous 
Synaptic Localization of 5-HT2A Receptors. ACS Chem. Neurosci. 8, 897–899 (2017). 
385. Fiorica-Howells, E., Hen, R., Gingrich, J., Li, Z. & Gershon, M. D. 5-HT2A receptors: 
location and functional analysis in intestines of wild-type and 5-HT 2A knockout mice. Am. 
J. Physiol. Liver Physiol. 282, G877–G893 (2002). 
386. Allen, J. A., Yadav, P. N. & Roth, B. L. Insights into the regulation of 5-HT2A serotonin 
receptors by scaffolding proteins and kinases. Neuropharmacology 55, 961–968 (2008). 
387. Sorkin, A. & Von Zastrow, M. Endocytosis and signalling: Intertwining molecular networks. 
Nat. Rev. Mol. Cell Biol. 10, 609–622 (2009). 
388. Berg, K. A. et al. Effector Pathway-Dependent Relative Efficacy at Serotonin Type 2A and 
2C Receptors: Evidence for Agonist-Directed Trafficking of Receptor Stimulus. Mol. 
Pharmacol. 54, 94–104 (1998). 
389. Abbs, B. et al. The 3rd Schizophrenia International Research Society Conference, 14-18 
April 2012, Florence, Italy: Summaries of oral sessions. Schizophr. Res. 141, 14–18 (2012). 
390. Cotter, D. R., Schubert, K. O. & Föcking, M. Clathrin-Mediated-Endocytosis and Clathrin-
Dependent Membrane and Protein Trafficking; Core Pathophysiological Processes in 
Schizophrenia and Bipolar Disorder? Schizophr. Res. 136, S15–S16 (2012). 
391. Schubert, K. O. et al. Hypothesis review: Are clathrin-mediated endocytosis and clathrin-
dependent membrane and protein trafficking core pathophysiological processes in 
136 
 
schizophrenia and bipolar disorder. Mol. Psychiatry 17, 669–681 (2012). 
392. Harrison, P. J. & Weinberger, D. R. Schizophrenia genes, gene expression, and 
neuropathology: On the matter of their convergence. Mol. Psychiatry 10, 40–68 (2005). 
393. Harrison, P. J. & Law, A. J. Neuregulin 1 and Schizophrenia: Genetics, Gene Expression, 
and Neurobiology. Biol. Psychiatry 60, 132–140 (2006). 
394. Morris, D. W. et al. Dysbindin (DTNBP1) and the Biogenesis of Lysosome-Related 
Organelles Complex 1 (BLOC-1): Main and Epistatic Gene Effects Are Potential 
Contributors to Schizophrenia Susceptibility. Biol. Psychiatry 63, 24–31 (2008). 
395. Straub, R. E. et al. Genetic variation in the 6p22.3 Gene DTNBP1, the human ortholog of 
the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 71, 337–
348 (2002). 
396. Weickert, C. S. et al. Human dysbindin (DTNBP1) gene expression in normal brain and in 
schizophrenic prefrontal cortex and midbrain. Arch. Gen. Psychiatry 61, 544–555 (2004). 
397. Nikolenko, V. N. et al. The mystery of claustral neural circuits and recent updates on its role 
in neurodegenerative pathology. Behav. Brain Funct. 17, 8 (2021). 
398. Wong, K. L. L., Nair, A. & Augustine, G. J. Changing the Cortical Conductor’s Tempo: 
Neuromodulation of the Claustrum. Front. Neural Circuits 15, 32 (2021). 
399. Talbot, K. et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the 
hippocampal formation in schizophrenia. J. Clin. Invest. 113, 1353–1363 (2004). 
400. Ji, Y. et al. Role of dysbindin in dopamine receptor trafficking and cortical GABA function. 
Proc. Natl. Acad. Sci. U. S. A. 106, 19593–19598 (2009). 
401. Iizuka, Y., Sei, Y., Weinberger, D. R. & Straub, R. E. Evidence that the BLOC-1 protein 
dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 
internalization. J. Neurosci. 27, 12390–12395 (2007). 
402. Numakawa, T. et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene 
for schizophrenia. Hum. Mol. Genet. 13, 2699–2708 (2004). 
403. Talbot, K. The sandy (sdy) mouse: A dysbindin-1 mutant relevant to schizophrenia 
research. Prog. Brain Res. 179, 87–94 (2009). 
404. McBride, H. M. et al. Oligomeric complexes link Rab5 effectors with NSF and drive 
membrane fusion via interactions between EEA1 and syntaxin 13. Cell 98, 377–386 (1999). 
405. Sun, W., Yan, Q., Vida, T. A. & Bean, A. J. Hrs regulates early endosome fusion by inhibiting 
formation of an endosomal SNARE complex. J. Cell Biol. 162, 125–137 (2003). 
406. Peter, A. T. J. et al. The BLOC-1 complex promotes endosomal maturation by recruiting 
the Rab5 gtpase-activating protein Msb3. J. Cell Biol. 201, 97–111 (2013). 
407. Hartwig, C. et al. Neurodevelopmental disease mechanisms, primary cilia, and endosomes 
converge on the BLOC-1 and BORC complexes. Developmental Neurobiology 78, 311–
330 (2018). 
408. Marley, A. & von Zastrow, M. Dysbindin promotes the post-endocytic sorting of G protein-
coupled receptors to lysosomes. PLoS One 5, e9325 (2010). 
409. Owen, M. J., Williams, N. M. & O’Donovan, M. C. Dysbindin-1 and schizophrenia: from 
genetics to neuropathology. J. Clin. Invest. 113, 1255–1257 (2004). 
410. Moghaddam, B. & Javitt, D. From revolution to evolution: The glutamate hypothesis of 
137 
 
schizophrenia and its implication for treatment. Neuropsychopharmacology 37, 4–15 
(2012). 
411. Abdolmaleky, H. M. et al. Epigenetic dysregulation of HTR2A in the brain of patients with 
schizophrenia and bipolar disorder. Schizophr. Res. 129, 183–190 (2011). 
412. Holloway, T. & González-Maeso, J. Epigenetic Mechanisms of Serotonin Signaling. ACS 
Chem. Neurosci. 6, 1099–1109 (2015). 
413. Sealfon, S. C. & Olanow, C. W. Dopamine receptors: From structure to behavior. Trends in 
Neurosciences 23, S34–S40 (2000). 
414. Meltzer, H. Y. & Stahl, S. M. The dopamine hypothesis of schizophrenia: a review. 
Schizophrenia Bulletin 2, 19–76 (1976). 
415. Meltzer, H. Y. Clinical studies on the mechanism of action of clozapine: the dopamine-
serotonin hypothesis of schizophrenia. Psychopharmacology (Berl). 99, S18–S27 (1989). 
416. Duan, J. et al. Translational Psychiatry Transcriptomic signatures of schizophrenia revealed 
by dopamine perturbation in an ex vivo model. Transl. Psychiatry 8, 158 (2018). 
417. Joyce, J. N. The dopamine hypothesis of schizophrenia: limbic interactions with serotonin 
and norepinephrine. Psychopharmacology (Berl). 112, 16–34 (1993). 
418. Brisch, R. et al. The role of dopamine in schizophrenia from a neurobiological and 
evolutionary perspective: Old fashioned, but still in vogue. Frontiers in Psychiatry 5, (2014). 
419. Alfimova, M. V., Monakhov, M. V., Abramova, L. I., Golubev, S. A. & Golimbet, V. E. 
Polymorphism of Serotonin Receptor Genes (5-HTR2A) and Dysbindin (DTNBP1) and 
Individual Components of Short-Term Verbal Memory Processes in Schizophrenia. 
Neurosci. Behav. Physiol. 40, 934–940 (2010). 
420. Hernandez, I. & Sokolov, B. P. Abnormalities in 5-HT2A receptor mRNA expression in 
frontal cortex of chronic elderly schizophrenics with varying histories of neuroleptic 
treatment. J. Neurosci. Res. 59, 218–225 (2000). 
421. Kasai, R. S. & Kusumi, A. Single-molecule imaging revealed dynamic GPCR dimerization. 
Curr. Opin. Cell Biol. 27, 78–86 (2014). 
422. Pellissier, L. P. et al. G protein activation by serotonin type 4 receptor dimers: evidence that 
turning on two protomers is more efficient. J. Biol. Chem. 286, 9985–97 (2011). 
423. Lee, S. P. et al. Dopamine D1 and D2 receptor Co-activation generates a novel 
phospholipase C-mediated calcium signal. J. Biol. Chem. 279, 35671–8 (2004). 
424. Toneatti, R. et al. Interclass GPCR heteromerization affects localization and trafficking. Sci. 
Signal. 13, eaaw3122 (2020). 
425. Jain, A., Liu, R., Xiang, Y. K. & Ha, T. Single-molecule pull-down for studying protein 
interactions. Nat. Protoc. 7, 445–452 (2012). 
426. Jain, A. et al. Probing cellular protein complexes using single-molecule pull-down. Nature 
473, 484–488 (2011). 
427. Levitz, J. et al. Mechanism of Assembly and Cooperativity of Homomeric and Heteromeric 
Metabotropic Glutamate Receptors. Neuron 92, 143–159 (2016). 
428. Crilly, J. The history of clozapine and its emergence in the US market: A review and 
analysis. History of Psychiatry 18, 39–60 (2007). 
429. Meltzer, H. Y. Update on Typical and Atypical Antipsychotic Drugs. Annual Review of 
138 
 
Medicine 64, 393–406 (2013). 
430. Lieberman, J. A. et al. Antipsychotic drugs: Comparison in animal models of efficacy, 
neurotransmitter regulation, and neuroprotection. Pharmacological Reviews 60, 358–403 
(2008). 
431. Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W. & Lieberman, J. A. 
Pharmacological treatment of schizophrenia: A critical review of the pharmacology and 
clinical effects of current and future therapeutic agents. Molecular Psychiatry 17, 1206–
1227 (2012). 
432. Ellaithy, A., Younkin, J., González-Maeso, J. & Logothetis, D. E. Positive allosteric 
modulators of metabotropic glutamate 2 receptors in schizophrenia treatment. Trends 
Neurosci. 38, 506–516 (2015). 
433. De La Fuente Revenga, M. et al. Chronic clozapine treatment restrains via HDAC2 the 
performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity. 
Neuropsychopharmacology (2018). doi:10.1038/s41386-018-0143-4 
434. Kurita, M. et al. HDAC2 regulates atypical antipsychotic responses through the modulation 
of mGlu2 promoter activity. 15, 1245–1254 (2013). 
435. Kinon, B. J., Millen, B. A., Zhang, L. & McKinzie, D. L. Exploratory Analysis for a Targeted 
Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist 
Pomaglumetad Methionil in Schizophrenia. Biol. Psychiatry 78, 754–762 (2015). 
436. Martin, G. R., Eglen, R. M., Hamblin, M. W., Hoyer, D. & Yocca, F. The structure and 
signalling properties of 5-HT receptors: An endless diversity? in Trends in Pharmacological 
Sciences 19, 2–4 (Elsevier Ltd, 1998). 
437. Harvey, J. A. Role of the serotonin 5-HT2A receptor learning. Learning and Memory 10, 
355–362 (Cold Spring Harbor Laboratory Press, 2003). 
438. Hu, C.-D., Grinberg, A. V. & Kerppola, T. K. Visualization of Protein Interactions in Living 
Cells Using Bimolecular Fluorescence Complementation (BiFC) Analysis. Curr. Protoc. Cell 
Biol. 29, 21.3.1-21.3.21 (2005). 
439. Kerppola, T. K. Complementary methods for studies of protein interactions in living cells. 
Nat. Methods 3, 969–971 (2006). 
440. Atwood, B. K., Lopez, J., Wager-Miller, J., Mackie, K. & Straiker, A. Expression of G protein-
coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as 








Rudy Toneatti was born on June 10th, 1977 in Paris, France. He is a French citizen and spent 
about four years working and studying at the VCU department of Physiology and Biophysics. He 
received a Bachelor of Art in Philosophy at the Nice University after being graduated with a 
Baccalauréat in Math, Physics and Biology. He also obtained a Master in Social and Political 
Sciences at the Sorbonne University in Paris. He did a Master in Integrative Biology and completed 
a first internship in Paris at the Centre du Fer à Moulin under the supervision of Dr Marta Garcia 
on tracking mitochondria trafficking along genetically modified mice piriform cortex neurons. Then 
travelled to Richmond for completion of the second graduating internship. After a year as a 
research assistant in the González-Maeso’s Lab, he entered the Graduate School at the VCU 







Fig. A1. Average spectra and sensorFRET analysis for Flp-In T-REx HEK293 cells stably 
expressing mGluR2-eYFP or mGluR2 TM4-eYFP, and harboring 5-HT2AR-eCFP at the inducible 
locus. (A and E) Linear unmixing of the eCFP (donor) component from the raw spectra, the ratio 
of which provides the alpha parameter used in the sensorFRET analysis. (B and F) Fitting of the 
β parameter, which is the difference between the 405 and 458 nm spectra after scaling 405 by α. 
(C and G) Raw spectra at both frequencies after the acceptor direct excitation component is 
removed using β339. (D and H) Linear unmixing of the donor and acceptor from the corrected 
spectra, where the FRET efficiency is proportional to the ratio of acceptor magnitude to donor 
magnitude. It can be seen that the ratio of eYFP magnitude to eCFP magnitude is larger in the 







Fig. A2. Effect of clozapine on mGluRs density. (A to C) Flp-In T-REx HEK293 cells stably 
expressing mGluR2-eYFP (A), mGluR3-eYFP (B) or mGluR2ΔTM4-eYFP (C) and harboring 5-
HT2AR-eCFP at the inducible locus were treated with doxycycline, exposed overnight to clozapine 
(10 µM), or vehicle, and harvested to perform radioligand binding assays with the mGluR2/3 
antagonist [3H]LY341495 (n = 4 independent groups of membrane preparations). Cell surface 
localization of mGluR2-eYFP with an Alexa Fluor 647 (AF647)-tagged antibody (D) and total 
mGluR2-eYFP signal (E) density were assessed by flow cytometry assays (n = 3 – 5 independent 
experiments). Data are mean  SEM. Statistical analysis was performed using the F test. ***P < 






Fig. A3. Representative photomicrographs showing excitatory synapses in mouse frontal cortex 
scored as membrane only (A), intracellular only (B), or both (C) based on postsynaptic distribution. 
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